



26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

FINAL PROGRAM

 www.pharmacoepi.org



Serious Fun!

JOINTLY SPONSORED BY:

- International Society for Pharmacoepidemiology
- European Association for Clinical Pharmacology and Therapeutics
- International Society for Pharmacovigilance

August 19-22, 2010 • Hilton Brighton Metropole • Brighton, UK

ISPE Board of Directors & Committees

ISPE Board of Directors

Officers

Sebastian Schneeweiss, FISPE / *President*
Stephen JW Evans, FISPE / *President-Elect*
Miriam CJM Sturkenboom, FISPE / *Immediate Past President*
Nancy A. Dreyer, FISPE / *Vice President Finance*
Matthew Reynolds / *Vice President Finance - Elect*
Mark H. Epstein / *Executive Secretary*

Directors

Elizabeth Andrews, FISPE	Colleen Maxwell
Alejandro Arana, FISPE	Nicholas D. Moore, FISPE
Ariel E. Arias	Robert Reynolds
Ulf Bergman, FISPE	Elena Rivero, FISPE
Stella Blackburn, FISPE	Scott R. Smith
Lolkje T de Jong-van den Berg	Alexander M. Walker, FISPE
Daniel Fife, FISPE	Songlin Xue
Sonia Hernández-Díaz, FISPE	Stanley A. Edlavitch
Kate L. Lapane, FISPE	<i>Lifetime Emeritus</i>

Scientific Program Committee

Corinne S. de Vries, FISPE / *Chair*

Core Program Committee

Stella Blackburn, FISPE	Bert Leufkens, FISPE
Maureen Cronin	James Lewis, FISPE
Cynthia DeLuise	Anke-Hilse Maitland- van der Zee
Wei Dong	Frank May, FISPE
Mark H. Epstein	Yola Moride, FISPE
Stephen JW Evans, FISPE	BJ Park, FISPE
Andrew Gilbert	Susana Perez Gutthann, FISPE
Jean-Pierre Grégoire, FISPE	Glen Schumock
Joanna Haas	John Seeger
Jesper Hallas	Robert Vander Stichele
Tarek Hammad	Alexander M. Walker, FISPE
Yea-Huei Kao Yang	
Kiyoshi Kubota, FISPE	
Kate Lapane, FISPE	

27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management



AUGUST 14-17, 2011

HYATT REGENCY CHICAGO

CHICAGO, ILLINOIS

Abstract

Deadline:

FEBRUARY 16, 2011

Photo courtesy of Chicago Convention and Tourism Bureau

*The online abstract site will be
operational by mid-December 2010.*

*Meeting information will be posted
at www.pharmacoepi.org*

Alejandro Arana, FISPE
 Elizabeth Andrews, FISPE
 Daniel Ankrach
 Ariel E Arias
 Ali Artaman
 Yan Bai
 Steven Bailey
 Swapu Banerjee
 Kristina Bardenheuer
 Andrew Bate
 Begler Begovic
 Pipasha Biswas
 Stella Blackburn, FISPE
 William Blumentals
 Rhonda Bohn, FISPE
 Christina Booth
 Richard Boyce
 Nancy Brandenburg
 Miles Braun, FISPE
 Kimberly Brodovicz
 Cheryl Broussard
 Jeffrey Brown
 Suzanne Cadarette
 Aisling Caffrey
 Jordi Castellsague
 Ola Caster
 Ruby Castilla
 Gillian Coughay
 Yan Chen
 Chi Wen Chiang
 Jennifer Christian
 Mary Clouser
 Alexander Cole
 Lyn Colvin
 Michael Cook
 Deborah Covington
 Maureen Cronin
 Deirdre Cronin-Fenton
 Marianne Cunnington
 Suellen Curkendall
 Jeffrey Curtis
 Andrzej Czarnecki, FISPE
 Godofreda Dalmacion
 Kourtney Davis
 Sandra de Bie
 Marieke De Bruin

Lolkje de Jong-van den Berg
 Cynthia de Luise
 Corinne S. de Vries, FISPE
 Frank de Vries
 Cynthia DeLuise
 Jeanne Dieleman
 Rachael DiSantostefano
 Wei Dong
 David Dore
 Cecile Droz-Perroteau
 Sascha Dublin
 Stanley A. Edlavitch
Conference Chair Emeritus
 Stephen JW Evans, FISPE
 Germano Ferreira
 Kristian Filion
 Annie Fourrier-Reglat
 Michele Jonsson Funk
 Kari Furu
 Joshua Gagne
 Helga Gardarsdottir
 Christiane Gasse
 Tobias Gerhard
 Andrew Gilbert
 Alicia Gilsenan
 Cynthia Girman
 Earl Goehring
 Kyna Gooden
 Michael Goodman
 Jean-Pierre Grégoire, FISPE
 Andrea Gruneir
 Dianlin Guo
 Jeff Guo
 Joanna Haas
 Jesper Hallas
 Tarek Hammad
 Christian Hampp
 Joseph Hanlon
 Reina Haque
 Spencer Harpe
 Catherine Harrington
 Jeff Harrison
 Kevin Haynes
 Klaas Heinemann

Sean Hennessy, FISPE
 Sharon Hensley Alford
 John Hermos
 Sonia Hernandez-Diaz, FISPE
 Richard Hill
 Ishan Hirji
 Ceri Hirst
 Billy Holden
 Ken Hornbuckle
 Laura Horne
 Gail Hughes
 John Iskander
 Amalia Issa
 Jessica Jalbert
 Catherine Johannes
 Judith K. Jones, FISPE
 Yea-Huei Kao Yang
 James Kaye
 Judith Kelly
 Farhad Ali Khan
 Alena Khromava
 Tomomi Kimura
 Victor Kiri
 Doug Kou
 Edeltraut Kruger
 Kiyoshi Kubota, FISPE
 Fatmatta Kuyateh
 Stephan Lanes
 Kate L. Lapane, FISPE
 Marie-Laure Laroche
 Tamar Lasky
 Elizabeth Lawler
 Deborah Layton
 Charles Leonard
 Bert Leufkens, FISPE
 James Lewis, FISPE
 Michael Lewis, FISPE
 Jie Li
 Huifang Liang
 Stephan Linden
 Sandra Lopez
 Jeanne Loughlin
 Christine Lu
 Anke-Hilse Maitland-van der Zee

Andrea Margulis
 Marie-Josée Martel
 Ramona Mateos-Campos
 Frank May, FISPE
 Giampiero Mazzaglia
 Jay McDonald
 Jessina McGregor
 Anita McGrogan
 Hans-Ulrich Melchert
 David Miller
 Donald Miller
 Kimberly Miller
 Daniel Mines
 Montserrat Miret
 Allen Mitchell, FISPE
 Jingping Mo
 Peter Mol
 Yola Moride, FISPE
 Jonathan Morris
 Pavel Napalkov
 Steve Niemcryn
 Beth Nordstrom
 Niklas Norén
 Mette Nørgaard
 Jude Nwokike
 Antoine Pariente
 Byung Joo Park, FISPE
 Amanda Patrick
 Sallie Pearson
 Susana Perez Gutthann, FISPE
 Ingemar Persson
 Hans Petri
 Kenneth Petronis
 Jennifer Polinski
 Mary Prince Panaccio
 Jingjing Qian
 Brian Quilliam
 Sudha Raman
 Jeremy Rassen
 Robert Reynolds
 Mary Ritchey
 Elena Rivero, FISPE
 Susan Roberts
 Michel Rotily
 Libby Roughead

Stefan Russmann
 Susan Sacks, FISPE
 Patricia Saddier
 Maribel Salas
 Nancy Santanello
 Surasak Saokaew
 Brian Sauer
 Hedi Schelleman
 John Seeger
 Sarah Sellers
 Soko Setoguchi
 Gloria Shalviri
 Jason Simeone
 Meredith Smith
 Patrick Souverein
 Michael Steinbuch
 Miriam CJM
 Stürkenboom, FISPE
 Til Stürmer, FISPE
 Michael Taylor
 Martina Teichert
 Sengwee Toh
 Gianluca Trifiro
 Ilse Truter
 Marianne Ulcickas Yood
 Jan-Willem van der Velden
 Charlotte van Noord
 Robert Vander Stichele
 Zdravko Vassilev
 Katia Verhamme
 Peter Wahl
 Alexander M. Walker, FISPE
 Doug Watson, FISPE
 Li Wei
 Sheila Weiss Smith, FISPE
 Michael Wess
 Suzanne L. West, FISPE
 Gregg Wilkinson
 James Wilson
 Wolfgang Winkelmayer
 Jasmanda Wu
 Yu Yan
 Wai Ping Yau
 Muhammad Younus
 Wei Zhou

Development Committee

Rhonda Bohn, FISPE,
 Chair
 Annlouise Assaf,
 Vice Chair
 Dimitri Bennett
 Melissa Campanelli
 Jennifer Christian

Andrzej Czarnecki,
 FISPE
 Nancy Dreyer, FISPE
 Mark H. Epstein
 Kyna Gooden
 Kim Lowe
 Kirk Midkiff

Susan Oliveria, FISPE
 Cynthia O'Malley
 Marieke Schoonen
 Marianne Ulcickas Yood
 Natalie Volkova



MEETING At-a-Glance

Wednesday, August 18, 2010

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm	
				11:00am - 6:00pm Registration Open Sussex Lounge									
				11:00am - 5:00pm Speaker Ready Room Office I									
						1:00 - 5:00pm Educational Sessions: Introduction to Pharmacoepidemiology Balmoral							
						1:00 - 5:00pm Introduction to Pharmacogenetics — Part I Dukes				5:30 - ? Student Meet & Greet Revolution			
	8:30am - 5:00pm ISPE Board of Directors Meeting Buckingham					1:00 - 5:00pm Student Skills Workshop Ambassador							

Thursday, August 19, 2010

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 6:00pm Registration Open Sussex Lounge												
7:00am - 5:00pm Speaker Ready Room Office I												
	8:30am - 12:00pm Educational Sessions: Pharmacogenetics 2 Dukes Regulatory Pharmacoepi/Public Health Decision Making Ambassador Introduction to Drug Utilization Research Buckingham Intermediate Pharmacoepi: Concepts, Data and Methods Clarence Medications in Pregnancy Balmoral Comparative Effectiveness Research Hall 4					12:00 - 1:30pm Lunch on Your Own		1:30 - 6:00pm Educational Sessions: Advanced Topics in Pharmacoepidemiology Hall 4 Introduction to Risk Management Balmoral Advanced Drug Utilization Research: Using Drug Data to Guide Planning and Evaluation of Quality Use of Medicines Interventions Ambassador				
					12:00 - 1:30pm New Members Luncheon Windsor Restaurant						6:00 - 7:30pm Welcome Reception/ Hilton Metropole Beach (weather permitting)	

Friday, August 20, 2010

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 6:00pm Registration Open Sussex Lounge												
7:00am - 5:00pm Speaker Ready Room Office I												
	7:30am - 6:00pm Exhibitors/Posters Durham & Hall 7											7:00 - 9:00pm PDS Editorial Board (By invitation)
7:00 - 8:00am Poster Session A Set-Up Durham & Hall 7	8:00 - 9:00am Opening Session Oxford Welcome: Corinne de Vries	9:00 - 10:30am Diabetes Clarence Infection: Down with Resistance Dukes Methods: Exposure and Outcome Assessment Hall 4 Sundry Buckingham The Brighter Side of Cancer Balmoral Vaccines in the HINI Era Cambridge	10:30-11:00am Break/Posters/Exhibits Durham & Hall 7	11:00 - 12:00pm Keynote Address Oxford Thomas Lönngrén	12:00 - 1:30pm Lunch/ Poster Session A/Exhibits Durham, Durham Gallery, Hall 7&8	1:30 - 3:00pm EMA Scientific Debate Co-sponsored by ISPE & EMA Oxford	3:00-3:30pm Break/Posters/Exhibits Durham & Hall 7	3:30 - 5:00pm Symposia & Workshops Methodological Challenges of Drug Utilization Balmoral Methodological Controversies from Comparative Effectiveness Cambridge Biologics Dukes Guidance Regarding Electronic Healthcare Databases Hall 4 Identifying the Genetic Basis of Serious Adverse Events Buckingham Birth Defects Clarence The Public Health Burden of Acetaminophen Poisonings Ambassador			5:00 - 6:00pm ISPE Council Meetings Academic Hall 4 Government/Regulatory Hilton 3 Industry/Service Providers Lancaster	7:00 - ? Student Social Event A Night Out in Brighton at Al Duomo
7:00 - 8:00am Committees Education Lancaster Finance Hilton 3	Presidential Address: Sebastian Schneeweiss				ISPE Committee/ Council Meetings Development Lancaster Fellowship & Awards Hilton 3 Public Policy Buckingham Student Council Ambassador						6:00 - 7:00pm General Assembly/ European Drug Utilization/ Health Services Research SIG Ambassador	

MEETING At-a-Glance

Saturday, August 21, 2010

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:00am - 6:00pm Registration Open Sussex Lounge												
7:00am - 5:00pm Speaker Ready Room Office I												
7:00-8:00am Poster Session B Set-Up Durham & Hall 7	8:00am - 6:00pm Exhibitors/Poster Session Durham & Hall 7				12:45-1:30pm Poster Walks Durham & Hall 7			3:30-4:00pm Break/ Posters/ Exhibits Durham & Hall 7	4:00 - 5:30pm Symposia & Workshops Optimizing Global Vaccine Safety Monitoring: Lessons Learned from H1N1 Hall 4 Matching on Propensity Scores Balmoral Regulatory Risk Communication Are We Getting Ahead? Oxford Role of Meta-Analysis in Drug Safety Buckingham The Panacea of Study Designs in Pharmacoepidemiology Dukes How Can Better Scientific Methods Result in Better Drug Regulation Studies Clarence Evaluating Adverse Pregnancy Outcomes Ambassador			
	8:30am - 10:00am CNS: The Brain and the Heart Balmoral Mapping and Validating Critical Data Elements Cambridge Miscellaneous Buckingham NSAIDs and Associated Treatments Dukes P4M: Pharmacogenomics, Predictors, Prognosis, & Personalised Medicine Clarence Risk Management: Are We Taking the Bull by the Horn? Oxford	10:00-10:30am Break/ Posters/ Exhibits Durham & Hall 7	10:30am - 12:00pm Clinically Important Public Health Issues and New Insights in Rare Diseases Dukes CNS: Potpourri Oxford Methods in Pregnancy Studies: Practical Applications Cambridge Pharmacovigilance - Needles in Haystacks? Balmoral Potpourri Buckingham Prescribing Problems in Older Persons Clarence	12:00 - 1:30pm Lunch/Poster Session B/Exhibits Durham, Durham Gallery, Hall 7&8 ISPE Committee Council Meetings Bylaws and Policies Sandringham External Communications Hilton 3 Global Development Lancaster Membership Osborne Publications Surrey I	1:30 - 2:30pm Plenary Session: Benefits and Risks of Drug Treatments Oxford	2:30 - 3:30pm Annual Meeting of ISPE Members & Awards Ceremony Oxford				5:30 - 6:30pm SIGs Biologics Ambassador Comparative Effectiveness Research Balmoral Database Buckingham Drug Utilization/Health Services Research Cambridge Medications in Pregnancy Clarence Molecular Epidemiology/Pharmacogenetics Dukes	7:30pm - 11:30pm Evening at the Corn Exchange/Brighton Dome	

Sunday, August 22, 2010

7:00am	8:00am	9:00am	10:00am	11:00am	12:00pm	1:00pm	2:00pm	3:00pm	4:00pm	5:00pm	6:00pm	7:00pm
7:30am - 4:30pm Registration Open Sussex Lounge												
7:30am - 3:30pm Speaker Ready Room Office I												
7:00-8:00am Poster Session C Set-Up Durham & Hall 7	8:00am - 1:45pm Exhibitors/Posters Durham & Hall 7				12:00 - 1:30pm Lunch/Poster Session C/Exhibits Durham, Durham Gallery, Hall 7&8 Roundtable Discussions TBA ISPE Board of Directors Luncheon Ambassador	1:30 - 3:00pm Symposia & Workshops Lessons Learned from Collaboration Among EU Biologics Registries in Rheumatology Hall 4 The Industry-Academic Nexus Cambridge The Alternate Life of Regulators Oxford Rare Diseases: Dukes Linking Administrative and Electronic Medical Record Databases Balmoral Challenges and Opportunities in Shaping Medical Device Epidemiology Buckingham Observed vs Expected Methodologies in Vaccine Safety Surveillance Clarence			3:00 - 4:30pm Hot Topics Session: Pandemic, Not Many Dead - What We Should Do Differently Next Time Oxford	4:30-5:00pm The Final Word: •Poster Awards •ICPE 2011 •Adjournment Oxford		5:15 - 6:15pm 2011 ICPE Scientific Program Committee Ambassador
	8:30 - 10:00am Bias and Confounding Oxford Clotting or Bleeding Buckingham Compliance & Utilization I Balmoral Outcomes After Prenatal Exposure Cambridge Pharmacovigilance - Real or Fool's Gold Clarence Stimulating Findings from Medicine Use in Children Dukes	10:00-10:30am Break/ Posters/ Exhibits Durham Hall 7	10:30am - Noon Analysis Methods - The Details that Bedevil Us Oxford Atypical Prescribing in Older People Balmoral Cardiovascular Cambridge Compliance & Utilization II Buckingham Pediatric Potpourri Dukes Random Women Clarence									

ISPE gratefully acknowledges the generous support of the following organizations, institutions and programs. Their contributions helped to enhance the scientific program content and increase attendance at the ICPE 2010.

Thank you

Serious Fun!

Exhibitors

- | | |
|------------------------------------|---|
| * i3 Drug Safety | * Premier healthcare alliance |
| * Bayer Schering Pharma AG | * ProSanos |
| * DrugLogic | * REGISTRAT-MAPI |
| * Erasmus MC | * RTI Health Solutions |
| * GPRD | * The Degge Group, LTD |
| * HealthCore | * Thomson Reuters |
| * IMS Health | * United BioSource Corporation |
| * Kantar Health | * WHO Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring Centre |
| * Kendle | * WHO Collaborating Centre for Drug Statistics Methodology |
| * LA-SER | * Wiley-Blackwell |
| * Outcome | |
| * ParagonRx | |
| * Phase Forward | |
| * Pope Woodhead & Associates, Ltd. | |

Academic Supporters

- * Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- * Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- * Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women's Hospital & Harvard Medical School
- * Drug Safety Research Unit, Associated Department of the School of Pharmacy and Biomedical Sciences, Portsmouth University
- * Eu2P Programme in Pharmacovigilance and Pharmacoepidemiology, Université Victor Segalen
- * London School of Hygiene & Tropical Medicine
- * McGill Pharmacoepidemiology Research Unit, McGill University
- * Pharmacoepidemiology Program, Department of

ICPE Sponsors

Corporate Benefactor

- | | |
|----------------------|----------|
| * Astra Zeneca R & D | * Pfizer |
|----------------------|----------|

Joint Sponsors

- | | |
|---|---|
| * European Association for Clinical Pharmacology and Therapeutics | * International Society for Pharmacovigilance |
|---|---|

Annual Meeting Sponsors

Platinum

- | | |
|------------------|-------------------|
| * Pfizer | * Wiley-Blackwell |
| * REGISTRAT-MAPI | |

Gold

- | | |
|-----------------------------|----------------------------------|
| * i3 Drug Safety | * Kantar Health |
| * Amgen | * LA-SER |
| * Bayer Schering Pharma AG | * Outcome |
| * Boehringer Ingelheim GmbH | * ParagonRx |
| * Celgene | * Phase Forward |
| * Eli Lilly & Company | * Pope Woodhead & Associates Ltd |
| * GlaxoSmithKline | * ProSanos |
| * HealthCore | * RTI Health Solutions |
| * Hoffmann-La Roche | * The Degge Group, LTD |
| * IMS Health | * United BioSource Corporation |

Silver

- | | |
|-----------------------|------------------|
| * Cephalon | * PPD |
| * Genzyme Corporation | * Sanofi Pasteur |
| * Novartis | |

Bronze

- | | |
|--|--------------|
| * Boston Collaborative Drug Surveillance Program, Boston University School of Medicine | * CSD-EPIC |
| | * EpiSource |
| | * PharmIdeas |
| | * WHISCON |

- * Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- * Program in Pharmacoepidemiology, Harvard School of Public Health
- * Slone Epidemiology Center at Boston University
- * University of Texas at Austin, College of Pharmacy

The Society expresses its sincere appreciation to those supporters listed below for their contribution in honor of the 26th Annual Meeting (ICPE).

Organizational & Institutional Members

Corporate Benefactors

- * Astra Zeneca R & D
- * Pfizer

Members

Pharmaceuticals

- * Sanofi-Aventis
- * F. Hoffmann-LaRoche AG

Service Providers

- * RTI Health Solutions

Government/Regulatory Agency

- * Department of Health, Pharmaceutical Services, Hong Kong Special Administrative Region, People's Republic of China
- * Drug Safety and Effectiveness Network, Canadian Institute of Health Research

Academic Programs

- * Center for Clinical Epidemiology & Biostatistics, University of Pennsylvania School of Medicine
- * Center for Drug Safety, School of Pharmacy, University of Maryland
- * Department of Pharmaceutical Outcomes & Policy, College of Pharmacy, University of Florida
- * Drug Safety Research Unit, Associated Department of the School of Pharmacy and Biomedical Sciences, Portsmouth University
- * Harvard School of Public Health
- * London School of Hygiene and Tropical Medicine
- * McGill Pharmacoepidemiology Research Unit, McGill University
- * Pharmacoepidemiology Program, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill
- * Program in Pharmacoepidemiology and Pharmacoecomics, College of Pharmacy, University of Rhode Island
- * Slone Epidemiology Center at Boston University
- * University of Texas at Austin, College of Pharmacy

- | | |
|---|--|
| <ul style="list-style-type: none"> Edgar Adams Michael Adena Obehi Akoria Anna Birna Almarsdottir Keith Altman Pierre Anhoury Kwame Appenteng Ivar Aursnes Keith Beard, FISPE Alison Bourke, FISPE David Bradford Miles Braun, FISPE Emily Brouwer James Buchanan Claudia Cabrera-Moksnes Javier Cid Ruzafa Alexander Cole Lyn Colvin Suellen Curkendall Marie-Christyne Cyr Hassy Dattani Josta de Jong Lolkje de Jong-van den Berg Juergen Dinger Thomas Einarson, FISPE Cheryl Enger Kimberly Farrand Genevieve Gabb David Gagnon Anna Greenacre Jeff Guo Eelko Hak Marte Handal Klaas Heinemann Deborah Hennessey Marlene Hoynch Zhiping Huang Helen Huang Jacqueline Hugtenburg Betsey Jackson Saga Johansson Jeffrey Johnson Yea-Huei Kao Yang Oystein Karlstad Junichi Kawakami Judy Kempf Farhad Ali Khan Maarit Korhonen | <ul style="list-style-type: none"> Tzuyung Kou Kiyoshi Kubota, FISPE Sarah Landis Linda Levesque Michael A. Lewis, FISPE Marina Maggini Milada Mahic Frank May, FISPE Carl Metzdorff Montserrat Miret Ditte Molgaard-Nielsen Nancy E. Morden Yola Moride, FISPE Mette Norgaard Susan Oliveria, FISPE Cynthia Phillips Paola Primatesta Elham Rahme Joe Reilly Adriano Reis Susan Roberts Jamie Robinson Motonobu Sakaguchi Ida Schnabel Markus Schuerch Barbara Schwierin Prashanti Shah Hee-Young Shin Rosemary Sift-Carter Herik Toft Sorensen Montse Soriano Gabarro Patrick Souverein Miriam Sturkenboom, FISPE Bharat Thakrar Sengwee Toh Toshimitsu Tokimoto Gianluca Trifiro Ilse Truter Marianne Ulcickas Yood Carla M. Van Bennekom Mari-Ann Wallander, FISPE Alex Ward Mark Waring Made Wenten Jean-Frederic Westphal Almut Winterstein Zhong Yuan Xiaofeng Zhou |
|---|--|

IN THIS PROGRAM

26th ICPE Agenda

Wednesday, August 18.....	9
Thursday, August 19.....	10
Friday, August 20.....	14
Saturday, August 21.....	20
Sunday, August 22.....	34

26th ICPE Posters

Poster Guidelines.....	42
Poster Session A.....	43
Poster Session B.....	52
Poster Session C.....	60

Indexes

Abstract Index.....	70
Advertisers Index.....	78

FUTURE MEETINGS

Meeting Information

2010

5th Asian Conference on Pharmacoepidemiology

(Convened in conjunction with the Japanese Society for Pharmacoepidemiology 16th Annual Meeting)

October 29-31, 2010 * IOI Hall * Tokyo, Japan

2011

ISPE Mid-Year Meeting

April 9-11, 2011 * Grand Hotel Baglioni * Florence, Italy

27th ICPE

August 14-17, 2011 * Hyatt Regency Chicago * Chicago, Illinois

2012

ISPE Mid-Year Meeting

April 21-23, 2012 * Eden Roc Hotel * Miami Beach, Florida

28th ICPE

August 23-26, 2012 * CICC * Barcelona, Spain

Badges

All attendees at ICPE 2010 must wear their name badges to all events.




A badge will be needed for admission to meeting related functions, such as the Welcome Reception, scientific sessions, exhibit/poster hall, and evening at the Corn Exchange. Badges will be included in the registration packet material. In some cases, tickets for admission will be required.




Badge Legend

-  Student
-  New Member
-  One-Day Attendee

Footstep Legend

Follow the color to your session.

-  To Clarence, Lancaster, Sandringham & Viscount
-  To Balmoral, Buckingham, Dukes, Ambassador & Osborne
-  To Exhibit Hall (Durham), General Session (Oxford), Cambridge & Hall 4



HealthCore®

real world insight

Safety & Epidemiology Research
Prospective Effectiveness Research
Health Economics & Outcomes Research

We Provide Clarity that Empowers Decision-Makers to Act with Precision to Improve Quality, Safety and Affordability in Healthcare.

A comprehensive, proven and innovative research environment:

- Rich data assets – the HealthCore Integrated Research Database (HIRDSM)
- Deep scientific expertise and data capabilities provide unparalleled insights
- Strategic collaborations with delivery systems, academia, government and managed care

800 Delaware Ave., Fifth Floor • Wilmington, DE 19801 • P 302.230.2156 • F 302.230.2046
info@healthcore.com • www.healthcore.com • For more information, contact Michael Chance at 610.613.2979

AGENDA Wednesday, August 18

8:30am-5:00pm ISPE Board of Directors Meeting (Buckingham)

(Open to ISPE members; notify ISPE staff if you would like to attend.)

11:00am-6:00pm Registration (Sussex Lounge)

11:00am-5:00pm Speaker Ready Room (Office 1)

NOTE:

Topics in Day 1 and Day 2 are complementary. Individuals registered for either day may attend both sessions. On Day 1, there will be a focus on didactic teaching. On Day 2 there will be small group workshop that will use real pharmacogenetic case studies catering to both novice and advanced participants, focused on methodology.

Pre-Conference Educational Sessions* (Registration required)

1:00-5:00pm Introduction to Pharmacoepidemiology (Balmoral)

Chair: Andrew McAfee

Harry Seifert, GSK, Spontaneous Reporting

Soko Setoguchi, Duke University, Cohort Studies

Andrew McAfee, Brigham & Women's Hospital, Case-Control Studies

Anita McGrogan, University of Bath, Confounding and Bias

* Included as part of full meeting registration; registration required

1:00-5:00pm Introduction to Pharmacogenetics – Part I: Didactic Approach Infused with Practical Examples (Dukes)

Educational Objectives

This year's course will focus more on methodologic approaches in pharmacogenetics in Day 1 and in Day 2.

- Understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at analysis
- Know the study design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology
- Understand statistical approaches used in Pharmacogenetics
- Understand how pharmacogenetics relates to current focus of Personalized Medicine
- Have an overview of clinical utility of pharmacogenetics and associated regulatory issues.

Faculty

Geoffrey Liu, Introduction to Pharmacogenetic and Biospecimen Terminology, and Approach Overview

Anke-Hilse Maitland-van der Zee/Efrosini Setakis, Advanced Pharmacogenetic Methods for Epidemiologists

Andrew Freedman, Application of Methods: From Discovery to Confirmation to Clinical Utility

Steven Kimmel, FISPE, Application of Methods: Warfarin as a Prototype Pharmacogenetic Example

Amalia Issa, Methodology to Investigate Policy-Relevant Aspects of Pharmacogenomics: Tools of the Trade (Methodology)

1:00-5:00pm STUDENTS ONLY Student Skills Workshop (Ambassador)

–Organized by ISPE Student Council

Introduction

Presentation Clinic

Careers Panel

Stella Blackburn, FISPE, EMA, Drug Regulation

Robert Reynolds, Pfizer, Pharmaceutical Industry

Kenneth J. Rothman, FISPE, RTI Health Solutions, Contract Research Organization

Sean Hennessy, FISPE, Academic

* Included as part of full meeting registration; registration required

5:30-?

Student Meet and Greet

- Open to all students.
- Organized by the ISPE Student Council
- Assemble at ICPE Registration Desk, then walk to Revolution.

AGENDA Thursday, August 19

7:00am-6:00pm
Registration
(Sussex Lounge)

7:00am-5:00pm
Speaker Ready Room (Office 1)

NOTE:

Topics in Day 1 and Day 2 are complementary. Individuals registered for either day may attend both sessions. On Day 1, there will be a focus on didactic teaching. On Day 2 there will be small group workshop that will use real pharmacogenetic case studies catering to both novice and advanced participants, focused on methodology.

Pre-Conference Educational Sessions* (Registration required)

8:30-Noon

Pharmacogenetics 2 – Practicum/Small Group Case-based Projects (Dukes)

Educational Objectives

- This year's course will focus more on methodologic approaches in pharmacogenetics in Day 1 and in Day 2.
- Understand the genetic and pharmacogenetic terminology and how cellular and molecular biology informs pharmacogenetic studies at analysis
- Know the study design and methodologic approaches, their strengths and weakness used in pharmacogenetic epidemiology
- Understand statistical approaches used in Pharmacogenetics
- Understand how pharmacogenetics relates to current focus of Personalized Medicine
- Have an overview of clinical utility of pharmacogenetics and associated regulatory issues.

Faculty

Andrew Freedman
Anke-Hilse Maitland van der Zee
Efrosini Setakis
Amalia Issa
Steven Kimmel
Geoffrey Liu

8:30-Noon

Regulatory Pharmacoepidemiology/Public Health Decision Making (Ambassador)

Educational Objectives

- Understand the intent and structure of regulation to protect the Public Health
- Appreciate the challenges of decision making with weak data
- Know about practical approaches typically chosen by regulators
- Recognize the challenges epidemiology faces to provide sufficient information for public health decision making
- Have an overview of world wide challenges for drug regulatory agencies and variation in approaches
- Know about current strategies to strengthen regulation in the face of these challenges

Faculty

Gerald Dal Pan, US FDA, *Regulation & Challenges of Decision-Making with Weak Data*
June Raine, MHRA, *Regulatory Decision Making Approaches in Europe*
Stephen Evans, FISPE, London School of Tropical Medicine, *An Epidemiologist's View of Public Health Decision Making*
Ralph Edwards, WHO Collaborating Centre for International Drug Monitoring, *Global Perspective on Regulatory Utilization of Pharmacovigilance Data*

8:30-Noon

Introduction to Drug Utilization Research (Buckingham)

Educational Objectives

- To explain the definition and scope of the eclectic discipline of Drug Utilization Research within the context of Pharmacoepidemiology.
- To motivate researchers providing international cross-national comparisons of national drug utilization data to cooperate on the collection of a minimal dataset of reliable and comparable drug utilization data in their country, in terms of volume, expenditures and quality of drug use.
- To explain the process of developing and validating prescribing quality indicators.
- To give an applied overview of methods useful for drug policy research (time series analysis)

Faculty

Robert Vander Stichele, *Course Objectives, Definitions of Research Fields and Methodological Framework*
Hanne Strom, *The Anatomical Therapeutic Chemical Classification and the Defined Daily Dose: Classifying and Quantifying Drug Use for Cross-National Comparison*
Julie Zito, *Overview of Drug Utilization Research in the US*
Monique Elseviers, *Using DUR – Data for Descriptive Cross National Comparisons*
Flora Haaïjer-Ruskamp, *Using DUR – Data to Create Valid Prescribing Quality Indicators*
Colin Dormuth, *Testing Interventions on Drug Utilization (time series analysis and other methods)*

AGENDA Thursday, August 19

8:30-Noon

Intermediate Pharmacoepidemiology: Concepts, Data and Methods (Clarence)

Course Description

- This course is for the general epidemiologist who wishes to review topics that are particular to pharmacoepidemiology. Concepts: drugs, devices and biologics as "exposures"; time-courses of their risks; confounding by indication; clinical and epidemiologic inference. Data: use of insurance claims and electronic medical records. Analysis: propensity, instruments, time-varying exposures and confounders.

Faculty

Alec Walker, FISPE, World Health Information Science Consultants, Harvard School of Public Health

8:30-Noon

Medications in Pregnancy (Balmoral)

Educational Objectives

- Recognize the unique methodological challenges of discovering unintended drug effects in pregnant women in pre-marketing and post-marketing studies.
- Understand the circumstances around the discovery and management of known drug safety crises affecting pregnant women and their offspring. This includes the critical evaluation of the available scientific evidence.
- Evaluate and design pharmacoepidemiologic studies for pregnant populations.

Faculty

Carol Louik, Assistant Professor, Slone Epidemiology Center at Boston University

Sonia Hernandez-Diaz, FISPE Associate Professor, Department of Epidemiology, Director of Pharmacoepidemiology Program, Harvard School of Public Health

8:30-Noon

Comparative Effectiveness Research (Hall 4)

Educational Objectives

- Appreciate the differences between comparative effectiveness and efficacy research and implications for improving routine care
- Understand the basic study design issues for non-randomized data recorded in routine care settings
- Recognize the advantages and limitations of a variety of data sources for comparative effectiveness research and how to combine sources
- Understand methodologic challenges and proposed solutions in non-randomized effectiveness research
- Learn how to generate and synthesize evidence with the decision maker in mind

Faculty

Eric S Johnson, Course Chair, Kaiser Permanente's Center for Effectiveness and Safety Research, *Introduction to Comparative Effectiveness Research via Pragmatic Cohort Studies*

David J Magid, Kaiser Permanente's Institute for Health Research, *Combining Electronic Health Record and Registry Data Sources for Comparative Effectiveness*

Sebastian Schneeweiss, FISPE, Harvard Medical School, *Methodological Challenges in Non-Randomized Studies of Comparative Effectiveness*

Kenneth R Paterson, Scottish Medicines Consortium, *Generating and Synthesizing Evidence with the Decision Maker in Mind*

Noon - 1:30pm

Lunch On Your Own

Noon-1:30pm

New Member Luncheon (Windsor Restaurant)

—By Invitation

Pre-Conference Educational Sessions* (Registration required)

1:30-6:00pm

Advanced Topics in Pharmacoepidemiology

(Hall 4)

This course is a series of four lectures covering new and advanced methods for pharmacoepidemiology research.

Chair: Jim Lewis, FISPE

Paddy Farrington, *Methods for Use of Self-Controlled Designs*

Byrony Dean Franklin, *Methods to Study the Risk, Consequences, and Prevention of Medication Errors*

Til Stürmer, FISPE, *Update on Propensity Scoring*

Reed Johnson, *Methods of Quantitative Risk Benefit Analysis*

1:30-6:00pm

Introduction to Risk Management (Balmoral)

Educational Objectives

- To provide basic overview/framework for biopharmaceutical risk management -- both EU-based risk minimization plans (RMP) and US-based risk evaluation & mitigation strategies (REMS) -- including the regulatory context and perspective
- To describe the use of surveys in planning and evaluating the effectiveness of RMPs/REMS
- To present key concepts in the design and conduct of survey research
- To illustrate key concepts of survey research with examples of RMP/REMS assessment surveys
- To provide an opportunity for interactive session in developing and evaluating RMP/REMS assessment surveys

Faculty

Elizabeth Andrews, FISPE, *Course Objectives and Introductions; Overview of Risk Management the Role of Evaluation, with Focus on Survey Research*

Stella Blackburn, FISPE, *Implementation and Experiences in Risk Management in the EU*

Carla van Bennekom, *Selected Topics and Examples - Survey Design and Analysis*

Judith Jones, FISPE, *Workshop for Participants to Develop/Review an Assessment Survey*

1:30-6:00pm

Advanced Drug Utilization Research: Using Drug Data to Guide Planning and Evaluation of Quality Use of Medicines Interventions (Ambassador)

Educational Objectives

- To gain an advanced understanding of planning, implementation and evaluation requirements for an effective quality use of medicines intervention.
- To develop a sophisticated understanding of the importance of behavioral and project planning processes to the effectiveness of interventions.
- To develop a sophisticated appreciation of the significance of this work to knowledge transfer at the patient care practice and policy change levels of the health system.

Faculty

Andrew Gilbert, *Introductions, Workshop Objectives, and Plan*

Libby Roughead, *Theoretical Methods Underpinning Intervention Planning*

Jerry Avorn, FISPE, *Expert Commentary*

6:00-7:30pm

Welcome Reception (Hilton Metropole Beach, weather permitting)

—Admission by badge or ticket. Cash Bar

Welcome

Corinne S. de Vries, FISPE, Chair,
2010 Scientific Program Committee

Sebastian Schneeweiss, FISPE, ISPE President



Working together for a healthier world™

Pfizer Epidemiology: Committed to Patient Safety

The Epidemiology Group at Pfizer pursues excellence in developing and executing pharmacoepidemiology safety strategies to inform benefit-risk decisions about our medicines.

Pfizer, Inc. discovers, develops, manufactures, and markets leading prescription medicines for humans and animals. Our diversified global health care portfolio includes biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.

With 2009 actual spending of \$7.8 billion in research & development (R&D), Pfizer has the industry's largest pharmaceutical R&D organization. Our search for new treatments spans hundreds of research projects across 58 major disease groups in 10 therapeutic areas.

We build our success on the innovation, skills, and entrepreneurial spirit of each of our colleagues.

Every year we help 150 million patients, utilize the skills of medical researchers, and work in partnership with governments, individuals, and other payers for healthcare to treat and prevent illnesses – adding both years to life, and life to years.

We are proud to support the **26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management** and welcome the opportunity for the open exchange of scientific ideas and research findings in order to advance the fields of pharmacoepidemiology and risk management.

AGENDA Friday, August 20

7:00am-6:00pm

Registration (Sussex Lounge)

7:00am-5:00pm

Speaker Ready Room (Office 1)

7:00-8:00am

ISPE Committee Meetings

–Open to all participants.

- * **Education Committee** (Lancaster)
- * **Finance Committee** (Hilton 3)

7:00-8:00am

Poster Session A Set-up

(Durham & Hall 7)

7:30am-6:00pm

Exhibits/Posters (Durham & Hall 7)

8:00-9:00am

Opening Session (Oxford)

- * **Welcome**
Corinne S. de Vries, FISPE, Chair,
2010 Scientific Program Committee
- * **Presidential Address**
Sebastian Schneeweiss, FISPE,
ISPE President

9:00am - 10:30am

Concurrent Sessions: Contributed Papers

Diabetes (Clarence)

Moderators: **Bert Leufkens, FISPE, & Jurgen Dinger**

9:00 am

- * **Clinical and Demographic Characteristics of Newly Diagnosed Diabetes Patients Prescribed Oral Hypoglycemics [1]**
S L West, E S Brouwer, M N Kluckman, A L Masica, E Ewen, R Kudryakov.
(United States)

9:15 am

- * **Improved Glycemic Control and Cancer Risk in Type 2 Diabetes: A Meta-Analysis of Major Trials [2]**
Jeffrey A Johnson, Samantha L Bowker. (Canada)

9:30 am

- * **A Retrospective Cohort Study To Assess the Relative Risk of Acute Pancreatitis among Initiators of Exenatide Compared to Initiators of Other Anti-Diabetic Medication: A Follow-Up Study [6]**
Made Wenten, Julia Gaebler, Elise Pelletier, Dan Smith, Prafulla Girase, Rebecca Noel, Daniel Braun, Gary Bloomgren, Mohamed Hussein.
(United States)

9:45 am

- * **Comparative Cardiovascular Morbidity and Mortality of Metformin in Older Adults with Diabetes: A Population-Based Cohort Study [4]**
Linda E Levesque, James M Brophy, Sophie Dell'Aniello, Samy Suissa.
(Canada)

10:00 am

- * **Risk of Acute Pancreatitis in Association with Type 2 Diabetes Mellitus [5]**
Antonio González-Pérez, Raymond G Schlienger, Luis A García Rodríguez. (Switzerland)

10:15 am

- * **Hypoglycemic Agents and the Risk of Cancer [3]**
Hui Zhang, Hammad A Tarek, David C Christiani, Edward Giovannuci.
(United States)

Infection: Down with Resistance (Dukes)

Moderators: **Kay Johannes & Mari-Ann Wallander, FISPE**

9:00 am

- * **Time-Varying Antibiotic Exposure and Risk of *Clostridium Difficile* Infection (CDI) [7]**
Vanessa Stevens, Ghinwa Dumyati, Susan Fisher, Lynn Fine, Edwin van Wijngaarden. (United States)

9:15 am

- * **Fluoroquinolone Resistance in *Campylobacter jejuni* in the United States, 1997-2007 [8]**
Nkuchia M M'ikanatha, A Russell Localio, Collette Fitzgerald, Irving Nachamkin. (United States)

AGENDA Friday, August 20

9:30 am

*** Antibiotic-Induced Liver Injury Among Hospitalized Patients [9]**

Marie L De Bruin, Yang Yu, Hanneke J den Breeijen, Wouter W van Solinge, Anke Hilse Maitland-van der Zee. (Netherlands)

9:45 am

*** The Risk of Infections among Patients Treated with TNFi: Population-Based Continuous ADRs Monitoring Using the Maximized Sequential Probability Ratio Testing [10]**

Yan Chen, Indiana Strombom, Dale Marmaduke, Olivier Benichou, Ilya Lipkovich. (United States)

10:00 am

*** Hepatitis C Treatment Adherence over Time and Virologic Response [11]**

V Lo Re, V Teal, R Localio, V Amorosa, R Gross. (United States)

10:15 am

*** Tuberculosis Risk Awareness and Screening Practices among Prescribers of Anti-Tumor Necrosis Factor (TNF) Agents in the European Union [12]**

Meredith Y Smith, Brian Attig, Thomas Eagle. (United States)

Powerful solutions at every phase.



The Phase Forward™ Integrated Clinical Research Suite

eClinical Solutions • Safety Solutions • Clinical Development Center

PHASE•FORWARD™
www.phaseforward.com

Copyright © 2010 Phase Forward Incorporated. All rights reserved. Phase Forward and the Phase Forward logo are trademarks or registered trademarks of Phase Forward Incorporated in the U.S. Patent and Trademark Office and other jurisdictions. Other marks may be trademarks or registered trademarks of their respective owners.

AGENDA Friday, August 20

Methods: Exposure and Outcome Assessment (Hall 4)

Moderators: Yola Moride, FISPE & Michele Johnson Funk

9:00 am

* **The Impact of Stockpiling and Minimum Required Adherence on Estimating Persistence on Oral Anti-Diabetic Therapy from Electronic Health Records [13]**

Robert A Greevy, Mary M Huizinga, Christianne L Roumie, Carlos G Grijalva, Harvey Murff, Xulei Liu, Kristen Kotter, Marie R Griffin. (United States)

9:15 am

* **Variability in Measurement of Medication Exposure in Pharmacoepidemiologic Studies of COPD [14]**

Caitlyn T Wilke, Fang-Ju Lin, Todd A Lee, Bruce L Lambert, Min J Joo, A Simon Pickard. (United States)

9:30 am

* **A Framework for Developing a Database of Definitions for Diabetes Mellitus Research [15]**

Jodi B Segal, Suzanne West, Marie R Griffin, Elizabeth Selvin, Patrick O'Conner, Eric B Bass. (United States)

9:45 am

* **Identification of Novel Post-Vaccine Syndromes Using Information Theory [16]**

Alexander M Walker, Gregory W Daniel, Karen Smoyer-Tomic, Tosmai Puenpatom, Tao Gu, Hector Izurieta. (United States)

10:00 am

* **Benefit-Risk Assessment Based on Ordered Clinical Outcomes [17]**

Ola Caster, G Niklas Norén, Love Ekenberg, I Ralph Edwards. (Sweden)

10:15 am

* **Impact of Medicare Claim Resubmissions on Drug and Health Identifiers [18]**

Abraham G Hartzema, Thomas E MaCurdy, Jonathan M Gibbs, Judith A Racoosin, Chris Worrall, Jeffrey A Kelman. (United States)

Sundry (Buckingham)

Moderator: Michael Peng & Kiyoshi Kubota, FISPE

9:00 am

* **Trends of Oseltamivir Usage in the United States During the 2009 Influenza A (H1N1) Pandemic [19]**

John K Iskander, Craig Hales, Charbel El Bcheraoui, Robert T Chen. (United States)

9:15 am

* **Prescribing of Anti-Osteoporotic Therapies Following the Use of Proton Pump Inhibitors in General Practice [20]**

Bernie McGowan, Kath Bennett, Michael Barry. (Ireland)

9:30 am

* **Vaccine Safety: Background Rates of Events of Specific Interest [21]**

J Dieleman, A Hviid, T Kilpi, J Storsaeter, S Mannino, H Heijbel, F de Abajo, C de Vries, G Mazzaglia, K Johansen, P Kramarz, D Weibel, J Bonhoffer, M Sturkenboom. (Netherlands)

9:45 am

* **Tiotropium Use and the Risk of Cerebrovascular Events [22]**

Mendel Haag, Katia Verhamme, Ana Afonso, Charlotte Van Noord, Peter Koudstaal, Miriam Sturkenboom. (Netherlands)

10:00 am

* **Prevalence of Co-Morbidities and Drug Exposure in Patients with Alzheimer's Disease around the Time of Diagnosis [557]**

Patrick Imfeld, Yolanda B Brauchli, Markus Schuerch, Christoph R Meier. (Switzerland)

10:15 am

* **Impact of Regulatory Risk Communication in the Netherlands; 30 Time Series Analyses [24]**

S Piening, K Reber, J Wieringa, S Straus, P de Graeff, F Haaijer-Ruskamp, P Mol. (Netherlands)

AGENDA Friday, August 20

The Brighter Side of Cancer (Balmoral)

Moderators: **Marieke Schoonen & Jim Kaye**

9:00 am

* **Validation of Cancer Diagnoses Recorded in the General Practice Research Database [25]**

Hui Zhang, Tarek A Hammad, Edward Giovannuci, Elizabeth Kang, David C Christiani. (United States)

9:15 am

* **Liver Function Test Abnormalities in Patients Treated with Small Molecule Tyrosine Kinase Inhibitors [26]**

Beth L Nordstrom, Kathy H Fraeman, Weixiu Luo, Sumitra Shantakumar, Sarah H Landis. (United States)

9:30 am

* **High-Ceiling Diuretics Are Associated with an Increased Risk of Basal Cell Carcinoma in a Population-Based Follow-Up Study [345]**

Rikje Ruiter, Loes Visser, Mark Eijgelsheim, Eline Rodenburg, Albert Hofman, Jan-Willem Coebergh, Tamar Nijsten, Bruno Stricker. (Netherlands)

9:45 am

* **Lymphoma among Patients with Atopic Dermatitis Treated with Topical Corticosteroids (TCS) and/or Topical Calcineurin Inhibitors (TCIs) [28]**

Alejandro Arana, Charles W Wentworth, Elena Rivero, Estel Plana, Eulogio Conde. (Spain)

10:00 am

* **Use of Cyclosporine and Risk of Squamous Cell Carcinoma in the Skin: A Population Based Cohort Study in Denmark [29]**

Julie Lavole, Annette Østergaard Jensen, Malene Cramer Engebjerg, Bente Jespersen, Knud Kragballe, Henrik Toft Sørensen. (France)

10:15 am

* **Relative Risk of Bladder Cancer with Pioglitazone for Diabetes Mellitus: Mid-Way Report of a 10-Year Follow-Up Study [30]**

James Lewis, Assiamira Ferrara, Tiffany Peng, Monique Hedderson, Warren Bilker, Charles Quesenberry, Lisa Nessel, Brian Strom. (United States)

popewoodhead

Leading the way in drug development consulting

Pope Woodhead, a benefit/risk consultancy, has provided thought leadership and support services to a wide range of clients in the pharmaceutical and biotech sectors for 25 years.

Risk management – meet your safety, regulatory and commercial objectives

- Pope Woodhead provides risk management services throughout the product lifecycle.
- Development-stage and submission-ready risk management plans, risk mitigation and pharmacovigilance activities.

Drug safety – develop proactive strategies for drug safety

- Pope Woodhead holds knowledge and expertise in all aspects of the drug safety process.
- Drug safety training and safety documentation support.

Regulatory affairs – strategic support for successful filing

- Pope Woodhead has an in-depth understanding of all aspects of global regulatory affairs.
- EU/US filings, regulatory strategy and preparation of expert regulatory documentation.

Visit www.popewoodhead.com or contact Swapu Banerjee, Head of Development Consulting, to discuss your need.
Tel: +44 (0) 1480 300 300. Email: Swapu.Banerjee@popewoodhead.com

AGENDA Friday, August 20

Vaccines in the H1N1 Era (Cambridge)

Moderators: Patricia Saddier & Montserrat Soriano

9:00 am

* **Factors Predictive of H1N1 Influenza Vaccine Uptake among 'At-Risk' Patients in the UK General Practice Research Database [31]**

Cormac Sammon, Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)

9:15 am

* **Background Incidence of Disease for Assessment of Pandemic A/H1N1 Vaccine Safety in Taiwan [32]**

Wan-Ting Huang, Chia-Luen Tsai, Jen-Hsiang Chuang, Cheng-Hua Lee, Shou-Hsia Cheng, Hsu-Sung Kuo. (Taiwan)

9:30 am

* **H1N1 Influenza Vaccine Surveillance Project [33]**

Cheryl Enger, Bruce Turnbull, Robert Gately, Jeanne Loughlin, K Arnold Chan. (United States)

9:45 am

* **Surveillance for Guillain-Barré Syndrome after Influenza Vaccination among the Medicare Population, 2009-2010 [34]**

D Burwen, S Sandhu, T MaCurdy, J Kelman, J Gibbs, B Garcia, M Markatou, R Forshee, R Gullet, H Izurieta, C Worrall, R Ball. (United States)

10:00 am

* **Confounding in Studies of Influenza Vaccination and Mortality in the Elderly [35]**

Amanda R Patrick, M Alan Brookhart. (United States)

10:15 am

* **Effectiveness of One or Two Doses of the Pentavalent Rotavirus Vaccine (RV5) in Preventing Gastroenteritis in the United States [36]**

Florence T Wang, T Christopher Mast, Roberta J Glass, Jeanne Loughlin, John D Seeger. (United States)

10:30-11:00am

Break/Posters/Exhibits (Durham & Hall 7)

SPONSORED BY: CSD - EPIC

11:00-12:00pm

Keynote Address (Oxford)

Moderator: **Stephen J.W. Evans, FISPE**, ISPE President-Elect

Thomas Lönngren, Executive Director, European Medicines Agency

* **The Future of Medicines Regulation: Where Does Pharmacoepidemiology Fit into Risk Management and Comparative Effectiveness Measurement?**

Thomas Lönngren has been the Executive Director of the European Medicines Agency since 1 January 2001. He is currently serving a second five-year term, which expires at the end of 2010. Mr Lönngren qualified as a pharmacist from the University of Uppsala, Sweden, in 1976 and holds an MSc in social and regulatory pharmacy. From 1976-78 he was a lecturer at the same university. He served with the Swedish National Board of Health and Welfare from 1978-90, where his responsibilities included herbal medicines, cosmetics, medical devices, narcotics and contraceptives. From 1982-94, he acted as senior pharmaceutical consultant for the Swedish International Development Agency's health cooperation programme in Vietnam. In 1990 he was appointed Director of Operations of the Swedish Medical Products Agency (MPA), of which he later became the Deputy Director-General. He became an Honorary Member of the Royal Pharmaceutical Society of Great Britain in 2003 and was made an Honorary Fellow of the Royal College of Physicians in 2004. He was granted an Honorary Doctorate from the University of Uppsala in January 2008, and received the Drug Information Association's Distinguished Career Award in March 2008.

12:00pm-1:30pm

Lunch/Poster Session A/Exhibits

(Durham, Durham Gallery, Hall 7 & 8)

SPONSORED BY ACADEMIC SUPPORTERS (listed on page 6)

ISPE Committee/Council Meetings

—Open to all participants.

- * **Development Committee** (Lancaster)
- * **Fellowship & Awards Committee** (Hilton 3)
- * **Public Policy Comm.** (Buckingham)
- * **Student Council** (Ambassador)

1:30-3:00pm

EMA Scientific Debate (Oxford)

CO-SPONSORED BY ISPE & EMA

Motion: *Results from epidemiology and pharmacoepidemiology studies mislead the public because of a failure to adjust for multiple comparisons. Journals should not publish studies that do not account for multiplicity.*

* **For the motion:**

Stan Young, National Institutes of Statistical Sciences, USA
Stuart Pocock, London School of Hygiene and Tropical Medicine, UK

* **Against the motion:**

Sonia Hernández-Díaz, FISPE, Harvard School of Public Health, USA
Kenneth J. Rothman, FISPE, RTI Health Solutions, USA

AGENDA Friday, August 20

3:00-3:30pm

Break/Posters/Exhibits (Durham & Hall 7)

3:30-5:00pm

Concurrent Sessions: Symposia And Workshops

Methodological Challenges in Cross-National Comparisons of Drug Utilization [37] (Balmoral)

SPONSORED BY THE DRUG UTILIZATION / HEALTH SERVICES RESEARCH SIG

- * Björn Wettermark, Monique Elseviers, Brian Godman, Marit Rønning, Lesley Tilson, Vera Vlahovic Palcevski. (Sweden)

Methodological Controversies from Comparative Effectiveness (CE) Studies Using Claims vs. Electronic Health Record (EHR) Data [38] (Cambridge)

- * Soko Setoguchi, Nirav Shah, Jason Roy, Wolfgang Winkelmayr, Robert Glynn. (United States)

Ascertaining the Use of Biologics [39] (Dukes)

SPONSORED BY THE BIOLOGICS SIG

- * Thijs Giezen, Judith Jones, Will Dixon, Michael Taylor, Bert Leufkens, Earl Goehring. (Netherlands)

Guidance Regarding the Identification, Development, Validation and Translation of Coding Algorithms in Electronic Healthcare (EH) Databases [40] (Hall 4)

SPONSORED BY THE DATABASE SIG

- * Vinay Mehta, Robert J Locasale, Matthew W Reynolds, Rhonda L Bohn, Gianluca Trifiro, Tami L Mark. (United States)

Identifying the Genetic Basis of Serious Adverse Events: Will High-Profile Genome-Wide Association (GWA) Studies Improve Drug Safety in the Next Decade? [41] (Buckingham)

JOINTLY SPONSORED BY THE MEBPHARMACOGENOMICS SIG & ISAEC

- * Anke-Hilse Maitland-van der Zee, Andrew Freedman, Ann K Daly, Arthur Holden. (Netherlands)

Identification and Classification of Birth Defects in Pharmacoepidemiology: A Comparison of Approaches [42] (Clarence)

SPONSORED BY THE MEDICATIONS IN PREGNANCY SIG

- * L de Jong-van den Berg, H Dolk, E Andrews, S Hernandez-Diaz, A Mitchell, C de Vries. (Netherlands)

The Public Health Burden of Acetaminophen Poisonings: Risk Management Efforts To Mitigate It [575] (Ambassador)

- * Syed Rizwanuddin Ahmad, June Raine, Keith Hawton, Gerald Dal Pan. (United States)

5:00-6:00pm

ISPE Council Meetings

–Open to all interested participants

- * **Academic Council** (Hall 4)
- * **Government/Regulatory Council** (Hilton 3)
- * **Industry/Service Providers Council** (Lancaster)

6:00pm-7:00pm

General Assembly/European Chapter of Drug Utilization/Health Services Research SIG (Ambassador)

7:00-9:00pm


PDS Editorial Board

–By Invitation

7:00pm- ?

Student Social Event – A Night Out in Brighton

- Open to all students.
- Organized by the ISPE Student Council
- Assemble at ICPE Registration Desk, then walk to Al Duomo.



AGENDA Saturday, August 21

7:00am-6:00pm
Registration
(Sussex Lounge)

7:00am-5:00pm
Speaker Ready Room (Office 1)

7:00-8:00am
Poster Session B Set-up
(Durham & Hall 7)

8:00am-6:00pm
Exhibits/Posters
(Durham & Hall 7)

8:30-10:00am

Concurrent Sessions: Contributed Papers

CNS: The Brain and the Heart (Balmoral)

Moderators: **Nadia Foskett & Cristina Varas-Lorenzo**

8:30 am

* **Risk of Heart Failure with Dopamine Aganist Use in Parkinson's Disease [237]**

G Trifirò, M Mokhles, J Dieleman, E van Soest, G Mazzaglia, R Herings, C de Luise, D Ross, G Brusselle, A Colao, W Haverkamp, R Schade, G van Camp, R Zanettini, M Sturkenboom. (Netherlands)

8:45 am

* **Serum Cholesterol Levels and Risk of Parkinson's Disease [238]**

Stephen K Van Den Eeden, Jun Shan, Charles P Quesenberry. (United States)

9:00 am

* **The Effect of Antidepressants on Cardiovascular Morbidity and Mortality in Older Adults: A Population-Based Cohort Study [239]**

Gregory L Kennedy, Kristan Aronson, Linda E Levesque. (Canada)

9:15 am

* **Use of Serotonergic Medications and Cardiac Valvulopathy: A Nested Case-Control Study in the Health Improvement Network (Thin) Database [240]**

Annalisa Rubino, Francesco Lapi, Federica Nicotra, Antonella Zambon, Lorenza Scotti, Mary Thompson, Alfredo Vannacci, Giovanni Corrao, Alessandro Mugelli. (Italy)

9:30 am

* **Antipsychotics and the Risk of Sudden Cardiac Death and Ventricular Arrhythmia [241]**

Charles E Leonard, Warren B Bilker, Craig Newcomb, Stephen E Kimmel, Brian L Strom, Sean Hennessy. (United States)

9:45 am

* **Risk of Death and Major Medical Events Associated with Psychotropic Medications in Patients Newly Admitted to Nursing Homes [242]**

Krista Huybrechts, Kenneth J Rothman, Rebecca Silliman, M Alan Brookhart, Sebastian Schneeweiss. (United States)

Mapping and Validating Critical Data Elements (Cambridge)

Moderators: **Rhonda Bohn, FISPE & Marianne Ulcickas Yood**

8:30 am

* **Validating Pneumonia Hospitalizations in the THIN Database [243]**

Sharon B Meropol, Joshua P Metlay. (United States)

8:45 am

* **Validity of Claims-Based Definitions of Impaired Left Ventricular Systolic Function in Medicare Patients [244]**

Qian Li, Robert J Glynn, Nancy A Dreyer, Jun Liu, Helen Mogun, Soko Setoguchi. (United States)

9:00 am

* **Implementing and Evaluating Standard Cohort Definitions across Disparate Databases [245]**

Stephanie Reisinger, Patrick Ryan, Richard Murray. (United States)

9:15 am

* **Validation of the Health Improvement Network (THIN) Database for Epidemiologic Studies of Chronic Kidney Disease [246]**

Michelle R Denburg, Kevin Haynes, Justine Shults, James Lewis, Mary B Leonard. (United States)

9:30 am

* **Automated Classification of Free Text Electronic Health Records for Epidemiological Studies [247]**

Martijn J Schuemie, Emine Sen, Eva M van Soest, Miriam C Sturkenboom, Jan A Kors. (Netherlands)

9:45 am

* **Comparing Bias of Two Different Instrumental Variable (IV) Approaches with Logistic Regression [190]**

Bing Cai, Dylan S Small, Sean Hennessy, Thomas R Ten Have. (United States)

Celgene Corporation is proud to sponsor the 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Committed to improving the lives of patients worldwide®

Celgene shares ISPE's dedication to enhancing public health through the creation of critical and innovative safety and risk management programs in areas of great medical need

www.celgene.com



AGENDA Saturday, August 21

Miscellaneous (Buckingham)

Moderators: Susan Olivera, FISPE & John Logie

8:30 am

- * **A Propensity Score Adjusted Cohort Study To Measure the Impact of Statin Therapy on Short-Term Mortality Following a Pneumonia Episode [464]**

Ian J Douglas, Liam Smeeth, Stephen J Evans. (United Kingdom)

8:45 am

- * **Assessment of the Cost-Effectiveness of Pharmacogenomic Diagnostics for Breast Cancer [250]**

Mo Yang, Amalia Issa. (United States)

9:00 am

- * **The Epidemiology of HIV-1 Co-Receptor Tropism in Patients Infected with Non-Clade B HIV from India, Uganda and South Africa [251]**

Anna Greenacre, Quazi Ataher, Simon Portsmouth, Randy Tressler, Sybil Eng. (United States)

9:15 am

- * **Cohort Studies in Chronic Diseases Using Routinely Collected Databases When a Prescription Is Used as Surrogate Outcome [252]**

Sara Lodi, James Carpenter, Stephen Evans. (United Kingdom)

9:30 am

- * **Methodological Challenges When Applying ICD-10 Codes to Research Data: Findings from the Post-Hoc Endpoint Readjudication of Sudden Death for the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC) Large Simple Trial [253]**

Jamie Geier, Onur Karayal, Michael Lewis, John Camm, Martin Keane, Charlotte Kremer, Sheela Kolluri, Robert Reynolds, Brian L Strom. (United States)

9:45 am

- * **Potential Ascertainment Bias in Assessment of Obesity and Smoking History and Its Impact on Type 2 Diabetes Disease in the General Practice Research Database [254]**

Tzuyung D Kou, Kimberly G Brodovicz, Charles Alexander, Leonid Katz, Cynthia J Girman. (United States)


SAFETYWORKS

Rapid. Observational. Pharmacovigilance.

From ProSanos Corporation

Signal Detection and Evaluation in any Observational Database

- » Standardized Approach
- » Robust and Transparent Analytic Methodology
- » Interactive Workflow
- » Familiar Vocabulary
- » Saves Time and Money



FOR MORE INFORMATION, PLEASE VISIT US TODAY AT WWW.PROSANOS.COM

NSAIDs and Associated Treatments (Dukes)

Moderators: **Jordi Castellsague & Tobias Gerhard**

8:30 am

- * **Concordance of Nonsteroidal Anti-Inflammatory Drug Prescriptions with Recent Clinical Practice Guidelines in Quebec, Canada [255]**
Elham Rahme, Jean-Philip LaFrance, Jean-Pascal Roussy, Suzanne Morin. (Canada)

8:45 am

- * **Adherence to Proton Pump Inhibitors and the Risk of Upper Gastrointestinal Complications in Coxib Users [256]**
V Valkhoff, E van Soest, G Mazzaglia, R Schade, M Molokhia, J Dieleman, M Sturkenboom. (Netherlands)

9:00 am

- * **Factors Associated with Proton Pump Inhibitor Discontinuation in Nursing Homes [257]**
Amy Linsky, John A Hermos, James L Rudolph, Elizabeth V Lawler. (United States)

9:15 am

- * **Cyclooxygenase (COX)-2 Selective and Non-elective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Risk of Hyperkalemia [258]**
Jean-Philippe Lafrance, Donald R Miller. (Canada)

9:30 am

- * **Nonsteroidal Anti-Inflammatory Drug Use and Risk of Atrial Fibrillation or Flutter: A Population-Based Case-Control Study [259]**
Morten Schmidt, Christian F Christiansen, Frank Mehnert, Kenneth J Rothman, Henrik Toft Sørensen. (Denmark)

9:45 am

- * **Pain Relief Medication Following Cessation of Co-Proxamol Use: An Analysis Using the GPRD [260]**
David Irvine, Jakob Petersen, Lesley Wise. (United Kingdom)

P4M: Pharmacogenomics, Predictors, Prognosis, and Personalised Medicine (Clarence)

Moderators: **Geoff Liu & Joanna Haas**

8:30 am

- * **Single Nucleotide Polymorphisms (SNPs) in the Matrix Metalloproteinase (MMP) Gene Family, Gastroesophageal Reflux Disease (GERD), and Risk of Esophageal Adenocarcinoma (EAC) [261]**
Winson Y Cheung, Rihong Zhai, Matthew Kulke, Rebecca Heist, Kofi Asomaning, Clement Ma, Zhaoxi Wang, Li Su, Geoffrey Liu, David Christiani. (Canada)

8:45 am

- * **Analysis of Proteomic Biomarkers for Acute Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Non-Small Cell Lung Cancer (NSCLC) Patients [262]**
Fredrik Nyberg, Atsushi Ogiwara, Chris G Harbron, Takao Kawakami, Yasuhiko Komatsu, Toshihide Nishimura, György Marko-Varga. (Sweden)

9:00 am

- * **Integrating Pharmacogenetics into Clinical Trials: Implications for Sample Size to Test Gene-Drug Interactions [263]**
Kimberly A Lowe. (United States)

9:15 am

- * **Results of the First European Genome-Wide Association Study of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [264]**
Emmanuelle Genin, Peggy Sekula, Diana Zelenika, Mark Lathrop, Martin Schumacher, Jean-Claude Roujeau, Maja Mockenhaupt, Regiscar Group. (Germany)

9:30 am

- * **Pharmacogenetic-Based Warfarin Dosing: Simplified Pharmacogenetic Tables vs. Pharmacogenetic Algorithms [265]**
Brian S Finkelman, Brian F Gage, Julie A Johnson, Colleen M Brensinger, Stephen E Kimmel. (United States)

9:45 am

- * **The PCSK9 E670G Polymorphism Modifies the Effectiveness of Statins in Reducing the Risk of Myocardial Infarction [266]**
B JM Peters, H Pett, A de Boer, O H Klungel, A H Maitland-van der Zee. (Netherlands)

AGENDA Saturday, August 21

Risk Management: Are We Taking the Bull by the Horn? (Oxford)

Moderator: **Klaas Heinemann & June Raine**

8:30 am

* **Additional Safety Risk to Exceptionally Approved Drugs in EU? [267]**

A H Arnardottir, F M Haaijer-Ruskamp, S M Straus, P A de Graeff, P G Mol. (Netherlands)

8:45 am

* **One Year after: The EU Strategy for Epidemiological Monitoring of Pandemic H1N1 Vaccines [268]**

X Kurz, A Hidalgo-Simon, K Johansen, B Ciancio, A Nicoll, P Arlett. (United Kingdom)

9:00 am

* **Not-in-Trial Simulation: Predicting Cardiovascular Risk from Clinical Trial Data [269]**

Anne Chain, Jeanne Dieleman, Meindert Danhof, Bruno Stricker, Jacqueline Witteman, Oscar Della Pasqua, Miriam Sturkenboom. (Netherlands)

9:15 am

* **Increasing the Benefit of EU Risk Management Plans (EU-RMPs) – Is There Room for Improvement? [270]**

Steve Mayall, Carol Walton, Aruna Jeans, Mazhar Thakur, Simon Ingate, Swapu Banerjee. (United Kingdom)

9:30 am

* **Charting a New Course in Long-Term Safety: The Critical Role of Cancer Registries [271]**

Alicia W Gilsean, Elizabeth B Andrews, Kirk D Midkiff, Amy Ladner. (United States)

9:45 am

* **Assessing the Effectiveness of an IT-Based Pharmacist-Led Intervention Aimed at Reducing Proportions of Patients at Risk of Medication Errors in Family Practice: The Pincer Trial [272]**

Anthony J Avery, Sarah Rodgers, Judith A Cantrill, Sarah Armstrong, Martin Eden, Denise Kendrick, Aziz Sheikh. (United Kingdom)

10:00-10:30am

Break/Posters/Exhibits (Durham & Hall 7)



Our Swiss-American story of success

Roche and Genentech have successfully teamed up. It is our shared ambition to change the practice of medicine with novel approaches. Together, we provide millions of patients with the best results of our cooperation: Innovative medicines that help fight severe diseases and improve patients' lives.

Roche

We Innovate Healthcare

The Only Global CRO Dedicated Exclusively to Late Phase Research

Pharmaco-epidemiology, Risk Management and Drug Safety



Visit REGISTRAT-MAPI at Booth #18

- Global Reach
- Unique Solutions
- Flexible Technology
- Customized Services
- Scientific Expertise

AGENDA Saturday, August 21

10:30am-12:00pm

Concurrent Sessions: Contributed Papers

Clinically Important Public Health Issues and New Insights in Rare Diseases (Dukes)

Moderators: Judith Jones, FISPE & Michael Taylor

10:30 am

* **Prevalence, Predictors, and Treatment of Very High Triglycerides in US Adults: NHANES 2001 – 2006 [273]**

Jennifer B Christian, Nancy E Bourgeois, Rose G Snipes. (United States)

10:45 am

Frequency and Risk Factors of Gout Flares in a Large Population-Based Cohort of Incident Gout [274]

* Dietrich Rothenbacher, Paola Primatesta, Alberto Ferreira, Lucia Cea Soriano, Luis A Garcia Rodriguez. (Switzerland)

11:00 am

* **Avascular Osteonecrosis in Untreated Patients with Type I Gaucher Disease [275]**

Pramod K Mistry, Patrick Deegan, Ashok Vellodi, J Alexander Cole, Michael Yeh, Neal J Weinreb. (United States)

11:15 am

* **Catheter-Related Complications in Patients with Central Venous or Hemodialysis Catheters [276]**

Pavel Napalkov, Diana Felici, Laura Chu, Joan Jacobs, Susan M Begelman. (United States)

11:30 am

* **The Incidence of Ischemic and Hemorrhagic Stroke in Pediatric Patients [277]**

Pavel Napalkov, Diana Felici, Laura Chu. (United States)

11:45 am

* **Hemoglobinuria, Hemoglobinemia, and Renal Impairment in ITP Patients [278]**

Fei Xue, Chuck Wentworth, Vanitha Ganesh, Victor Gastanaga, Gail Hughes, Scott Stryker, Steven Cha, Sean Zhao. (United States)

CNS: Potpourri (Oxford)

Moderators: Suellen Curkendall & Jessica Jalbert

10:30 am

* **Switching of Antiepileptic Drugs and Seizure-Related Events after Refill Adjustment [279]**

Joshua J Gagne, Jerry Avorn, William H Shrank, Sebastian Schneeweiss. (United States)

STUDENT AWARD RECIPIENT – THIRD BEST ABSTRACT

10:45 am

* **Anticonvulsant Medications and the Risk of Suicide, Attempted Suicide, and Injury or Accident Related Death [280]**

Elisabetta Patorno, Rhonda Bohn, Peter Wahl, Jerry Avorn, Amanda Patrick, Jun Liu, Sebastian Schneeweiss. (United States)

11:00 am

* **Risk of Cataract in Patients with Multiple Sclerosis: A Population-Based Cohort Study [612]**

S Müller-Schotte, M Bazelier, T P van Staa, HGM leufkens, F de Vries. (Netherlands)

STUDENT PRIZE RECIPIENT – SECOND BEST ABSTRACT

11:15 am

* **Use of Antidepressant Drugs and Risk of Osteoporotic and Non-Osteoporotic Fractures: Focus on the Affinity for the Serotonin Receptor [282]**

Bertha Maria Verdel, Patrick C Souverein, Toine CG Egberts, Tjeerd P van Staa, Hubert GM Leufkens, Frank de Vries. (Netherlands)

11:30 am

* **Risk of Bleeding with Combined SSRI and Antiplatelet Therapy in Patients Following Myocardial Infarction [283]**

Christopher Labos, Kaberi Dasgupta, Elham Rahme. (Canada)

11:45 am

* **Comparative Effectiveness of Antipsychotic Medications for the Treatment of Behavioral and Psychological Symptoms of Dementia [284]**

Tobias Gerhard, Edmond S Malka, Judith Lucas, Krista Huybrechts, Sebastian Schneeweiss, Stephen Crystal. (United States)

AGENDA Saturday, August 21

Methods in Pregnancy Studies: Practical Applications (Cambridge)

Moderators: **Deborah Covington & Alicia Gilsenan**

10:30 am

* **Recording of Pregnancy Losses on the General Practice Research Database [285]**

Rachel Charlton, Julia Snowball, John Weil, Marianne Cunnington, Corinne de Vries. (United Kingdom)

10:45 am

* **Drug Certainty-Response in Interview-Based Studies [286]**

Kuei-Yu Lin, Wai-Ping Yau, Allen A Mitchell, Sonia Hernández-Díaz. (United States)

11:00 am

* **Maternal Use of Macrolide Antibiotics and the Risk of Congenital Heart Defects [287]**

Kuei-Yu Lin, Allen A Mitchell, Wai-Ping Yau, Sonia Hernández-Díaz. (United States)

11:15 am

* **Validity of an Algorithm for the Identification of Premature Infants Using Medicaid Administrative Data [288]**

Efe Odia, Christian Hampp, Almut G Winterstein. (United States)

11:30 am

* **Differing Strategies for Analyzing Multiple Gestation Pregnancies in Pregnancy Registries: Impact on Birth Defect Rates [289]**

Carl deMoor, Deborah Covington, Amanda Golembesky. (United States)

11:45 am

* **Comparative Safety of Topiramate During Pregnancy [290]**

Sonia Hernandez-Diaz, Robert Mittendorf, Lewis B Holmes. (United States)

Answers

Wouldn't it be wonderful if you always had the best information to help you take care of yourself?

If you could count on having reliable answers for those times when your health is a concern?

If you could be assured breakthrough medicines would continue to be sought?

We think that would be wonderful, too. And we're working to make it happen. Your good health is our passion.

MG36735-6/7 PRINTED IN USA ©2010, Lilly USA, LLC. ALL RIGHTS RESERVED.

lilly.com


Answers That Matter.

AGENDA Saturday, August 21

Pharmacovigilance - Needles in Haystacks? (Balmoral)

Moderators: **Andrez Czarnecki, FISPE, & Marieke de Bruin**

10:30 am

* **Vaccine Signal Detection: A Pilot To Determine Effects of Varying Data Mining Strategies on VAERS [291]**

Steven R Bailey, Robert Azadian, Peter Huber. (United States)

10:45 am

Substantiation of Drug Safety Signals: Taking Automated Signal Detection a Step Further [292]

A Bauer-Mehren, E van Mulligen, P Avillach, P Coloma, R Garcia-Serna, R Herings, M Sturkenboom, S Boyer, F Sanz, J Mestres, J Kors, L Furlong. (Spain)

11:00 am

Ongoing Monitoring in Active Surveillance: A Case Study in Performance of Observational Screening over Time [293]

Patrick B Ryan, Gregory E Powell, Ed N Pattishall. (United States)

11:15 am

Polyethylene Glycol and Acute Renal Failure in Elderly: Data-Mining Study Using National Health Insurance Claims Database [294]

Nam-Kyong Choi, Yu-Kyong Choi, Sun-Young Jung, Yoosoo Chang, Ju-Young Kim, Hong-Ji Song, Joongyub Lee, Byung-Joo Park. (Republic of Korea)

11:30 am

* **Evaluation of a Proposed Classification System for Adverse Drug Reactions for Biologicals Using The WHO-ADR Database VigiBase [295]**

Thijs Giezen, Aukje Mantel-Teeuwisse, Sabine Straus, Bert Leufkens, Toine Egberts. (Netherlands)

11:45 am

* **The Contribution of Patient Reporting To Signal Detection in the Netherlands [296]**

Florence van Hunsel, Eugene van Puijenbroek, Kees van Grootheest. (Netherlands)

Potpourri (Buckingham)

Moderators: **Susana Perez Gutthann, FISPE, & Usha Gungabissoon**

10:30 am

* **Genetic Polymorphisms and the Development of Secondary Primary Cancers (SPC) in Patients with Head and Neck Cancer (HNC) [297]**

Abul K Azad, Dangxiao Cheng, Wei Xu, Elodie Samson, Maryam Mirshams, Sevtap Savas, Zhuo Chen, John Waldron, Geoffrey Liu, Francois Meyer, Isabelle Bairati. (Canada)

10:45 am

* **Race, Oxaliplatin Use, and Treatment Outcomes for Stage III Colon Cancer among Elderly Medicare Patients [298]**

Christina D Mack, William Carpenter, Til Stürmer. (United States)

11:00 am

* **Can Tricyclic Antidepressant Use Explain the Observed Associations between Baseline Depressive Symptoms and Incident Hypertension? [299]**

Joseph AC Delaney, Bruce E Oddson, Holly Kramer, Steven Shea, Bruce M Psaty, Robyn L McClelland. (United States)

11:15 am

* **Safety Profile of Thiazolidinediones on the Basis of the FDA-AERS Database: Cardiovascular and Bone Fracture Risks for Rosiglitazone and Pioglitazone [300]**

Domenico Motola, Elisabetta Poluzzi, Anna Marra, Chiara Biagi, Carlo Piccini, Nicola Montanaro. (Italy)

11:30 am

* **Risk of Fracture in Patients with Multiple Sclerosis: The General Practice Research Database [301]**

Marloes Bazelier, Tjeerd van Staa, Hubert Leufkens, Peter Vestergaard, Frank de Vries. (Netherlands)

11:45 am

* **Patterns of Antipsychotic (APM) Initiation in US Nursing Homes [302]**

Judith A Lucas, Sujoy Chakravarty, John R Bowblis, Tobias Gerhard, Michele Siegel, Ece Kalay, Stephen Crystal. (United States)

AGENDA Saturday, August 21

Prescribing Problems in Older Persons (Clarence)

Moderators: Keith Beard, FISPE, & Kevin Haynes

10:30 am

- * **Drug Related Problems among Elderly Patients Using Five or More Chronic Drugs Who Are Discharged from the Hospital [303]**
Abeer Ahmad, Jacqueline Hugtenburg, Ruth Mast, Laura MC Welschen, Jacqueline M Dekker, Giel Nijpels. (Netherlands)

10:45 am

- * **Adverse Outcomes Associated with Potential Prescribing Cascades [304]**
Gillian Caughey, Elizabeth Roughead, Nicole Pratt, Sepehr Shakib, Agnes Vitry, Andrew Gilbert. (Australia)

11:00 am

- * **Treatment with Cholinesterase Inhibitors May Increase the Risk of Urinary Incontinence [305]**
Edeltraut Kröger, Rob van Marum, Patrick Souverein, Pierre-Hugues Carmichael, Toine Egberts. (Netherlands)

11:15 am

- * **Use of Opioids or Benzodiazepines and Risk of Pneumonia in Older Adults [306]**
Sascha Dublin, Rod L Walker, Michael L Jackson, Jennifer C Nelson, Noel S Weiss, Michael Von Korff, Lisa A Jackson. (United States)

11:30 am

- * **Major Bleeding Risk Associated with Warfarin and Co-Medications in the Elderly Population [307]**
Agnes I Vitry, Elizabeth E Roughead, Emmae N Ramsay, Adrian K Preiss, Gillian E Caughey, Andrew L Gilbert, Philip Ryan. (Australia)

11:45 am

- * **A Randomized Trial of a Warfarin Management Protocol To Enhance Communication between Nursing Home Staff and Physicians: The SBAR Approach [308]**
Terry S Field, Jennifer Tjia, Kathleen M Mazor, Jennifer L Donovan, Abir O Kanaan, Leslie R Harrold, Peter Doherty, Ann Spenard, Jerry H Gurwitz, George Reed. (United States)

12:00-1:30pm

Lunch/Poster Session B/Exhibits

(Durham, Durham Gallery, Hall 7 & 8)

ISPE Committee Meetings

–Open to all participants.

–Lunches will be available in meeting rooms

- * **Bylaws and Policies Committee** (Sandringham)
- * **External Communications Committee** (Hilton 3)
- * **Global Development Committee** (Lancaster)
- * **Membership Committee** (Osborne)
- * **Publications Committee** (Surrey 1)

12:45-1:30pm

Poster Walks (Durham/Hall 7)

- * **Biologic SIG**
- * **Comparative Effectiveness Research SIG**
- * **Database SIG**
- * **Drug Utilization SIG**
- * **Medicines in Pregnancy SIG**
- * **Molecular Epidemiology - Biomarkers -Pharmacogenetics SIG**

1:30-2:30pm

Plenary Session

Moderator: **Bert Leufkens, FISPE**, Chairman of the Dutch Medicines Evaluation Board & Professor of Pharmacoepidemiology, University of Utrecht

Professor Jan P. Vandenbroucke, University of Leiden, The Netherlands (Oxford)

- * **Benefits and Risks of Drug Treatments: How to Combine the Best Evidence on Benefits with the Best Evidence on Harms?**



AGENDA Saturday, August 21

2:30-3:30pm

–Open to all participants.

Annual Meeting of ISPE Members, Awards Ceremony (Oxford)



Annual Meeting of ISPE Members

- * Sebastian Schneeweiss, FISPE, ISPE President
- * Nancy Dreyer, FISPE, ISPE Vice President Finance

Awards Ceremony

ICPE 2010

Student Awards

- * Presented by **Corinne S. de Vries, FISPE**,
Chair, 2010 Scientific Program Committee
- Best Drug Utilization Abstract:* **Krista Huybrechts**
- Third Best Abstract:* **Joshua Gagne**
- Second Best Abstract:* **Sigrid Müller-Schotte**
- Etlavitch Award (Best Student Abstract) & Oral Presentation:*
Caitlyn T. Wilke, *Sensitivity of Hazard Estimates to Exposure Definition:
A Simulation Study (309)*

Induction of ISPE Fellows (FISPE)

- * **Sebastian Schneeweiss, FISPE**, ISPE President
- Inductees:*
Corinne S. de Vries, FISPE **Susan Ann Oliveria, FISPE**
Stephen JW Evans, FISPE **Miriam CJM Sturkenboom, FISPE**
Kiyoshi Kubota, FISPE **Douglas J. Watson, FISPE**
- * **Miriam Sturkenboom, FISPE**, Chair, Fellowship & Awards Committee
- Honorary Lifetime Fellow*
Ronald D. Mann, FISPE

Pharmacoepidemiology & Drug Safety

ISPE-PDS Prizes for Best Papers published in PDS Volume 18 (2009)

- Brian Strom, FISPE**, Editor-in-Chief
- Joerg Hasford**, Regional Editor for Europe
- Richard Hughes**, Managing Editor, Pharmacoepidemiology & Drug Safety (PDS)
- Ronald Mann, FISPE**, Founding Editor
- Sean Hennessy, FISPE**, Regional Editor for the Americas
- B J Park, FISPE**, Regional Editor for Asia, Africa, Oceania

Installation of New President

- * **Stephen JW Evans, FISPE**

3:30-4:00pm

Break/Posters/Exhibits (Durham & Hall 7)

4:00-5:30pm

Concurrent Sessions: Symposia And Workshops

Optimizing Global Vaccine Safety Monitoring: Lessons Learned from H1N1 [310] (Hall 4)

- * **Jan Bonhoeffer, Miriam Sturkenboom, Xavier Kurz, Piotr Kramarz, Patrick Zuber, Hector Izurieta.** (Switzerland)

Matching on Propensity Scores: Good Practices and New Directions [311] (Balmoral)

- * **Jeremy A Rassen, Robert J Glynn, Mark Lunt, Kenneth Rothman.** (United States)

Regulatory Risk Communication Are We Getting Ahead? [312] (Oxford)

- * **P Mol, P Bahri, J Avorn, P Benkimoun, A Arias, E Morrato, G del Pan, F Haaijer-Ruskamp, S Straus.** (Netherlands)

Role of Meta-Analysis in Drug Safety: Methodological Considerations and Regulatory Implications [313] (Buckingham)

- * **Tarek Hammad, Simone P Pinheiro, David Irvine, Steven Kesten.** (United States)

The Panacea of Study Designs in Pharmacoepidemiology: Which One? Antipsychotics and Myocardial Infarct in the Demented Elderly Population [314] (Dukes)

- * **Yola Moride, Antoine Pariente, Anne Fourrier, Thierry Ducruet, Patrick Farrington.** (Canada)

How Can Better Scientific Methods Result in Better Drug Regulation – Two Recent Case Studies [315] (Clarence)

- * **Marie L De Bruin, Stella Blackburn, Ingemar Persson, Jeremy Rassen, Lamiae Grimaldi.** (Netherlands)

Evaluating Adverse Pregnancy Outcomes – A Workshop To Develop an Inventory of Methodological Issues Related to Different Approaches [780] (Ambassador)

- * **L de Jong-van den Berg, H Dolk, E Andrews, S Hernandez-Diaz, A Mitchell, C de Vries.** (Netherlands)



minimized risk

Safety & Risk Management

UBC understands that the greatest risk is the unknown. We help clients assess, identify and plan for risk by developing and implementing Risk Evaluation and Mitigation Strategies (REMS), Risk Management Plans, epidemiology studies, registries and large simple safety studies globally. All of our solutions are designed and executed by industry-leading experts to assess and demonstrate product safety, mitigate risk and meet regulatory requirements.

UBC is a global scientific and medical affairs organization that partners with life science companies to develop and commercialize their products. We bring together scientific experts, research professionals and new technologies to generate authoritative, real-world evidence of product effectiveness, safety and value.



United BioSource Corporation

Evidence Matters®

US +1 866 458 1096
EU +44 (0) 207 299 4550
unitedbiosource.com

AGENDA Saturday, August 21

5:30-6:30pm

Special Interest Group (SIG) Meetings

–Open to all participants.

- * **Biologics SIG** (Ambassador)
- * **Comparative Effectiveness Research SIG** (Balmoral)
- * **Database SIG** (Buckingham)
- * **Drug Utilization/Health Services Research SIG** (Cambridge)
- * **Medications in Pregnancy SIG** (Clarence)
- * **Molecular Epidemiology/Biomarkers/Pharmacogenetics SIG** (Dukes)

7:30-Midnight

Evening at the Corn Exchange/Brighton Dome



Early in their career, ABBA was looking for what every pop group is looking for: that one magic moment that would give them the boost needed to catapult them to rock stardom. They found it at the Brighton Dome during the Eurovision Song Contest (1974). As the final notes of their song "Waterloo" echoed through the packed auditorium, the Swedish group had officially arrived. They ultimately won the Eurovision Song Contest, achieving a stunning upset against favorite contender Olivia Newton-John. ABBA went on to become Sweden's most successful pop rock group, and continues to charm music lovers to this day. Join your colleagues to relive those golden moments with Abba's Angels – one of the UK's premier tribute bands!

–Admission is by badge or ticket. Cash bar

Cutting edge epidemiology contributing to the discovery and development of safe and effective medicines

We are a global team of epidemiologists and other professionals that bring population-based evidence on disease and treatment to influence decision-making from drug discovery through development to medical practice. By designing, analyzing, and interpreting observational information from a public health perspective we play an important role in bringing new medicines to the market. The breadth of our responsibilities includes:

- Analyzing the occurrence and distribution of diseases, including underlying disease process
- Determining the burden of illness and unmet medical need
- Exploring traditional and new risk factors for diseases
- Evaluating the effect of treatment in the real world, including beneficial effects, patterns of drug uses and adverse events
- Detecting opportunities for possible new drug uses and new paths of drug development

Please visit our website at <http://epidemiology.gsk.com/organization.html> to find out more detailed information about Worldwide Epidemiology at GlaxoSmithKline.

Developing talent through equality of opportunity





BAYER SCHERING PHARMA AG

Expanding it's Epidemiology Organization around the World

Bayer Schering Pharma AG, division of Bayer HealthCare, is one of the ten largest specialty pharmaceutical companies in the world. We market our products in more than 100 countries, and generated total net sales of about € 10.5 billion in 2009.

More than 36,000 employees – with more than 5,800 of them in research and development – work for Bayer Schering Pharma around the world.

We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs and novel therapeutic approaches in four core areas: General Medicine, including oncology and cardiovascular diseases, Specialty Medicine, Women's Healthcare and Diagnostic Imaging. In addition, our clinical development drives the introduction of new products as well as the further development of marketed products across all business areas. Our top 10 products are:

- YAZ® / Yasmin® / Yasminelle® (hormonal contraceptive)
- Betaferon®/Betaseron® (multiple sclerosis)
- Kogenate® (hemophilia)
- Adalat® (high blood pressure)
- Nexavar® (kidney and liver cancer)
- Mirena® (hormonal intrauterine delivery system for contraception)
- Avalox®/Avelox® (respiratory tract infections)
- Levitra® (erectile dysfunction)
- Cipro®/ Ciprobay (infectious diseases, especially of the urinary tract)
- Glucobay® (diabetes)

Our Global Epidemiology organization is currently expanding its team around the world. Opportunities for Global Epidemiology Directors and Professionals exist in Berlin, Beijing, and New Jersey. To learn more, visit at our booth no 26.

You can also contact: Melanie Wolff at + 49 171 6222507 (melanie.wolff@bayerhealthcare.com) or Montse Soriano-Gabarro (montse.soriano-gabarro@bayerhealthcare.com)

For Information about Bayer Schering Pharma go to

<http://www.bayerscheringpharma.de/scripts/pages/en/index.php>.

Bayer is an equal opportunity employer, embracing diversity throughout our global workforce.

AGENDA Sunday, August 22

7:30am-4:30pm
Registration
(Sussex Lounge)

7:30am-3:30pm
Speaker Ready Room (Office 1)

7:00-8:00am
Poster Session C Set-up
(Durham & Hall 7)

8:00am-1:45pm
Exhibits/Posters
(Durham & Hall 7)

8:30-10:00am

Concurrent Sessions: Contributed Papers

Bias and Confounding: Methods for Control Freaks (Oxford)

Moderators: Til Stürmer, FISPE & Alan Brookhart

8:30 am

* **Conceptualizing Confounding by Measured and Unmeasured Covariates in Pharmacoepidemiology with Directed Acyclic Graphs (DAGs) [500]**

Aisling R Caffrey, Kerry L LaPlante, Brian J Quilliam. (United States)

8:45 am

* **Impact of Collider-Stratification Bias (M-bias) in Pharmacoepidemiologic Studies: A Simulation Study [501]**

Wei Liu, M Alan Brookhart, Soko Setoguchi. (United States)

9:00 am

* **Simulating the Application of Propensity Scores Estimated in a Full Cohort To Adjust for Confounding in Subgroup Analyses [502]**

Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

9:15 am

* **Effect of Weight Trimming on IPW Estimates and Standard Errors: An Applied Analysis [503]**

Michele Jonsson Funk, Jennifer S Fusco, Til Sturmer, Stephen R Cole. (United States)

9:30 am

* **New Method for Stabilizing the Variance of Instrumental Variable Physician Preference-Based Estimates of Treatment Effect [504]**

Michal Abrahamowicz, Marie-Eve Beauchamp, Raluca Ionescu-Iltu, Joseph AC Delaney. (Canada)

9:45 am

* **Modifying the High-Dimensional Propensity Score (hd-PS) Algorithm To Improve Small Sample Performance [456]**

Jeremy A Rassen, Robert J Glynn, Sebastian Schneeweiss. (United States)

Clotting or Bleeding (Buckingham)

Moderators: Soko Setouchi & Frank de Vries

8:30 am

* **Risk of Venous Thromboembolism in Patients with Chronic Immune Thrombocytopenic Purpura (cITP) [506]**

Marianne Tang Severinsen, Malene Cramer Engbjerg, Mette Nørgaard, Sean Zhao, Henrik Toft Sørensen. (Denmark)

8:45 am

* **The Risk of Venous Thromboembolism in OC Users: Time Patterns after Initiation of Treatment [507]**

Juergen Dinger, Thai Do Minh, Sabine Moehner. (Germany)

9:00 am

* **Use of NSAID, Aspirin, Acetaminophen, Statins and Risk of VTE in Women [508]**

Annica Bergendal, Anders Sundström, Shahram Bahmanyar, Ingemar Persson, Helle Kieler. (Sweden)

9:15 am

* **Drug Interactions with Phenprocoumon and the Risk of Serious Hemorrhage: A Nested Case-Control Study in a Large Population-Based German Database [509]**

Kathrin Jobski, Sigrid Behr, Edeltraut Garbe. (Germany)

9:30 am

* **Diuretic Use and the Risk of Gastrointestinal Bleeding in the United Kingdom General Population [510]**

Joseph AC Delaney, Alain Bitton, Samy Suissa. (United States)

9:45 am

* **Antiplatelet Medicine Prescribing and Subsequent Events Following Intracerebral Haemorrhage [511]**

Robert W Flynn, Thomas M MacDonald, Gordon D Murray, Ronald S MacWalter, Alexander S Doney. (United Kingdom)

Compliance & Utilization I (Balmoral)

Moderators: **Miriam Sturkenboom, FISPE & Deborah Layton**

8:30 am

- * **Appropriateness of Care after Myocardial Infarction in Cancer Survivors [512]**
Winson Y Cheung, Mary McBride, Raisa Levin, Soko Setoguchi. (Canada)

8:45 am

- * **Cost-Effective Proton Pump Inhibitor Prescribing: Potential Strategies for More Rational Prescribing [513]**
Cairiona Cahir, Tom Fahey, Conor Teljeur, Lesley Tilson, Kathleen Bennett. (Ireland)

9:00 am

- * **Antiplatelet Agents' Effectiveness for Secondary Prevention of Ischemic Stroke [514]**
Mi-Sook Kim, Ye-Jee Kim, Jong-Mi Seong, Nam-Kyong Choi, Byung-Joo Park. (Korea)

9:15 am

- * **Placebo Adherence, Clinical Outcomes and Mortality in the Women's Health Initiative Randomized Hormone Therapy Trials [515]**
J R Curtis, J Larson, E Delzell, MA Brookhart, S Cadarette, R Chlebowski, S Judd, M Safford, D Solomon, A LaCroix. (United States)

9:30 am

- * **Adherence to Gastroprotective Agents and the Risk of Upper Gastrointestinal Complications in NSAID Users [516]**
E van Soest, V Valkhoff, G Mazzaglia, R Schade, M Molokhia, J Dieleman, M Sturkenboom. (Netherlands)

9:45 am

- * **Low Income Workers Face the Largest Cost Burden for Prescription Medicines in Australia [517]**
Anna Kemp, Elizabeth E Roughead, David B Preen, John Glover, James Semmens. (Australia)

Outcomes After Prenatal Exposure: Causes Versus Biases

(Cambridge)

Moderators: **Susan Roberts & Elizabeth Andrews, FISPE**

8:30 am

- * **Systemic Immunosuppressive Drug Use During Pregnancy May Be Associated with Preeclampsia [518]**
Kristin Palmsten, Sonia Hernández-Díaz, Daniel H Solomon, Soko Setoguchi. (United States)

8:45 am

- * **Maternal Use of Antibiotics and the Risk of Oral Facial Clefts: A Nationwide Danish Cohort Study [519]**
Ditte Mølgaard-Nielsen, Anders Hviid. (Denmark)

9:00 am

- * **Maternal Exposure to Amoxicillin and the Risk of Oral Clefts [520]**
Kuei-Yu Lin, Allen A Mitchell, Wai-Ping Yau, Sonia Hernández-Díaz. (United States)

9:15 am

- * **Prenatal Exposure to Decongestants and the Risk of Pyloric Stenosis [521]**
Wai-Ping Yau, Allen A Mitchell, Kuei-Yu Lin, Sonia Hernández-Díaz. (United States)

9:30 am

- * **Phthalates in Drugs and Male Genital Malformations [522]**
Sonia Hernandez-Diaz, Russ Hauser, Allen A Mitchell. (United States)

9:45 am

- * **The Impact of Methadone Maintenance Treatment During Pregnancy on Perinatal Outcomes [523]**
Brian J Cleary, Jean Donnelly, Judith Strawbridge, Paul J Gallagher, Tom Fahey, Deirdre J Murphy. (Ireland)

AGENDA Sunday, August 22

Pharmacovigilance - Real or Fool's Gold (Clarence)

Moderators: **Suzie Seabroke & Anita Assmann**

8:30 am

- * **Postlicensure Safety Monitoring of Pandemic A/H1N1 Vaccine — Taiwan, November 1, 2009–January 7, 2010 [524]**
Wan-Ting Huang, Wen-Wen Chen, Chia-Ping Su, Huai-Te Tsai, Angela S Huang, Yu-San Chien, Yen-Nan Chao, Jen-Hsiang Chuang. (Taiwan)

8:45 am

- * **Adverse Drug Reactions to Antiretroviral Therapy (ART) Identified by Intensive Monitoring at an ART Centre in India [525]**
Pathasarathi Gurumurthy, Retty R Modayil, Anand Harugeri, Madhan Ramesh, S Rajendra Prasad. (India)

9:00 am

- * **Delays in the Detection of Signals of Serious Adverse Events Due to the Inclusion of Non-Serious Adverse Event Reports in Analyses [526]**
Keith L Altman. (United States)

9:15 am

- * **Pharmacovigilance Data Mining with False Discovery Rate Based Methods: A Comparative Simulation Study [527]**
Ismail Ahmed, Frantz Thiessard, Ghada Miremont-Salamé, Bernard Bégau, Pascale Tubert-Bitter. (United Kingdom)

9:30 am

- * **Impact of Drug Product Litigation on Safety Signal Detection in AERS [528]**
G Gipson, R Schaaf, W DuMouchel, R Valentino, A Wisniewski. (United States)

9:45 am

- * **Early Indicators of Drug Dependence [529]**
Ola Caster, Anna Kindlundh-Högberg, Johan Hopstadius, G Niklas Norén. (Sweden)

Stimulating Findings from Medicine Use in Children (Dukes)

Moderators: **Jesper Hallas & Tamar Lasky**

8:30 am

- * **Use of Antipsychotic Medications in US Youth, 2001-2007 [530]**
Stephen Crystal, Tobias Gerhard, Cecilia Huang, Mark Olfson. (United States)

8:45 am

- * **Payer Source & Atypical Antipsychotic (AP) Use in Pediatric Inpatients [531]**
Shirley Wang, Tamar Lasky, Frank R Ernst, Jay Greenspan, Liliana Gonzalez. (United States)

9:00 am

- * **Methylphenidate Treatment in Germany – Are Co-Morbidities Taken into Account? [532]**
Christina Lindemann, Kraut Angela, Langner Ingo, Mikolajczyk Rafael, Garbe Edeltraut. (Germany)

9:15 am

- * **Incidence of Epilepsy and Anti-Epileptic Drug (AED) Prescribing in Children in the UK [533]**
W H Meeraus, R Gilbert, R F Chin, I Petersen. (United Kingdom)

9:30 am

- * **Stimulant Prescription and Risk of Injury among Children with Attention Deficit Hyperactivity Disorder (ADHD) in the United Kingdom (UK): Preliminary Results [534]**
Sudha R Raman, Stephen W Marshall, Til Stürmer. (United States)

9:45 am

- * **Use of Stimulants Following the Public Discussion and Regulatory Actions on ADHD Drug's Cardiovascular Safety [116]**
CY Chen, Almut Winterstein. (United States)

10:00-10:30am

Break/Posters/Exhibits (Durham & Hall 7)



Serious Fun!

**ISPE 26th International Conference
on Pharmacoepidemiology and Therapeutic
Risk Management**

AGENDA Sunday, August 22

10:30-Noon

Concurrent Sessions: Contributed Papers

Analysis Methods - The Details that Bedevil Us (Oxford)

Moderators: John Seeger & Alec Walker, FISPE

10:30 am

- * **Using Inverse Probability Weighting To Estimate Warfarin Adverse Effects: Concerns with Large and Variable Inverse Probability Weights [536]**

Joseph AC Delaney, Robert W Platt, Samy Suissa. (United States)

10:45 am

- * **Evaluating a Hybrid Self Controlled Analysis Method [537]**

Shirley Wang, Crystal Linkletter, David Dore, Malcolm Maclure, Vincent Mor, Stephen Buka. (United States)

11:00 am

- * **A Comparison of Statistical Approaches for Clustered Pharmacoepidemiology Data with Survival Outcomes [538]**

Margaret R Stedman, David R Gagnon, Robert A Lew, Elena Losina, Daniel H Solomon, M Alan Brookhart. (United States)

11:15 am

- * **Treatment Effects in Frail Patients: A Simulation Study of Treatment Contrary to Prediction [539]**

Til Stürmer, Kenneth J Rothman, Jerry Avorn, Robert J Glynn. (United States)

11:30 am


- * **Self-Controlled Case Series and Prescription Event Symmetry Analysis: How Different Are They Really? [540]**

Nicole L Pratt, Libby E Roughead, Robert Peck, Gilbert Andrew. (Australia)

11:45 am

- * **Effects of Cox-2 Selectivity NSAID Groupings in UGIB and MI ADR Substantiation Using Bayesian Hierarchical Modeling: Comparison of IPCI and PHARMO Databases: EU-ADR Project [541]**

D Prieto, M Molokhia, S Evans, M Schuemie, R Herings, J van der Lei, M Sturkenboom. (United Kingdom)



RTI HEALTH SOLUTIONS®



RISKS AND BENEFITS:

Define. Measure. Evaluate. Communicate.

We provide full-service solutions for your international epidemiological, safety, and risk management needs.

Visit our exhibit booth to learn how we can help you *define, measure, evaluate and communicate* the risks and benefits of your products.

Research Triangle Park • Ann Arbor • Barcelona • Lund • Manchester • Sheffield • Waltham

**ENTER
TO WIN
our book
drawing!**

www.rtihs.org

LEADING RESEARCH...
MEASURES THAT COUNT

AGENDA Sunday, August 22

Atypical Prescribing in Older People (Balmoral)

Moderators: Jerry Gurwitz & Jamie Robinson

10:30 am

* **Psychotropic Drug Use in the Elderly across Europe: A Perspective from the EU-ADR Project [542]**

Preciosa Coloma, Gianluca Trifirò, Martijn Schuemie, Rosa Gini, Ron Herings, Julia Hippisley-Cox, Giampiero Mazzaglia, Giovanni Corrao, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom. (Netherlands)

10:45 am

* **Explained Variation in Antipsychotic Medication Prescribing in Patients Admitted to Nursing Homes [543]**

Krista Huybrechts, Kenneth J Rothman, M Alan Brookhart, Rebecca Silliman, Stephen Crystal, Sebastian Schneeweiss. (United States)
STUDENT AWARD RECIPIENT: BEST METHODS ABSTRACT

11:00 am

* **Antipsychotic Use and the Risk of Diabetes in Older Adults with Dementia [544]**

Jessica J Jalbert, Lori A Daiello, Charles B Eaton, Susan C Miller, Kate L Lapane. (United States)

11:15 am

* **Suicidality Assessment in Placebo-Controlled Studies of Ziprasidone [104]**

Onur N Karayal, Susan D Anway, Evan Batzar, Douglas G Vanderburg. (United Kingdom)

11:30 am

* **Comparison of Different Approaches to Confounding Adjustment in a Study on the Effect of Antipsychotic Medication on Mortality in Elderly Nursing Home Patients [448]**

Krista Huybrechts, M Alan Brookhart, Kenneth J Rothman, Rebecca Silliman, Tobias Gerhard, Sebastian Schneeweiss. (United States)

11:45 am

* **Did the US FDA Black Box Advisory Reduce Use of Antipsychotics for Dementia? [547]**

Tami L Mark, Suellen Curkendall. (United States)

Cardiovascular (Cambridge)

Moderators: Tom MacDonald, FISPE & Klaas Heinemann

10:30 am

* **Long-Term Active Surveillance Study for Oral Contraceptives (LASS): Impact of Oral Contraceptive Use on the Start of Antihypertensive Treatment [548]**

Juergen Dinger, Anita Assmann, Sabine Moehner. (Germany)

10:45 am

* **Lipid Lowering Agents and Non-Traumatic Tendon Rupture [549]**

Elizabeth V Lawler, Jennifer R Fonda, Soe Soe Thwin, J Michael Gaziano, Mary T Brophy, David R Gagnon. (United States)

11:00 am

* **The Cost-Effectiveness of Using Statins To Treat Patients with Elevated C-Reactive Protein and Normal Cholesterol Levels [550]**

Niteesh K Choudhry, Amanda R Patrick, Robert J Glynn, Jerry Avorn. (United States)

11:15 am

* **Impact of Allopurinol Use on Urate Concentration and Cardiovascular Outcome [551]**

Li Wei, Isla S Mackenzie, Yang Chen, Allan D Struthers, Thomas M MacDonald. (United Kingdom)

11:30 am

* **Comparative Effectiveness of Angiotensin Receptor II Blockers (ARBs) vs. Angiotensin-Converting Enzyme Inhibitors (ACEIs) in Hypertensive Elderly Patients with Cardiovascular Comorbidities [552]**

Soko Setoguchi, William H Shrank, Jun Liu, Helen Mogun, Wolfgang C Winkelmayr, Nancy A Dreyer. (United States)

11:45 am

* **Associations between Anti-Retroviral Drug Use and HIV-Specific Risk Factors with Carotid Intima-Media Thickness: The Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) [553]**

Joseph AC Delaney, Rebecca Scherzer, Mary L Biggs, Michael G Shlipak, Joseph F Polak, Judith S Currier, Daniel O'Leary, Phyllis Tien, Christine Wanke, Richard A Kronmal, Peter Bacchetti, Carl Grunfeld. (United States)

Compliance & Utilization II (Buckingham)

Moderators: Frank May, FISPE & Amanda Golembesky

10:30 am

* **Magnitude and Determinants of Off-Label Prescribing in Primary Care [554]**

Tewodros Eguale, Andrea Beneditti, James A Hanley, David L Buckeridge, Robyn Tamblyn. (Canada)

10:45 am

* **Adherence Rates and Predictors of Early Termination to Niacinamide [555]**

Jennifer B Christian, Vincent Rabatin. (United States)

11:00 am

* **Adherence to Cardiovascular Medications after Myocardial Infarction in Cancer Survivors [556]**

Winson Y Cheung, Mary McBride, Raisa Levin, Soko Setoguchi. (Canada)

11:15 am

* **The Prevalence and Cost of Unapproved Uses of Orphan Drugs [23]**

Aaron Kesselheim, Daniel Solomon, Wolfgang Winkelmayr, Raisa Levin, Jerry Avorn. (United States)

11:30 am

* **Trends in the Consumption of Antidepressants in Portugal, 2004-2009 [558]**

Jose Guerreiro, Carla Torre, Suzete Costa. (Portugal)

11:45 am

* **Incidence of Statin Use before and after Restricting Reimbursement in Iceland [559]**

Gudrun Thengilsdóttir, Ingunn Björnsdóttir, Anna B Almarsdóttir. (Iceland)

Pediatric Potpourri (Dukes)

Moderators: Allen Mitchell, FISPE & Kourtney Davis

10:30 am

* **Rates of Spontaneous Reports of Adverse Drug Reactions in Children [560]**

Susanna M Wallerstedt, Gertrud Brunlöf, Anders Sundström. (Sweden)

10:45 am

* **Comparing the Mortality Risk of Exposure in Children to Different Opioids [561]**

Paul M Coplan, J David Haddock. (United States)

11:00 am

* **Determinants of Uncontrolled Asthma at Age 8: The Importance of Parental Perception towards Medication Use [562]**

Ellen S Koster, Gerard Koppelman, Alet Wijga, Dirkje Postma, Maarten Hoekstra, Johan de Jongste, Henriette Smit, Jan Raaijmakers, Anke-Hilse Maitland-van der Zee. (Netherlands)

11:15 am

* **Anti-Inflammatory Asthma Therapy Adherence in Paediatric Patients: The PACMAN Cohort Study [563]**

Ellen S Koster, Jan A Raaijmakers, Anke-Hilse Maitland-van der Zee. (Netherlands)

11:30 am

* **Claims Algorithms To Quantify Use of Live Attenuated Influenza Vaccine among Non-Recommended Children [564]**

Pat Tennis, Elizabeth Andrews, Seth Toback, Chris Ambrose, Lisa McQuay, Matthew Rousculp. (United States)

11:45 am

* **Antibacterial Drugs and the Risk of Community-Associated Methicillin Resistant Staphylococcus Aureus (C-MRSA) in Children [565]**

Verena Schneider-Lindner, Caroline Quach, James A Hanley, Samy Suissa. (Canada)



AGENDA Sunday, August 22

Random Women (Clarence)

Moderators: Lolkje de Jong-van den Berg & Maureen Cronin

10:30 am

Maternal Use of Proton Pump Inhibitors (PPI) during Pregnancy Is Associated with an Increased Risk for Cardiac Birth Defects: Analysis of 208,951 Pregnancies from the THIN Database [566]

Andrew D Rhim, Kevin Haynes, Janet R Hardy, Jeffery M Testani, Yu-Xiao Yang. (United States)

10:45 am

* **Clomiphene Citrate and Birth Defects, National Birth Defects Prevention Study 1997-2005 [567]**

Jennita Reefhuis, Margaret A Honein, Laura A Schieve, Sonja A Rasmussen. (United States)

11:00 am

* **Utilisation of Endocrine Therapy in Women with Breast Cancer in Australia [568]**

Agnes I Vitry, Loc Thai, Christine Lu. (Australia)

11:15 am

* **Differences in Drug Utilization of Oral Contraceptives in the US and Europe [569]**

Kristina Bardenheuer, Juergen Dinger, Thai Do Minh, Christian Franke, Janko Leddin. (Germany)

11:30 am

* **Adolescent and Young Adult Women's Use of Emergency Contraception [570]**

Sharon Hensley Alford, Rachel E Lappin, Karen E Wells, Amanda R Barone, Marianne Ulcickas Yood, Vanessa K Dalton. (United States)

11:45 am

* **Unintended Pregnancies in Women Using Intrauterine Devices: Results from the EURAS-IUD Study [571]**

Juergen Dinger, Clare Barnett, Sabine Moehner, Anita Assmann. (Germany)

Noon-1:30pm

Lunch/Poster Session C/Exhibits

(Durham, Durham Gallery, Hall 7 & 8)

Roundtable Discussions - TBA

ISPE Board of Directors Luncheon

(Ambassador)

(Meeting open to all members; check with staff if you wish to attend)

1:30-3:00pm

Concurrent Sessions: Symposia And Workshops

Lessons Learned from Collaboration among EU Biologics Registries in Rheumatology [572] (Hall 4)

* William G Dixon, Margaret Richards, Johan Askling, Hans Petri, Syed R Ahmad. (United States)

The Industry-Academic Nexus: Experiences, Perspectives, and Suggestions for Enhancing Research Relationships [573] (Cambridge)

* Jerry L Avorn, Sara A Ephross, Allen A Mitchell, Walter L Straus. (United States)

The Alternate Life of Regulators [574] (Oxford)

* Stella CF Blackburn, Peter Arlett, Xavier Kurz, Henry Fitt. (United Kingdom)

Rare Diseases: Unmet Medical Needs, Epidemiology and Regulatory Considerations [576] (Dukes)

* Wei Dong, Judith Jones, Joanna Haas, Michael Taylor, Pavel Napalkov. (United States)

Linking Administrative and Electronic Medical Record Databases Using Hybrid Probabilistic and Deterministic Techniques [577] (Balmoral)

* Erica Danielson, Stella Chang, Daniel Huse. (United States)

Challenges and Opportunities in Shaping Medical Device Epidemiology [781] (Buckingham)

* Danica Marinac-Dabic, Art Sedrakyan, Mary E Ritchey, Sharon-Lise Normand, Frederic Resnic. (United States)

Observed vs Expected Methodologies in Vaccine Safety Surveillance [782] (Clarence)

* June Raine, Martin Kulldorff, Stephen Evans, Suzie Seabroke, Vincent Bauchau. (United Kingdom)

AGENDA Sunday, August 22

3:00-4:30pm


Hot Topics Session:

Moderator: **Xavier Kurz**, Pharmacovigilance & Risk Management, EMA

Moderate Pandemic, Not Many Dead: What Should We Do Differently Next Time? (Oxford)

* **Professor Angus Nicoll**, Influenza Coordinator, European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden

* **Deborah Cohen**, Assistant Editor, BMJ



Serious Fun!

4:30-5:00pm

The Final Word (Oxford)

Poster Awards

ICPE 2011 Chicago, Illinois, USA

* **John Seeger**, Chair, 2011 Scientific Program Committee

5:00pm

Adjournment of ICPE 2010 (Oxford)

5:15-6:15pm

2011 ICPE Scientific Program Committee Meeting


(Ambassador)

—Open to interested ISPE members



26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Value through Innovation



Even after more than a century of experience, we remain intensely curious. For the sake of future generations.

Boehringer Ingelheim has always remained true to its character as an independent family-owned company. Our vision drives us forward. It helps to foster value through innovation in our company and to look to the future with constantly renewed commitment and ambition. Today, we operate globally with 142 affiliated companies in 50 countries. With more than 41,500 employees worldwide and a track record built up in nearly 125 years, we are continuously dedicated to improving the outlook for a healthier life.

Global epidemiology contributes substantially to achieving these goals by evaluating target populations and our products in real life settings. Would you like to join our epidemiological research group? Please send a fax to us indicating your interest. Fax: +49 (6132) 72-93367 www.boehringer-ingenelheim.com

PHARMAC
EPIDEMIOLOGY 



POSTER SESSION Guidelines

Overview

Poster sessions are designed to give presenters an opportunity to informally discuss their research with colleagues interested in their research. The purpose of the posters is to visually stimulate interest in the research, to present sufficient information for viewers to understand the methods, results, and significance of the research, and to promote conversations and networking among conference participants.

Note: Neither ISPE nor the Hilton will be responsible for any poster that is left up overnight or is lost or damaged.

Poster Session

Posters will be displayed in the Durham Room of the Hilton Metropole, August 20-22. Each day will have a separate poster session. All posters for a specific day's session must be removed that day.

- * **Friday, August 20**Poster Session A
- * **Saturday, August 21**Poster Session B
- * **Sunday, August 22**Poster Session C

1. Set Up:

- * 7:00am-8:00am; all posters must be in place by 8:00am. The poster sessions will be held in the Durham Room and Exhibit Hall 7.

2. Hours:

- * Posters will be displayed from 7:30am-6:00pm on Friday; 8:00am-6:00pm on Saturday, and 8:00am-1:45pm on Sunday.

3. Discussion Time:

- * **General:** Presenters should be at their posters between 12:15-1:15pm.
- * **Poster Walks:** organized by the ISPE Special Interest Groups (SIG).
Saturday, August 21, 12:45-1:30pm. Poster walks offer pre-selected presenters the opportunity to present their work and to discuss their results with an audience.

There will be poster walks for:

- | | |
|--|--|
| -Biologics | - Databases |
| -Drug Utilization/Health Services Research | - Medicines in Pregnancy |
| -Comparative Effectiveness Research | - Molecular Epidemiology/
Biomarkers/Pharmacogenetics |

Poster walk presenter:

Be at your poster 12:45-1:30pm
When the poster walk chair and audience stop at your poster, please give a brief, 3-minute presentation and be prepared to answer questions about your research.

Poster Prizes:

A group of judges will select the best posters of each poster walk. The best presenters will receive an invitation to display their poster for the duration of the ICPE. The best posters will be announced and prizes awarded during The Final Session at 4:30pm, August 22.

4. Take Down:

- All posters must be taken down by 6:30pm on Friday and Saturday, and by 5:00pm on Sunday.

Numbering System

- * Each poster board will be numbered. Presenters should attach their posters to the board number corresponding to the number assigned to their poster in the **Final Program**, which will be available at the ISPE Registration Desk (Sussex Lounge). The poster number is the first number listed. Please note the number may differ from that shown in the preliminary program. The abstract number is for use locating abstracts in the **Final Program** and the special issue of *Pharmacoepidemiology and Drug Safety*, is in brackets [] after the title of the abstract.

Poster Specifications

1. Posters must be designed to fit a free-standing poster board **3 feet WIDE x 5 feet HIGH (90 cm wide x 150 cm high) PORTRAIT**. Posters may be mounted using Velcro tape; please bring your own supplies. Business cards or small leaflet literature for distribution may be inserted in an envelope and affixed to the board.
2. Posters may be attached to the boards using Velcro. All poster presenters are encouraged to bring their own supplies.
3. **Disclosure Statement**
A disclosure statement must accompany each abstract submission and each presentation. This statement must list all funding sources for the current project, as well as other potentially conflicting relationships that existed at any time during the conduct of the study, or at a minimum, the one-year period before ICPE 2010. Non-financial conflicts (e.g., a close relationship with, or a strong antipathy to, a person whose interests may be affected) should also be disclosed. Potential conflicts must be listed on the poster in a type size consistent with the rest of the poster.

Anti-Infectives

- 1 **Describing Antimicrobial Use among Inpatients Infected with Methicillin-Resistant Staphylococcus aureus (MRSA) [43]**
Aisling R Caffrey, Brian J Quilliam, Kerry L LaPlante. (United States)
- 2 **Safety and Rationale of Antimicrobial Fixed Dose Combinations Marketed in Latin American Countries [44]**
Veronika J Wirtz, Jonneke Verdijk, Katja Taxis. (Mexico)
- 3 **Antibiotic Use: Main Indications and Their Therapies [45]**
Ria Benko, Maria Matuz, Edit Hajdu, Peter Doro, Gyongyver Soos. (Hungary)
- 4 **Characteristics of Inpatient Antibacterial Use in Hungary (1996-2007) [46]**
Ria Benko, Maria Matuz, Edit Hajdu, Reka Viola, Gyongyver Soos. (Hungary)
- 5 **Trends in Systemic Antibiotic Prescribing for Children in Ireland [47]**
C Keogh, U Reulbach, K Bennett, T Fahey. (Ireland)

Blood

- 6 **Utilization of Antithrombotic Agents after Major Orthopedic Surgeries in Southern Taiwan [48]**
Yu-Ying Yu, Li-Chia Chen, Hsueh-Er Chan, Jin-Song Wu. (Taiwan)
- 7 **Total Cholesterol Concentration Reductions with Statin Treatment in Chronic Disease Patients [49]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 8 **Use of Non-Steroidal Anti-Inflammatory Drugs and Risk of Re-Operation Due to Bleeding after Breast Cancer Surgery: A Danish Population Based Cohort Study [50]**
Deirdre Cronin-Fenton, Timothy L Lash, Heidi Hundborg, Henrik T Sørensen. (Denmark)
- 9 **Phenprocoumon Exposure and Risk of Intracerebral Bleeding [51]**
Sigrid Behr, Frank Andersohn, Edeltraut Garbe. (Germany)
- 10 **Persistence and Adherence to Antiplatelet Regimens in the Tayside Stroke Cohort [52]**
Robert W Flynn, Thomas M MacDonald, Gordon D Murray, Ronald S MacWalter, Alexander S Doney. (United Kingdom)

- 11 **Cardiovascular Drug Use in Patients Hospitalized with a First-Time Myocardial Infarction in Sweden [53]**
Andrejs Leimanis, Michael Fored, Niklas Hammar, Helena Schiöler, Björn Wettermark. (Sweden)
- 12 **Risk of Subarachnoid Hemorrhage Associated with Outpatient Anticoagulant Use [54]**
Sigrid Behr, Edeltraut Garbe. (Germany)
- 13 **Analysis of Aranesp Patient Exposure for Cancer Indications Using 2 Existing Databases [55]**
Fei Xue, David Quach, Greg Hess, Daniel Blaney, Julie Moloney, Victor Gastanaga, Jason Yuan, Scott Stryker, Gail Hughes, Cristina Damatarca, Sean Zhao. (United States)
- 14 **Effectiveness and Safety of Prophylactic Antithrombotic Agents after Major Orthopedic Surgeries in Southern Taiwan [56]**
Li-Chia Chen, Yu-Ying Yu, Hsueh-Er Chan, Jin-Song Wu. (Taiwan)

Cancer and Immunity

- 15 **Gastrointestinal Perforation (GIP), Fistula, and Abscess among Ovarian Cancer Patients [57]**
Michael Taylor, Wei Dong, Laura Chu. (United States)
- 16 **Interstitial Lung Disease (ILD) in Gefitinib-Treated Japanese Patients with Non-Small Cell Lung Cancer (NSCLC): Genome-Wide Analysis of Genetic Data [58]**
Fredrik Nyberg, Bryan Barratt, Yusuke Nakamura, Naoyuki Kamatani. (Sweden)
- 17 **Adverse Drug Reactions Induced by Antineoplastic Agents in Hospitalized Patients [59]**
Kheirollah Gholami, Mahdieh Fazlollahi, Sanambar Sadighi, Gloria Shalviri. (Islamic Republic of Iran)
- 18 **Risk of Lung Cancer in Users of Estradiol/Dydrogesterone or Other HRT Preparations [60]**
Cornelia Schneider, Susan S Jick, Christoph R Meier. (Switzerland)
- 19 **Osteoporosis and Esophageal Cancer [61]**
Bharat T Thakrar, Cees Schep, Alan Nevitt, Noah J Robinson. (Switzerland)
- 20 **Hip/Knee Arthroplasty and Risk of Hip Fracture: A Population-Based Case-Control Study [62]**
Arief Lalmohamed, Nigel Arden, Tjeerd P van Staa, Hubertus GM Leufkens, Frank de Vries. (Netherlands)

- 21 **Long Term Clinical Outcomes of Patients with Adult Chronic Immune Thrombocytopenic Purpura (cITP) [63]**
Mette Nørgaard, Annette Østergaard Jensen, Malene Cramer Engebjerg, Sean Zhao, Henrik Toft Sørensen. (Denmark)
- 22 **Effectiveness and Safety of Bevacizumab (BV)+FOLFIRI as 1st-Line Metastatic Colorectal Cancer (mCRC) Treatment: ETNA Cohort Study [64]**
A Fourrier-Reglat, M Rouyer, J Benichou, A Balestra, M A Bernard, A Grelaud, D Smith, A Ravaud, N Moore, and the ETNA Group. (France)
- 23 **Cardiotoxicity and Other Adverse Events Associated with Mitoxantrone Treatment for Multiple Sclerosis [65]**
Elaine Kingwell, Marcus Koch, Bonnie Leung, Saul Isserow, Jane Geddes, Peter Rieckmann, Helen Tremlett. (Canada)

Cardiovascular

- 24 **Epidemiology of Venous Thromboembolism Following Knee Replacement Surgery in the Taiwanese Population — A Ten-Year Nationwide Experience [66]**
Yea-Huei Kao Yang, Cheng-Han Lee, Ching-Lan Cheng, Chyun-Yu Yang, Li-Jen Lin, Tzu-Chieh Lin, Chia-Hsien Chang. (Taiwan)
- 25 **Relationship between Statin-Associated Total Cholesterol Concentration Change and Cardiovascular Outcome among Diabetes Patients: A Population-Based Cohort Study [67]**
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)
- 26 **Abstract Withdrawn by Author [68]**
- 27 **Utilization of a Computer-Based Reminder To Improve Surveillance of the Antipsychotic-Related Risk of Arrhythmia in a Teaching Hospital [69]**
Jean Frederic Westphal, Cathy Nonnenmacher. (France)
- 28 **EARTH – Epidemiology of Atherosclerotic Disease in The UK: Evidence of Reducing Incidence of Cardiovascular Disease (CVD), Particularly Coronary Heart Disease, in the UK Adult Population between 1999 and 2008 [70]**
Anna Shafe, Sally Lee, Martin Cowie. (United Kingdom)

POSTER SESSION A Friday, August 20

- 29 Risk Profile and OC Utilization Patterns of Women Enrolled in INAS-Score [71]**
Kristina Bardenheuer, Clare A Barnett, Juergen Dinger, Christian Franke. (Germany)
- 30 Compliance with Antihypertensive Agents and the Onset of End-Stage Renal Disease [72]**
Miriam Lessard, Louise Roy, Alice Dragomir, Sylvie Perreault. (Canada)
- 31 The Safety of Oral Hormone Replacement Therapy: Interim Results from the EURAS-HRT Study [73]**
Anita Assmann, Klaas Heinemann, Juergen Dinger. (Germany)
- 32 Trends in Statin Prescription in the UK 2002-2008 – Demographics and Determinants of Non-Adherence [74]**
Jakob Petersen, David Irvine, Lesley Wise. (United Kingdom)
- 33 Abstract Withdrawn by Author [75]**
- 34 Prescription Trends for Dopamine Agonists in UK Primary Care – The Influence of Safety Alerts Concerning Valvular Heart Disease [76]**
René Schade, Jeanne P Dieleman, Miriam C Sturkenboom. (Netherlands)
- 35 Aspirin Use in Elderly with Type 2 Diabetes: Effects on Myocardial Infarction and Gastro-Intestinal Bleeding [77]**
Caroline Sirois, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)
- 36 Cohort Description of the Drug-Induced Arrhythmia Risk Evaluation (DARE) Study [78]**
Vanessa Marshall, Elijah Behr, Victoria Cornelius, Saad Shakir, John Camm. (United Kingdom)
- 37 Prescribing Patterns of Antihypertensive Drugs in 78000 Incident Users [79]**
Randi Selmer, Hege S Blix, Knud Landmark, Aasmund Reikvam. (Norway)
- 38 Discontinuation Rates of Statins Vary If Different Calculation Methods Are Used [80]**
Harm CJ Geers, Marcel L Bouvy, Rob Heerdink. (Netherlands)
- 39 Comparison of Cardiovascular Risk Factors and Survival in Patients with Ischemic or Hemorrhagic Stroke [81]**
Karin M Henriksson, Bahman Frahmam, Signild Åsberg, Nils Edvardsson, Andreas Terént. (Sweden)
- 40 Comparison of Discontinuation of Pioglitazone Versus Rosiglitazone Utilization after Discordant Safety Concerns [82]**
Cat N Bui, Paul Godley, James Wilson, Karen Rascati. (United States)
- 41 A Randomized Controlled Trial of the Effect of a Pharmaceutical Care Program on Improving Adherence to Statin Therapy: The STatin Intervention Research Project (STIPT) [83]**
Simone Eussen, Menno van der Elst, Olaf Klungel, Cathy Rompelberg, Johan Garssen, Marco Oosterveld, Anthonius de Boer, Johan de Gier, Marcel Bouvy. (Netherlands)



**Bring
Science
to Action**

LA-SER Europe
20 Manchester Square
London W1U 3PZ
United Kingdom
Tel: +44 (0)20 3137 5800

Information on the LA-SER booth:

- PGRx systematic case-control information system
- Multipurpose cohort studies for relative benefit/risk assessment
- Patient Reported Outcomes and Use of Drugs capabilities

**ALSO IN POSTER AND ORAL PRESENTATIONS
DURING THE MEETING**

www.la-ser.com

London – Paris – Montreal – Milan – Frankfurt – Barcelona

- 42 **Regional Variation in Use of Secondary Prevention Medications among Medicare Part D Enrollees after an Acute Myocardial Infarction [84]**
Nancy E Morden, Gergory A Roth, Weiping Zhou, Jonathan A Skinner. (United States)
- 43 **Abstract Withdrawn by Author [85]**
- 44 **Medication Non-Adherence Affects Treatment Intensification for Hyperglycaemia but Not for Hypertension [86]**
Petra Denig, Jaco Voorham, Bruce HR Wolffenbuttel, Ronald P Stolk, Flora M Haaijer-Ruskamp. (Netherlands)
- 45 **Abstract Withdrawn by Author [87]**
- 46 **Recruitment Strategy for Genetic Data Collection: The UK General Practice Research Database [88]**
Efrosini Setakis, Frank de Vries, Munir Pirmohamed, Tjeerd-Pieter van Staa. (United Kingdom)
- 47 **Using Laboratory Data To Supplement Claims Data To Improve Control of Confounding in Studies of Treatment Effects [89]**
S Schneeweiss, JA Rassen, J Avorn, DH Solomon, SY Kim, G Daniel, KJ Rothman, J Liu, RJ Glynn. (United States)
- 48 **Risk of Circulatory Disorders among Patients with Asthma in a Large Integrated Health Care Delivery System [90]**
Carlos Iribarren, Irina Tolstykh, Mary K Miller, Mark D Eisner. (United States)

Classical Pharmacoepidemiology

- 49 **Statistical Models for the Comparison of the Average Per-Patient Cost of Lower Limb Osteoarthritis with or without Spa Therapy [91]**
P Blin, C Toussaint, R Lassalle, S Lignot, F Hamoud, A Abouelfath, J Benichou, JL Demeaux, C Garreau, C Ohayon-Courtes, T Schaefferbeke, M Vray, N Moore. (France)
- 50 **Drugs Inducing DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): The RegiSCAR Experience [92]**
Sylvia H Kardaun, Peggy Sekula, Maja Mockenhaupt, Jean-Claude Roujeau. (Netherlands)

- 51 **Estimating Clopidogrel Bisulfate Use in a Pediatric Population [93]**
S Phillips, A Meyers, A Gomez, F Ernst, M Ulcickas Yood, S Oliveria. (United States)
- 52 **Lymphoma Case Ascertainment in the US Pharmetrics Database [94]**
Eulogio Conde, Charles W Wentworth, Elena Rivero, Alejandro Arana. (Spain)
- 53 **Serum Sodium Concentration Monitoring and Hyponatremia in Thiazide-Treated Patients [95]**
Sarah E McDowell, Jamie J Coleman, Stephen JW Evans, Robin E Ferner. (United Kingdom)
- 54 **Generic Substitution in a Cohort of Swedish Patients with Heart Failure [96]**
Chamlin Nouri, Björn Wettermark, Morten Andersen, Anders Sundström, Karin Söderberg, Ulf Bergman. (Sweden)
- 55 **Body Mass Index and the Incidence of Influenza-Associated Complications in a UK Population [97]**
William A Blumentals, Alan Nevitt, Liping Huang, Michael M Peng, Stephen Toovey. (United States)
- 56 **Drug Utilization in Paediatric Hospitals: An International Perspective [98]**
Asia Rashed, Kenneth Lee, Noel Cranswick, Steve Tomlin, Wolfgang Rascher, Ian Wong, Antje Neubert. (United Kingdom)
- 57 **Drug-Drug Interactions: Theoretical or Clinically Relevant? [99]**
Gabriella Martha, Peter Doro, Ria Benko, Ilona Higysan, Maria Matuz, Gyongyver Soos. (Hungary)
- 58 **Comprehensive Survival Analysis of a Cohort of Patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) [100]**
Peggy Sekula, Yvonne Liss, Sylvia H Kardaun, Jean-Claude Roujeau, for the RegiSCAR-Study Group. (Germany)
- 59 **Risk of Hepatotoxicity-Related Hospitalizations among Patients Treated with Opioid/Acetaminophen Combination Prescription Pain Medications [101]**
Mei-Sheng Duh, Francis Vekeman, Caroline Korves, Patrick Lefebvre, Ellison Dial, Dominick Latremouille-Viau, Robert S Wei, Bruce E Stangle, Marie-Helene Lafeuille, Edward Michna, Paul E Greenberg. (United States)

CNS

- 60 **High Degree of Co-Medication of Benzodiazepines in Norway [102]**
Marte Handal, Svetlana Skurtveit, Jørg G Mørland. (Norway)
- 61 **A Comparison of Opioid Use Patterns in Medicare, Medicaid, and a National Prescription Tracker Service [103]**
Fatmatta Kuyateh, Hina Mehta, Rita Ouellet-Hellstrom, Farzana Ali, Emily Singer, Thomas E MaCurdy, David J Graham. (United States)
- 62 **Patterns and Predictors of Pharmacotherapy after Hospitalization for Major Depression [105]**
Jennifer Lund, Stacie Dusetzina, Bradley Gaynes, Richard Hansen, Michele Jonsson Funk. (United States)
- 63 **Patients' Value of Benefits and Harms of Migraine Treatments [106]**
Paul M Coplan, Brett A Hauber, Ateesha Mohamed, Reed F Johnson, Bennett Levitan. (United States)
- 64 **Antiepileptic Drug Use during Pregnancy: Perinatal Outcomes with Monotherapy, Polytherapy, or Discontinuation of Treatment [107]**
Sophie Kulaga, Odile Sheehy, Amir Zargarzadeh, Anick Bérard. (Canada)
- 65 **Accuracy of Reporting and Method for Classifying Progressive Multifocal Leukoencephalopathy (PML) within the FDA Adverse Event Reporting System (AERS) [108]**
Anokhi J Kapasi, Bao-Anh Nguyen-Khoa, Earl L Goehring, Jr, Kimberly Alexander, Pavel K Napalkov, Nadia Foskett, Judith K Jones. (United States)
- 66 **Can Pharmacoethnicity Be Studied in Spontaneous Reports? The Example of Vincristine Neurotoxicity [109]**
M Hauben, M Younus, A Bate. (United States)
- 67 **Analysis of Aripiprazole Utilisation from Prescription-Event Monitoring (PEM): Focus on Off Label Use in Support of Risk Management [110]**
Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

- 68 Prescribed Antipsychotic Drugs and Risk of Re-Hospitalization among Incident Patients with Schizophrenia-Related Diagnosis [111]**
Olof Stephansson, Johan Reutfors, Lena Brandt, Helle Kieler. (Sweden)
- 69 Co-Prescribing of Medications with Anticholinergic Properties to Those Using Cholinesterase Inhibitors for Dementia [112]**
Katherine Bloomfield, Nick John, Anita McGrogan, Roy Jones, Corinne de Vries. (United Kingdom)
- 70 Overdose Deaths in Relation to Filled Prescriptions with Methadone, Subutex and Suboxone [113]**
Helle Kieler, Lena Brandt, Henrik Druid, Johan Franck, Olof Stephansson. (Sweden)
- 71 The Impact of Regulatory Action on ECG Monitoring in Patients with Dopamine Agonists in Japan: Analysis of Claims Database [114]**
Nobuhiro Ooba, Takuhiro Yamaguchi, Kiyoshi Kubota. (Japan)
- 72 Risk of Falls in the Elderly Population Using Antipsychotics: A Systematic Review [115]**
Sarah-Gabrielle Beland, Anne-Marie Cloutier, Camille Craig, Michel Preville, Yola Moride. (Canada)
- 73 Factors Associated with Adherence and Persistency to Antidepressants in Korea [117]**
Sun-Young Jung, HyunJin Song, Sangjin Shin, Eunhee Shin, JooYeon Park, Jeonghoon Ahn. (Republic of Korea)
- 74 Heterogeneity in Drug Utilization in Three European Countries: A Study of Dopamine Agonists [658]**
Cynthia de Luise, Gianluca Trifirò, Mostafa Mokhles, Jeanne Dieleman, Eva van Soest, Giampiero Mazzaglia, Ron Herings, Doug Ross, Miriam Sturkenboom. (United States)

*Drug Utilization Research/
Health Services Research*

- 75 Abstract Withdrawn by Author [118]**
- 76 Hormone Replacement Therapy Prescription in France [119]**
Florence Gass, Christine Damase-Michel, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc. (France)
- 77 Medication Usage and Prominent Predictors of High Level Polypharmacy in Hospitalized Indian Elderly: A Study from Two Tertiary Care Hospitals [120]**
Gurumurthy Parthasarathi, Anand Harugeri, Madhan Ramesh, Shoba Guido. (India)
- 78 Utilization, Price and Expenditure Trends for Both Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Medicaid Program [121]**
Boyang Bian, Jeff Guo, Chris Kelton, Patricia Wigle. (United States)
- 79 Abstract Withdrawn by Author [122]**
- 80 Antiepileptic Drug Utilization and Medicaid Reimbursement Trends from 1991 to 2008 [123]**
Namita Tundia, Jeff J Guo, Patricia R Wigle, Pamela C Heaton. (United States)
- 81 The Epidemiology, Treatment and Care Patterns, and Medical Resource Utilization Following Hospitalization for Heart Failure [124]**
Caroline Korves, Joshua McHale, Marie-Helene Lafeuille, Rinat Arieli, Mei Sheng Duh. (United States)
- 82 Changes in Insulin Dose in Response to Severe Hypoglycemia in the Diabetes Control and Complication Trial [125]**
Zhiwen Liu, Timothy S Carey, Til Stürmer. (United States)
- 83 Utilization, Price, and Expenditure Trends for Anti-Migraine Drugs in the U.S. Medicaid Program from 1991 through 2008 [126]**
Chien-Hsiang Chiu, Jeff J Guo, Paricia R Wigle, Alex C Lin. (United States)
- 84 Racial and Ethnic Disparities in Quality of Health Care among Adults with Diabetes in the United States in 2005-2006 [127]**
Yan-Jun Zhang, Monica Holiday-Goodman, Aliaksandr Amialchuk, Jing-Bo Wang, Rose Jung. (United States)

- 85 Evaluation of Guideline-Conformity of Initiation of Oral Hypoglycemic Treatment for Incident Diabetes Mellitus Type 2 in Austria [128]**
Wolfgang C Winkelmayr, Margaret R Stedman, Michaela Pogantsch, Peter Wieninger, Anna Bucsecs, Alan Brookhart. (United States)
- 86 Knowledge and Attitudes towards Complementary and Alternative Medicine by Pharmacy Students [129]**
Ilse Truter. (South Africa)
- 87 Health Care Resource Utilization among Hispanic and Non-Hispanic White Adults in the United States [130]**
Margaret McDonald, Michael B Lustik. (United States)
- 88 Drug Utilization Study on the Prescribing Indications of Oral Contraceptives in Croatia [131]**
Kristina Bardenheuer, Juergen Dinger, Anita Assmann, Klaas Heinemann, Janko Leddin. (Germany)
- 89 News Reports of Medicines in Relation to Decisions of the Australian Pharmaceutical Benefits Advisory Committee [132]**
Jane Robertson, Marc D Bevan, Emily J Walkom, David A Newby. (Australia)
- 90 Use of Cytochrome P450 Inducers and Inhibitors in Patients with Osteoarthritis Compared to the General Population [133]**
Stephen P Motsko, John Roberts, Dharam Singh, Jill Chappell. (United States)
- 91 Descriptive Analysis of Antipsychotic Prescriptions in Primary Care [134]**
P Prah, I Petersen, I Nazareth, K Walters, D Osborn. (United Kingdom)
- 92 Drug Burden as a Predictor of Adherence to a Newly Prescribed Statin [135]**
Jennifer Polinski, Elisabetta Patorno, Amrita Desai, Wei Liu, Suyog Kamatkar, Kristin Palmsten, Joy Lee, Joshua Gagne. (United States)
- 93 The Challenge of Drug Regimen Surveillance When Changing Level of Care [136]**
Kirsten K Viktil, Hege S Blix, AnneK Eek, TronA Moger, Aasmund Reikvam. (Norway)

Gut

- 94 Validation of ICD-9-CM Codes To Identify Gastrointestinal Perforation (GIP) Cases in Administrative Claims Data in Rheumatoid Arthritis (RA) Patients [137]**
Jeffrey R Curtis, Shih-yin Chen, Winifred Werther, Ani John, David Johnson. (United States)
- 95 Long-Term Statin Use Reduces the Risk of Gallstone Disease – A Population-Based Case-Control Study [138]**
Rune Erichsen, Trine Frøslev, Lars Pedersen, Henrik T Sørensen. (Denmark)
- 96 Trends in the Consumption and Costs of Oral Antidiabetic Drugs in Portugal, 2004-2009 [139]**
Carla Torre, José Guerreiro, Suzete Costa. (Portugal)
- 97 Tysabri TOUCH Prescriber Program Risk Management Program (Risk-MAP) Surveys [140]**
Kelly Hollis, Brian Calingaert, Mark Price, Elizabeth Andrews, Liam Moy, Mariska Kooijmans, Lynda Cristiano, Carmen Bozic. (United States)
- 98 Antibacterial Use and Risk of Acute Pancreatitis: A Case-Control Study Using the National Veterans Affairs Database [141]**
Thamir M Alshammari, Aisling R. Caffrey, Kerry L LaPlante, Brian J Quilliam, Robert Laforge, E Paul Larrat. (United States)
- 99 Potential Diagnostic/Ascertainment Bias Associated with Endoscopic Findings among Bisphosphonates Users [142]**
Robert N Lubwama, Tzuyung D Kou, Julie Chandler. (United States)
- 100 Stable Incidence of Type I Diabetes in Children Observed in the Norwegian Prescription Database (NorPD) in the Period 2005-2009 [143]**
Hanne Strøm, Christian Berg, Randi Selmer. (Norway)
- 101 Clinical Outcomes in Familial Adenomatous Polyposis (FAP) Patients with a Long-Term Treatment of Celecoxib: A Matched Cohort Study [144]**
Kui Huang, Lia P Gutierrez, Steffen Bulow, Steven Gallinger, Antoni Castells, Craig J Eagle, James M Church. (United States)

- 102 Temporal Trends in Compliance with the Alosetron Risk Management Program (RMP) [145]**
Kelly Hollis, Pat Tennis, Jean Paul Nicandro, Paul Shin, Carolyn Sweeney, Lee Bennett, Elizabeth Andrews. (United States)
- 103 Influenza and the Incidence of Acute Pancreatitis in a UK Population [146]**
William A Blumentals, Alan Nevitt, Liping Huang, Michael M Peng, M Connie Abelardo. (United States)

Lungs

- 104 Adherence to Inhaled Corticosteroids among Adult Patients Privately Insured [147]**
Marie-Christyne Cyr, Amélie Forget, Lucie Blais. (Canada)
- 105 Characterization of Salmeterol Utilization and Concurrent Asthma Therapy [148]**
Sigal Kaplan, Yulan Ding. (United States)
- 106 Utilization of Cough/Cold Preparations among Pediatrics in Taiwan [149]**
Ching-Lan Cheng, Yea-Huei Kao Yang, Swu-Jane Lin. (Taiwan)
- 107 Risk of Serious Asthma Exacerbations Associated with Long-Acting-Beta-Agonists among Medicaid Patients with Asthma: A Retrospective Cohort Study [150]**
Jeff J Guo, Katherine Tsai, Christine ML Kelton, Boyang Bian, Patricia R Wigle. (United States)
- 108 Evaluating Safety of Long-Acting Beta Agonists (LABAs) in Patients with Asthma [151]**
Boyang Bian, Jeff Guo, Chris Kelton, Patricia Wigle. (United States)
- 109 Drug-Induced ECG Abnormalities in Patients with COPD [152]**
Miriam J Warnier, Marie L de Bruin, Frans H Rutten, Arno W Hoes, Ton de Boer. (Netherlands)
- 110 Economic Evaluation of an Inpatient Medication Reconciliation Process on Medication and Labour Costs [153]**
Fatma Karapinar, Sander D Borgsteede, Jan Zoer, Marjo JA Janssen, Antoine CG Egberts, Patricia MLA van den Bemt, Maurits van Tulder. (Netherlands)
- 111 Off Label Prescribing of Inhaled Corticosteroids to Children with Asthma in Primary Care [154]**
Hajer Elkout, Peter J Helms, Colin R Simpson, James S McLay. (United Kingdom)

Medications in Pregnancy

- 112 Pregnancy Outcomes Associated with Substitution Treatment for Opioid Dependency: A Pilot Study Using Danish Population Registries [155]**
Zhiping Huang, Helen Huang, Anne-Mette Bay Bjørn, Vera Ehrenstein. (United States)
- 113 Treatment of Diabetes before and during Pregnancy [156]**
Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)
- 114 Increased Risk for Spontaneous Abortion and Preterm Birth Associated with Antidepressant Use in Pregnancy: A Comparison between Continuers and Discontinuers [157]**
Adrienne Einarson, Jacqueline Choi, Pina Bozzo, Gideon Koren, Thomas Einarson. (Canada)
- 115 Fluoxetine and Infantile Hypertrophic Pylorus Stenosis: A Signal from a Birth Defects – Drug Exposure Surveillance Study [158]**
Marian K Bakker, Hermien EK De Walle, Bob Wilffert, Lolkje TW De Jong-van den Berg. (Netherlands)
- 116 Antidepressant Use during Pregnancy and Congenital Malformations: Systematic Review of Study Methods, Confounders and Limitations [159]**
Deborah A Kennedy, Adrienne Einarson, Marcio Machado, Sachi Sakaguchi, Irene Lara, Amy Sharma, Hisaki Fujii, Alexandra Balma-Mena, Hiroaki Aoki, Elena Reydman, Thomas R Einarson. (Canada)
- 117 Pregnancy Exposure Registries: Prenatal Testing Allowed? [160]**
Susan S Roberts, Jessica D Albano. (United States)
- 118 Trends in Prescriptions for Folic Acid among French Pregnant Women: Assessment of Accordance with Recommendations [161]**
Reginald Riwer, Caroline Hurault, Robert Bourrel, Jean Louis Montastruc, Christine Damase-Michel, Isabelle Lacroix. (France)
- 119 Medication Use during Pregnancy in Out-Patient Setting of an Indian Tertiary Care Hospital [162]**
Gurumurthy Parthasarathi, Nidudi R Veda, Madhan Ramesh, Anand Harugeri. (India)
- 120 Population-Based Antiepileptic Drug Utilization Study in Europe among Pregnant Women [163]**
Janneke Jentink, Christine Damase-Michel, Lolkje TW de Jong-van den Berg. (Netherlands)

121 Evaluation of the Representativeness of a Dutch Non-Malformed Control Group with the General Pregnant Population, Are They Useful as Controls for EUROCAT? [164]

Janneke Jentink, Lolkje TW de Jong-van den Berg. (Netherlands)

122 Prevalence of Antidepressant and/or Benzodiazepine Polytherapy during Pregnancy [165]

Odile Sheehy, Mélanie Soumaille, Martin St-André, Berard Anick. (Canada)

123 Socio-Demographic and Lifestyle Predictors of Folic Acid and Multi-vitamin Supplementation in Danish Pregnancy Planners [166]

Heidi T Cueto, Anders Riis, Lauren A Wise, Elizabeth E Hatch, Kenneth J Rothman, Henrik T Sørensen, Ellen M Mikkelsen. (Denmark)

124 Improving Accuracy in Enrollment Targets for Pregnancy Registries [167]

Deborah Covington, Hadley Mates, Paige Churchill, Amanda Golembesky, Laura McKain. (United States)

Methods

125 A Combined Comorbidity Score for Predicting 1-Year Mortality in Elderly Patients Using Healthcare Claims Data [168]

Joshua Gagne, Robert Glynn, Jerry Avorn, Raisa Levin, Sebastian Schneeweiss. (United States)

126 National Estimates of Pediatric Inpatient Medication Use in the US in 2008 [169]

Tamar Lasky, Shirley V Wang, Frank R Ernst, Jay Greenspan, M Lilianna Gonzalez. (United States)

127 Qualitative Evaluation of Medication Use in Two Different Geriatric Inpatient Populations of a University-Affiliated Hospital [170]

Jean Frederic Westphal, Cathy Nonnenmacher. (France)

128 Assessing the Effectiveness of Counter Matching as a Tool for Improving the Efficiency of the Nested Case Control Design in Pharmacoepidemiological Studies [171]

Victor A Kiri, Gilbert MacKenzie. (United Kingdom)

129 Room for Improvements in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs [172]

Grace Wangge, Olaf H Klungel, Kit CB Roes, Anthonius de Boer, Arno W Hoes, Mirjam J Knol. (Netherlands)

130 Validation of Claims-Based Diagnostic Codes for Severe Hypoglycemic Events (SHEs) in a Commercially-Insured Population [173]

Debra F Eisenberg, Gregory W Daniel, Usha Subramanian, Tracy Breen, Rhonda L Bohn, Peter M Wahl, William H Herman. (United States)

131 Accuracy of Identifying Outpatient Neutropenia Diagnoses in Claims Data [174]

Seo Young Kim, Daniel H Solomon, Jun Liu, Gina Chang, Gregory W Daniel, Sebastian Schneeweiss. (United States)

132 Extracting Meaningful, Searchable and Discrete Data from Unstructured Medical Text [176]

Aaron WC Kamauu, Gerasimos Petratos, Anthony Amey, Peter Bechtel, Daniel Dine. (United States)

133 Comparison of Two Penalized Regression Methods for Signal Detection [177]

Marietta Rottenkolber. (Germany)

134 A Combined Statistical and Non-Statistical Approach to Assessing Whether Adverse Events Associated with Different Lots of Identical Drug Are Clinically and Statistically Relevant [178]

Dorian Villegas, Wendy Ye, Fred Schneeweiss, Mark Von Tress, Sam Yonren. (United States)

135 The Effect of Reimbursement System Versus Global Financial System on Drug Cost, Percentage of Branded Drug and Adherence of Drug Prescription to Guideline [179]

Lili Komariah Darmawiredja, Iwan Dwiprahasto, Erna Kristin. (Indonesia)

136 Development of an Automated Pharmacovigilance System within the Military Healthcare System [180]

Trinka Coster, David Fram, Suji Xie, Karl Friedl, Paul Cordts. (United States)

137 Between and within Practice Variability among Practices within the Health Improvement Network [181]

Kevin Haynes, Warren B Bilker, Tom R TenHave, James D Lewis. (United States)

138 Signal Detection Biases Caused by the Use of Differentially Reported Non-Serious Events in the FDA AERS Database [182]

Keith L Altman. (United States)

139 A Demonstration of the Importance of Population Specification in Study Design [183]

Laura E Burlinson. (United States)

140 Generation of Safety Data in Clinical Trials: What Are Participants' Perspectives of Reporting? [184]

Elizabeth N Allen, Clare IR Chandler, Sarah G Staedke, Karen I Barnes. (South Africa)

141 How To Implement New Statistical Tools in Vaccine Safety? Hurdles Encountered [185]

Annette Koller Doser, Katharina Hartmann, Griot Monika. (Switzerland)

142 Bias Is Worse Than Noise: Handling Missing Data for Confounders in Observational Studies [186]

Eric P Elkin, Dave P Miller. (United States)

143 Development of a Claims-Based Healthcare Safety Sentinel System Featuring Signal Strengthening during Sequential Monitoring [187]

Peter M Wahl, Sebastian Schneeweiss, Thomas E Wasser, Debra F Eisenberg, Keith Rodgers, Joshua J Gagne, Jeremy A Rassen, Jerry Avorn, Rhonda L Bohn. (United States)

144 Automated EMR Data Processing System for Post-Market Surveillance [188]

Dukyong Yoon, Man Young Park, KiYoung Lee, Rae Woong Park. (Republic of Korea)

145 Data-Driven Analysis of Comorbidities Associated with Systemic Lupus Erythematosus in Marketscan Claims Database [189]

Hans Petri, Debra Maldonato, Noah J Robinson. (United Kingdom)

146 Quality of Reporting of Harms in Randomized Controlled Trials: An Example Using Human Papillomavirus (HPV) Vaccines [191]

Leah M Smith, Jeevitha Srighanthan, Karen KY Poon, Linda E Lévesque. (Canada)

147 Evaluating Adherence to Antihypertensive Medication Using Medication Event Monitoring System [192]

Peter Doro, Ria Benko, Aniko Czako, Maria Matuz, Ferenc Thurzo, Gyongyver Soos. (Hungary)

POSTER SESSION A Friday, August 20

- 148 Development of a Comorbidity Score To Predict Disability in Older Adults from Prescription Claims Data [193]**
Marie-France Dubois, Edeltraut Kröger, Nicole Dubuc, Ronald Girard, Réjean Hébert. (Netherlands)
- 149 The Relationship between Bisphosphonate Adherence and Fracture: Is It the Behavior or the Medication? Results from the Placebo Arm of the Fracture Intervention Trial [194]**
Jeffrey R Curtis, Elizabeth Delzell, Lang Chen, Suzanne Judd, Dennis Black, Kristine Ensrud, Lisa Palermo, Monika Safford, Ann Schwartz, Doug Bauer. (United States)
- 150 Linking UK Death Certificate Data to UK Primary Care Data (GPRD) To Obtain Cause of Death [195]**
Efrosini Setakis, Arlene Gallagher, Tim J Williams, Tjeerd P VanStaa. (United Kingdom)
- 151 Nephrogenic Systemic Fibrosis (NSF) and Gadolinium-Based Contrast Agents (GBCAs). A Statistical Simulation Study [196]**
Alexander Michel, Tilo Blenk. (Germany)
- 152 Prediction Equations for Adjusting Reporting Error in Self-Reported BMI [197]**
Lina Titievsky, Andrew G Rundle. (United States)
- 153 Tools and Methods for Sample Size Calculation Using Person-Time Data [198]**
X Zhou, R E Sobel, A Bate. (United States)
- 154 SALOME: A Pilot Study To Test Causality Assessment of Drug-Exposed Acute Liver Failure Cases Using Different Scales [199]**
Ezgi Gulmez, Georges Pageaux, Dominique Larrey, Franco Bissoli, Yves Horsmans, Jacques Bernuau, Bruno Stricker, Douglas Thorburn, Patrick Blin, Nicholas Moore. (France)
- 155 An Algorithm To Identify Practices Common to Both the GPRD and THIN Database [200]**
Bing Cai, Weifeng Xu, Edward Bortnichak, Watson Douglas. (United States)
- 156 Applying Data-Mining Techniques to Paediatric Data within the WHO-UMC Database; the Impact of Vaccines [201]**
S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturkenboom. (Netherlands)

- 157 Nimesulide Suspension in Acute Upper Respiratory Infection in Asian Indian Paediatric Population: Results from Post Authorization Safety Study [202]**
Manoj Sharma, Arani Chatterjee. (India)
- 158 Educating a Pharmacoepidemiology Researcher on Selecting Optimal Healthcare Databases for Research [203]**
S A Kamani, E L Goehring, Jr, A J Kapasi, B Nguyen-Khoa, V P Singh, J K Jones. (United States)
- 159 Drug Prescription Monitoring System To Estimate Incidence and Prevalence of Type 1 Diabetes [204]**
Marina Maggini, Roberto Da Cas, Carlotta Lunghi, Flavia Pricci. (Italy)
- 160 Missing Data in Primary Care Databases; Problems and a Possible Solution [205]**
Louise Marston, James Carpenter, Kate Walters, Richard Morris, Irwin Nazareth, Irene Petersen. (United Kingdom)
- 161 Sequential Analysis for Safety Surveillance [206]**
Alexander M Walker, Martin Kulldorff. (United States)
- 162 A Real Time Opioid Class REMS: User Acceptance Pilot [175]**
Edgar Adams, Nat Katz, Kevin Flynn, Robin Kinard, Rick Sage. (United States)
- 163 A Real Time Opioid Class REMS: Technical Feasibility [207]**
Edgar Adams, Nat Katz, Kevin Flynn, Robin Kinard, Rick Sage. (United States)
- 164 The RCT Participant Cohort Study [208]**
Daniel O Koralek, Nicolle M Gatto. (United States)
- 165 Evaluation of US Package Inserts Following the Physician Labeling Rule [209]**
James Buchanan, Sally Van Doren. (United States)
- 166 Suitable Study Designs for Pharmacogenetic Research [210]**
F H van der Baan, O H Klungel, D E Grobbee, A CG Egberts, M J Knol. (Netherlands)
- 167 Evaluation of Death Information in Claims Database [211]**
Shuko Nojiri, Tsugumichi Sato, Kiyoshi Kubota. (Japan)

Muscles and Bones

- 168 Persistency and Concurrency Analysis of Leflunomide Therapy [212]**
Sigal Kaplan, Esther Zhou. (United States)
- 169 Effectiveness of Osteoporosis Drugs in Preventing Secondary Fracture in Taiwan [213]**
Tzu-Chieh Lin, Yea-Huei Kao Yang, Chyun-Yu Yang. (Taiwan)
- 170 Nonsteroidal Anti-inflammatory Drug Use and Risk of Venous Thromboembolism: A Population-Based Case-Control Study [214]**
Morten Schmidt, Christian F Christiansen, Erzebét Horvath-Puho, Henrik Toft Sørensen. (Denmark)
- 171 Influence of Socioeconomic Factors on the Persistence of Alendronate Use. A Nationwide Prescription Database Study in Norway [215]**
Helene Devold, Kari Furu, Svetlana Skurtveit, Aage Tverdal, Jan A Falch, Anne Johanne Sogaard. (Norway)
- 172 Effects of Cox-2 Selectivity NSAID Groupings in UGIB and MI ADR Detection Using Bayesian Hierarchical Modeling: EU-ADR Project [216]**
D Prieto, M Molokhia, S Evans, M Schuemie, R Herings, J van der Lei, M Sturkenboom. (United Kingdom)

Pharmacovigilance

- 173 Abstract Withdrawn by Author [217]**
- 174 Incidence Rates of Edema in Solid Tumor Cancer Patients in the THIN Database [218]**
Victor Gastanaga, Chuck Wentworth, Vanitha Ganesh, Gail Hughes, Fei Xue, Mukesh Verma, Isaiah Dimery, Sean Zhao. (United States)
- 175 Pharmacoepidemiological Study of Antiretrovirals in Lagos University Teaching Hospital South West Nigeria [219]**
Ibrahim Adekunle Oreagba, Sikiru Olatunji Usman, Sulaiman Akanmu, Oluranti Opanuga. (Nigeria)
- 176 To Study the Extent of Off-Label Drug Use in Paediatric Population and Occurrence of Fatal ADRs: A 03 Months Study in a Large Multispeciality Hospital in India [220]**
Pradeep Kumar, Arun K Biswas, Pipasha N Biswas. (India)

177 To Study the Extent of Off-Label Drug Use in an Adult Population and Occurrence of Fatal ADRs: A 03 Month Study in a Large Multispeciality Hospital in India [221]

Pradeep Kumar, Arun K Biswas, Pipasha N Biswas. (India)

178 Active Monitoring of Antiviral Medications in Korea [222]

Hye Jin Park, JaYoung Kim, Junghoon Jang, Myung Jung Kim, Young Hoon Kim, Ji-Hye Ha. (Korea)

179 Sex-Related Differences in Hospital Admissions Due to Adverse Drug Reactions in the Netherlands [223]

Eline M Rodenburg, Bruno HCh Stricker, Loes E Visser. (Netherlands)

180 Adverse Events with Fatal Outcome, a Ten Year Survey of Iranian Spontaneous Reports Database [224]

Shadi Yousefian, Gloria Shalviri. (Islamic Republic of Iran)

181 Drug Dictionaries Information on the Risk of Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis: Discrepancies with Pharmacoepidemiology Studies [225]

Cynthia Haddad, Alexis Sidoroff, Sylvia Kardaun, Maja Mockenhaupt, Daniel Creamer, Jean Claude Roujeau, The RegiSCAR Study Group. (France)

182 Prescription Combination Medicines Significantly Contribute to Acetaminophen Exposure in the U.S. [226]

Gregory E Powell, Julie I Papay, Ed N Pattishall, Christine M Hunt. (United States)

183 Patient Reporting of Adverse Drug Reactions in the UK: Potential Signals Generated by Patients Compared to Healthcare Professionals [227]

Lorna Hazell, Victoria Cornelius, Saad Shakir, Anthony Avery. (United Kingdom)

184 Glaucoma Management in the Patient with Airways Disease: Are We Helping or Harming? [228]

Andrew L Gilbert, Elizabeth E Roughead. (Australia)

Risk Management / Communication

185 Medication Errors Made by Nurses – A Result of Interrelated Human and System Factors [229]

Monica Bergqvist, Eva Andersén Karlsson, Karin Sparring Björkstén, Carolin Modigh, Lina Benson, Johanna Ulfvarson. (Sweden)

186 An Environmental Scan of Risk Minimisation Interventions [230]

Lenhang Nkeng, Anne-Marie Cloutier, Camille Craig, Jacques Leloir, Yola Moride. (Canada)

187 Evaluation of Medication Safety in Neurological Inpatients Using the Clinical Decision Support Software MediQ [231]

Markus Guzek, Martin Huber, Stefan Russmann. (Switzerland)

188 Abstract Withdrawn by Author [232]

189 In-Hospital Therapeutic Risk Management Following a Fall in the Geriatric Population: Taking the Evidence to the Bedside [233]

Sarah Gabrielle Béland, Antoine Pariente, Marie-Jeanne Kerogat, Judith Latour, Yola Moride. (Canada)

190 Characterization of Current Risk Evaluation and Mitigation Strategies (REMS) [234]

Alicia W Gilsenan, Elizabeth B Andrews, Kelly A Hollis. (United States)

191 Regulatory Scientific Advice: Does Company Size Matter? [235]

Michelle Putzeist, Aukje M Mantel-Teeuwisse, Christine C Gispén-De Wied, Arno W Hoes, Hubert G Leufkens. (Netherlands)

192 Characteristics of Patients Prescribed Sitagliptin and Other Oral Antihyperglycemic Agents in a Large U.S. Claims Database [236]

Bing Cai, Leonid Katz, Charles M Alexander, Deborah Williams-Herman, Cynthia J Girman. (United States)

Miscellaneous

193 Automated Robust Mapping GPRD Medical Diagnosis Read Codes to SNOMED CT for OMOP Project [248]

Hoa V Le, Kathleen J Beach. (United States)

194 Effect of Different Trimming Methods for Propensity Score Distribution on Risk Estimates [249]

Hoa V Le, Kathleen J Beach. (United States)

195 Association between Bilirubin and Oxidative Stress Mediated Disease [604]

Laura Horsfall, Greta Rait, Kate Walters, Dallas M Swallow, Stephen P Pereira, Irene Petersen. (United Kingdom)

End Session A

Need Evidence?

Patient Registries	Comparative Effectiveness
Safety / Surveillance	Phase IIIB Expanded Access
Risk Management	Quality Measurement
Health Outcomes	Quality Improvement
Phase IV Studies	Health Interventions
Quality of Life	Observational Studies

Talk to the Leader in Real-World Research.

Visit Outcome booth #20 at the ICPE Annual Meeting!



www.outcome.com evidence@outcome.com 617-621-1600 +41 (0) 21 321 3560

Anti-Infectives

- 1 **Evaluating the Effects of a FDA Boxed Warning on Adverse Event Reporting: Is There a Difference in the Rate of Reporting of Tendon-Related Adverse Events Associated with the Use of Fluoroquinolones after a FDA Boxed Warning?** [316]
Axel Olsen, Mary Mease, John R Hall, Eric Gemmen, William Garvert. (United Kingdom)
- 2 **Adverse Events Induced by Ceftriaxone: A Ten Years Review of Reported Cases to Iranian Pharmacovigilance Centre** [317]
Gloria Shalviri, Shadi Yousefian, Kheirollah Gholami. (Islamic Republic of Iran)
- 3 **The Study of Adverse Drug Reaction of Telbivudine in Chronic Hepatitis B Virus Infection at Siriraj Hospital** [318]
Pramote Tragulpiankit, Naruemon Dhana, Tawesak Tanwandee, Nitiphout Phumjun, Ploylarp Lertvipapath. (Thailand)
- 4 **Comparison of Systemic Antimicrobials (AM) Consumption and Costs in Different Wards of Multi-Profile Hospital** [319]
Ljubov L Kozhuhova, Svetlana A Ratchina, Alexander A FoKin, Elena V Korneva, Vladimir M Mischenko, Roman A Pavlukov. (Russian Federation)
- 5 **Signal Detection Research of Osetamivir Using Administrative Data for Public Insurance** [320]
Suhyun Lee, Chungam Choi, Wan Gyoon Shin. (Korea)
- 6 **Factors Influencing Antimicrobial (AM) Prescribing to Adult Patients with Acute Rhinosinusitis (ARS)** [321]
E Shal, S Ratchina, V Mischenko, L Kozhuhova, S Palyutin, O Reshetko, S Suleymanov, I Toropova. (Russian Federation)
- 7 **A Drug Utilization Study of Posaconazole in French Hospitals** [322]
Helen Huang, Zhiping Huang, Sandrine Coulomb, Antoine Lafuma, Alejandro Arana. (United States)
- 8 **TdP Liability of Fluoroquinolones: Integrated Approach Based on FDA Spontaneous Reports and Literature Data** [323]
Emanuel Raschi, Elisabetta Poluzzi, Ugo Moretti, Fabrizio De Ponti. (Italy)
- 9 **Abstract Withdrawn by Author** [324]

- 10 **Detection of Fluoroquinolone-Induced Tendon Disorders Using a Hospital Database** [325]
Katsuhito Hori, Kasumi Yamakawa, Naoko Yoshida, Kazunori Ohnishi, Junichi Kawakami. (Japan)
- 11 **Trends in Consumption Antimicrobials for Six Years (2003-2008) in Clinical Centre University of Sarajevo** [326]
Begler Begovic, Lejla Begovic, Amra Cabaravdic. (Bosnia and Herzegovina)
- 12 **Exposure to Co-Trimoxazole and the Risk of Cardiac Dysrhythmia** [327]
William A Blumentals, Steven E Elkin, Miriam Adamcova. (United States)
- 13 **Abstract Withdrawn by Author** [328]
- 14 **Concomitant Use of Drugs That Prolong the QT Interval during Methadone Maintenance Treatment** [349]
Klaus Romero, Rowan Frost, Mary Brown, Raymond L Woosley. (United States)

Cardiovascular

- 15 **Antihypertensive Drug Use and Risk of Depression: A Nested Case-Control Study from the Panor@mica Database** [329]
F Salvo, F Bazin, P Noize, A Fourier-Réglat, V Arcoraci, D U Tari, S Moretti, A P Caputi, A Pariente. (France)
- 16 **Interim Results of a Modified Prescription Event Monitoring Study on Ivabradine: Case Series of Utilisation in Patients under the Age of Forty Years** [330]
C Doe, C Fogg, D Layton, Saad AW Shakir. (United Kingdom)
- 17 **Management of Acute Myocardial Infarction in France: Results from the EOLE Cohort** [331]
C Droz, C Dureau, D Thomas, N Danchin, J Tricoire, J Bénichou, F Paillard, P Ducimetière, S Hercberg, H Maïzi, E Guiard, M-A Bernard, P Blin, N Moore. (France)
- 18 **The SOS Project: Stroke Risk and Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). A Systematic Review of Epidemiological Studies** [332]
Cristina Varas-Lorenzo, Brian Calingaert, Nuria Riera-Guardia, Jordi Castellsague, Antoine Pariente, Lorenza Scotti, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 19 **The SOS Project: Risk of Acute Myocardial Infarction and Use of NSAIDs. A Meta-Analysis of Epidemiological Studies** [333]
Cristina Varas-Lorenzo, Nuria Riera-Guardia, Brian Calingaert, Jordi Castellsague, Francesco Salvo, Federica Nicotra, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)
- 20 **Effects of Phytosterol/-Stanol-Enriched Margarines on Effectiveness of Statins and Adherence to Therapy** [334]
Simone Eussen, Nynke de Jong, Cathy Rompelberg, Johan Garssen, Monique Verschuren, Olaf Klungel. (Netherlands)
- 21 **Drug Utilization Evaluation on the Combination of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Taiwan** [335]
Wen-Yi Chang, Li-Chia Chen, Li-Jen Cheng. (Taiwan)
- 22 **Past Adherence as a Predictor of Future Adherence to Preventive Drug Treatments** [336]
Colin Dormuth, Amanda Patrick, Sutherland Jenny, Alan Brookhart. (Canada)
- 23 **Identifying the Predictors for Adverse Drug Reaction Due to Angiotensin Converting Enzyme Inhibitors in Indian Hospitalized Patients** [337]
Thiyagu Rajakannan, Laxminarayana K Bairy, Padma GM Rao, Dipesh Patel, Padmakumar Ramachandran. (India)
- 24 **Abstract Withdrawn by Author** [338]
- 25 **Thromboprophylaxis of Patients Receiving Total Knee Replacement: 1998-2002 Versus 2003-2007** [339]
Willemijn M Meijer, Jetty A Overbeek, Kimberly Woodruff, Joseph Jackson, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)
- 26 **The Effect of Rosuvastatin on Hemoglobin Levels in Patients with Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial** [340]
Maurice A Brookhart, Daniel H Solomon, Robert J Glynn, Paul M Ridker. (United States)
- 27 **Angioedema and ACE Inhibitors or Angiotensin II Receptor Blockers, Revisited** [341]
Rachel L Jones, Genevieve M Gabb. (Australia)

- 28 Statin Use and the Prevalence of Autoantibodies in the Doetinchem Cohort [342]**
HJl de Jong, JW Cohen Tervaert, OH Klungel, PC Souverein, RJ Vandebriel, J Damoiseaux, H van Loveren, WMM Verschuren. (Netherlands)
- 29 Patient's Medication Adherence in Primary Hypertension [343]**
Josip Culig, Marcel Leppee, Jelena Boskovic. (Croatia)
- 30 The Impact of Prescribing Guidelines on Physician Selection of Drug Therapy for Newly Diagnosed Patients with Hypertension in the UK [344]**
Brian Serumaga, Anthony Avery, Rachel Elliott. (United States)
- 31 Association between the Use of Statins and Systemic Lupus Erythematosus [346]**
SRF Saldi, HJl de Jong, PC Souverein, RHB Meyboom, RJ Vandebriel, JW Cohen Tervaert, H van Loveren, OH Klungel. (Netherlands)
- 32 Sibutramine Adverse Drug Reactions [347]**
Pakawadee Sriphiromya. (Thailand)
- 33 Thromboprophylaxis of Patients Receiving Total Hip Replacement: 1998-2002 Versus 2003-2007 [348]**
Willemijn M Meijer, Jetty A Overbeek, Kimberly Woodruff, Joseph Jackson, Fernie JA Penning-van Beest, Ron MC Herings. (Netherlands)

Classical Pharmacoepidemiology

- 34 Signal Detection of Adverse Drug Reactions of Clopidogrel Using Administrative Data for Korean Public Insurance [350]**
Jinhyung Kim, Chungam Choi, Wan Gyoon Shin. (Korea)
- 35 Applied Epidemiology throughout the Lifecycle of Drugs: Two Case Studies [351]**
Quazi Ataher, Anna Greenacre. (United States)
- 36 Drug Use and the Risk of Road Traffic Crashes: Preliminary Results from the French CESIR-U Study [352]**
S Blazejewski, P Philip, R Ribeyreau-Gayon, E Lagarde, PO Girodet, A Pariente, P Noize, JL Montastruc, L Merle, D Orsoni, D Lauque, N Moore. (France)

- 37 Education and Use of Prescribed Drugs [353]**
Aage Tverdal, Solveig Sakshaug, Hege S Blix, Randi Selmer. (Norway)
- 38 The Association of Aggression and Medication Use with Treatment Outcome of Hospitalized Psychiatric Patients [354]**
Laurette E Goedhard, Joost J Stolker, Henk L Nijman, Toine C Egberts, Eibert R Heerdink. (Netherlands)

CNS

- 39 Actual State of Cancer Pain Management [355]**
Hwa J Kim, Joongyub Lee, Moo-song Lee, Byung-joo Park. (Korea)
- 40 The Influence of Using Methylphenidate on the Coming up of Psychiatric Disorders in Children with ADHD [356]**
Churn-Shiouh Gau, Chiou-Fu Chen, Susan Shur-Fen Gau. (Taiwan)
- 41 Trials Assessing Pharmacotherapeutic Management of Aggression in Psychiatric Patients: Comparability with Clinical Practice [357]**
Laurette E Goedhard, Joost J Stolker, Henk L Nijman, Toine C Egberts, Eibert R Heerdink. (Netherlands)
- 42 Complementary and Alternative Medicine for Attention Deficit/Hyperactivity Disorder in the Eastern Cape, South Africa [358]**
Sanmari Snyman, Ilse Truter. (South Africa)
- 43 Validation of a Monte-Carlo Markov Model for Schizophrenia [359]**
Alice Dragomir, Jean-Francois Angers, Jean-Eric Tarride, Ridha Joobar, Sylvie Perreault. (Canada)
- 44 The Association of Early Discontinuation of Antidepressants to Pharmaceutical Market or System Policies [360]**
Anna B Almarsdóttir, Ingunn Björnsdóttir, Atli Sigurjónsson. (Iceland)
- 45 Abstract Withdrawn by Author [361]**
- 46 Risk of Overuse When Taking Benzodiazepines [649]**
Tom J Lindquist, Ivar A Aursnes, Trine Bjørner, Ingunn F Tveté. (Norway)

Drug Utilization Research/ Health Services Research

- 47 Phelophepa Health Care Train: An Epidemiological Overview of the Western Cape in 2009 [362]**
Ilse Truter. (South Africa)
- 48 Factors Associated with Adverse Drug Events in an Intensive Care Unit [363]**
Adriano Max M Reis, Silvia Helena De B Cassiani. (Brazil)
- 49 Effect of the Universal Health Care Scheme on Prescribing Patterns across Thailand [364]**
Saksit Sripa, Christine Bond, Corri Black. (United Kingdom)
- 50 UK/USA Differences in Marketing Claim [365]**
Stephen R Chapman, Nicholas Thayer, Bernard Naughton. (United Kingdom)
- 51 The Use of Antimicrobial Drugs in the Treatment of Diabetic Patients: Analysis of 'Real World Data' from Electronic Health Records [366]**
Svetlana Sergeeva, Darya Dolotova, Nikolay Matveev, Gagik Galstyan. (Russian Federation)
- 52 Prevalence of Adverse Drug Effects/Adverse Drug Reactions in the 200 Most Commonly Prescribed Medications in the United States Corrected for Prescription Volume [367]**
Mary Kiersma, Aleda Hess, Kristin Villa, Brian Shepler, Matthew Murawski. (United States)
- 53 Characteristics and LDL-C Therapeutic Objectives of Patients Receiving Unusual Lipid-Modifying Therapy Regimens [368]**
Gaelle Desamericq, Laurent Laforest, Marie-Sophie Schwalm, Alison Bourke, Melanie Broquet, Eric Van Ganse, Philippe Moulin. (France)
- 54 Drug Utilization Physician Survey of Intron A® in Europe [369]**
Jamie T Laudati, Shirin Ahmed, Eu Jung Jo, Alejandro Arana. (United States)
- 55 Access to Drugs Via the Judiciary Power in Brazil: Obstacles for the Rational Use of Medicines [370]**
Marina Machado, Francisco Acurcio, Cristina Brandão, Daniel Faleiros, Augusto Guerra Jr, Mariângela Cherchiglia, Eli lola Andrade. (Brazil)

- 56 Socioeconomic Inequalities in Prescription Medicines Use [371]**
Claudia Furtado, João Pereira. (Portugal)
- 57 Abstract Withdrawn by Author [372]**
- 58 Services for Which Pharmacists May Levy a Fee: Primary Care Drug Therapy (PCDT) [373]**
Ilse Truter, Research and Development Task Team South African Pharmacy Council. (South Africa)
- 59 Effects of an Educational Intervention on the Prescribing of Antimalarials in a Nigerian Teaching Hospital [374]**
Obeh Akoria, Peter Akhideno, Stephen Ayinbuomwan, Abimbola Olowofela, Aghoghwo Akpajewwe. (Nigeria)
- 60 Utilization and Expenditures Trends of Potentiated Penicillins J01 in the Czech Republic in 1997-2008 [375]**
Vladimíra Vojtová, Karel Urbánek, Dominika Hajdú, Petra Langerová. (Czech Republic)
- 61 Drug Consumption in Old-Elderlies Admitted to Hospital between 1994 and 2004 [376]**
ML Laroche, T Penault, S Crépin, JP Charmes, L Merle. (France)
- 62 Determinants of Compliance with Oral Hypoglycemic Agent in Korean Type 2 Diabetic Patients [377]**
Young Sik Kim, Kyoung-Mi Park, Sung Sunwoo, Yun Jun Yang, Young Sung Suh. (Korea)
- 63 Prescribing in Compliance with Patient Formularies Increases Primary Adherence in Patients Receiving Electronic Prescriptions [378]**
Michael A Fischer, Niteesh K Choudhry, Jerry Avorn, Sebastian Schneeweiss, William H Shrank. (United States)
- 64 Comparison of Prescribing Patterns for Asthma in Five European Countries [379]**
Laurent Laforest, Marie-Sophie Schwalm, Marion Dufour, Mélanie Broquet, Alison Bourke, Eric Van Ganse. (France)
- 65 Could Adverse Reactions of Antibiotic Drugs in Children Be Detected in a Prescription Database? [380]**
Josta de Jong, Jens HJ Bos, Tjalling W de Vries, Lolkje TW de Jong - van den Berg. (Netherlands)
- 66 Drug Utilization Patterns of Antiplatelet Therapies among the Older Adults in Taiwan [381]**
Hsiang-Wen Lin, I-Wen Yu. (Taiwan)

- 67 Correlates of Intentional Interruption of Inhaled Corticosteroids and Spontaneous Changes in Doses by Asthma Patients: Results from a Pharmacy-Based Study [382]**
Laurent Laforest, Eric Van Ganse, Mélanie Broquet, Cécile Ritleng, Gilles Devouas-soux, Geneviève Chamba, French Council of Pharmacists. (France)
- 68 Long-Term Trends in Immunosuppressants Utilization the Czech Republic [383]**
Karel Urbanek, Jan Strojil, Vladimira Vojtova, Petra Langerova. (Czech Republic)

Gut

- 69 Uncontrolled Type 2 Diabetes Treated with Oral Hypoglycaemic Agents (OHA) in Monotherapy: Therapeutic Behaviour in Primary Care in France [384]**
B Balkau, S Halimi, JF Blicke, E Tocque, E Amelineau, S Bouée. (France)
- 70 Hepatic Risk among Patients with Chronic Pain: A Retrospective Cohort Study [385]**
Yingkai Cheng, Dale Marmaduke, Antonio Crucitti, Sharon Hoog, Indiana Strombom. (United States)
- 71 Antivertigo and Antiemetic Prescribing to Children and Adolescents [386]**
Ilse Truter. (South Africa)
- 72 Factors Associated with the Initiation of Proton Pump Inhibitors in New Corticosteroid Users [387]**
Jeffrey C Munson, Peter M Wahl, Gregory Daniel, Stephen E Kimmel, Sean Hennessy. (United States)
- 73 Treatment of Rare Diseases in Brazil [388]**
Cristina Mariano Ruas Brandao, Marina Amaral Ávila Machado, Anderson Lourenço da Silva, Francisco de Assis Acurcio. (Brazil)
- 74 Final Results from a Retrospective Cohort Study of the Incidence of Acute Pancreatitis in Exenatide Initiators Compared to Other Antidiabetic Drug Initiators [389]**
David D Dore, Gary L Bloomgren, Made Wenten, Rebecca A Noel, Daniel K Braun, John D Seeger. (United States)
- 75 Use of Serotonergic Drugs and the Risk of Bleeding [390]**
Bertha Maria Verdel, Patrick C Souverein, Eibert R Heerdink, Hubert GM Leufkens, Toine CG Egberts. (Netherlands)

- 76 Antidiabetic Utilization and Prescribing Patterns in Outpatients of Diabetic Pay-for-Performance Program [391]**
Ju-Huei Tseng, Li-Chia Chen. (Taiwan)
- 77 Pulmonary and Cardiovascular Safety of Inhaled Insulin in a Real-World Setting: The Exubera Large Simple Trial (VOLUME) [392]**
Nicolle M Gatto, Francesca M Kolitsopoulos, Richard J Riese, William T Duggan, Neville C Jackson. (United States)
- 78 Long-Term Patterns of Statin Therapy in Patients with Type 2 Diabetes Mellitus Compared to Long-Term Oral Antidiabetic Medication Patterns [393]**
Egbert Lamberts, Giel Nijpels, Jacqueline Dekker, Laura Welschen, Marcel Bouvy, Patrick Souverein, Jacqueline Hugtenburg. (Netherlands)
- 79 Abstract Withdrawn by Author [394]**
- 80 DPP-4 Inhibitors and the Occurrence of Infections: A Nested Case-Control Study [395]**
Marjolein J Willemen, Aukje K Mantel-Teeuwisse, Sabine M Straus, Toine C Egberts, Hubert G Leufkens. (Netherlands)
- 81 Factors Associated with Short-Term Adherence to Dietary and Lifestyle Guidelines in Secondary Prevention of Acute Myocardial Infarction in Real Life Practice in France (EOLE Cohort) [396]**
S Hercberg, D Thomas, C Droz, C Dureau, P Ducimetière, F Paillard, J Tricoire, M-A Bernard, J Bénichou, N Danchin, L Guize, P Blin, N Moore. (France)
- 82 Japan Statin Study (JSS), a Prospective Case-Cohort Study for Monitoring Multiple Adverse Events: Rationale, Design and Characteristics of Study Subjects [397]**
Shigeru Kageyama, Masaki Kitamura, Akira Kokan, Kiyoshi Kubota, Kenichi Matsui, Nobuhiro Ooba, Takao Orii, Tsugumichi Sato, Yoshihiro Shimodozono, Hiromi Uehara, Mitsunori Yagame, Yukari Yaju, Takuhiro Yamaguchi. (Japan)
- 83 Is There an Association between Selective Serotonin Reuptake Inhibitor Use and Uncomplicated Peptic Ulcers? – A Population-Based Case-Control Study [398]**
Michael Dall, Ove B Schaffalitzky de Muckadell, Annmarie Touborg Lassen, Jesper Hallas. (Denmark)

84 Does the Omega-3 Prescription Change the Post-MI Lifestyle Adjustment? Results from the EOLE Cohort [399]

C Dureau, C Droz, D Thomas, N Danchin, J Tricoire, J Bénichou, F Paillard, P Ducimetière, S Hercberg, H Maïzi, E Guiard, M-A Bernard, P Blin, N Moore. (France)

Methods

85 Challenges of Measuring Medicine Compliance: The Australian Context [400]

Louise Bartlett, Maxine Robinson. (Australia)

86 Abstract Withdrawn by Author [401]

87 Research Working Groups on Drug Utilization across Europe [402]

L Ibáñez, H Petri, P Solari, E Ballarín, M Sabaté, J Hasford, S Yeboah, K L Goh, JR Laporte, J Fortuny, R Schlienger. (Spain)

88 Use of NSAIDs in France: Analysis from Reimbursement (CNAM-TS) Database [403]

Manoj Sharma, Ezgi Gulmez, Regis Lassalle, Nicholas Moore. (India)

89 How Can the Economic Impact of Drug-Related Morbidity Be Measured? A Systematic Literature Review [404]

Hanna Gyllensten, Anna K Jönsson, Clas Rehnberg, Anders Carlsten. (Sweden)

90 A Tool for Facilitating Comparability in Prospective Observational Studies [405]

Victor A Kiri, Martin Lang, Gary Coward. (United Kingdom)

91 Drug Safety Data Mining with a Tree-Based Scan Statistic [406]

Martin Kulldorff, Inna Dashevsky, Taliser Avery, Arnold K Chan, Robert L Davis, David Graham, Susan E Andrade, Denise Boudreau, Margaret J Gunter, Lisa Herrinton, Pam Pawloski, Marsha A Raebel, Douglas Roblin, Richard Platt, Jeffrey S Brown. (United States)

92 Development of Hospital Based Computerized Drug Safety Database [407]

Thiyagu Rajakannan, SurulivelRajan Malayasamy, Rajesh Vilakkthala, Padma GM Rao, Laxminarayana K Baiyy. (India)

93 Joinpoint Regression To Examine the Impact of Drug Safety Warnings on Drug Utilization Trends When Interrupted Time-Series Analysis Is Not Feasible [408]

CY Chen, Almut Winterstein. (United States)

94 Is There a Need for Better Communication of Benefit Risk of Medicines to Patients and Prescribers? [409]

Deborah Szafir, Philip Watson, Simon Ingate, Francois Lucas, Swapu Banerjee, Philippe Van der Auwera. (United Kingdom)

95 Developing an Indicator-Based Performance Tool for Pharmacovigilance Systems [410]

Jude I Nwokike, Mohan P Joshi, Andy Stergachis, Shabir Banoo. (United States)

Muscles and Bones

96 Characteristics of Exposure to Non-Steroid Anti-Inflammatory Drugs in European Databases [411]

Frank de Vries, Helle Kieler, Liset van Dijk, Tobias Svensson, Tjeerd van Staa. (United Kingdom)

97 Assessing the Risk of Osteonecrosis of the Jaws (ONJ) Due to Bisphosphonates Therapy: A Nested Case-Control Study [412]

Francesco Lapi, Achille Caputi, Giovanni Corrao, Nicola Montanaro, Miriam Sturkenboom, Dario Gregori, Flavia Carle, Angelo Menna, Annarita Vestri, Giampiero Mazzaglia. (Italy)

98 Analysis of Strontium Ranelate Utilization from Prescription-Event Monitoring (PEM): Focus on 'Off Label' and Special Populations Use in Support of Risk Management [413]

Vicki Osborne, Deborah Layton, Saad AW Shakir. (United Kingdom)

99 Prescribing of Fall-Risk Increasing and Fracture-Preventing Drugs in Older Hip Fracture Patients: Observational Study [414]

Christina Sjöberg, Lina Bladh, Lars Klintberg, Dan Mellström, Claes Ohlsson, Susanna M Wallerstedt. (Sweden)

100 Analysis of Patient Exposure for Enbrel Using Insurance Claims Database [415]

Fei Xue, Jason Yuan, Victor Gastanaga, Scott Stryker, Gail Hughes, Peter McCroskey, Sean Zhao. (United States)

101 Maternal Use of Codeine and Other Analgesics in Sweden [416]

Anders Sundström, Fredrik Granath, Tobias Svensson, Helle Kieler. (Sweden)

Other

102 Administrative Complexities for a European Observational Study [417]

Ezgi Gulmez, Séverine Lignot, Corinne de Vries, Miriam Sturkenboom, Patrick Blin, Nicholas Moore. (France)

103 The Mondriaan Project: The Dutch Healthcare Landscape as a Population Laboratory [418]

Olaf H Klungel, Marc C Rietveld, Mark CH de Groot, Ronald P Stolk, Maarten J Postma, Hubert GM Leufkens, Toine CG Egberts, Anke M Hovels, Lex van de Langerijt, Willem de Bruijn, Arno W Hoes, Diederik E Grobbee. (Netherlands)

104 Adherence to Medication Safety Practices Recommendations in Developing Countries: Data from Saudi Arabia [419]

Hisham Aljadhey, Abdulaziz Alhusan, Khaled Alburaihan, Mansour Adam, Mohammed Al-sultan, Michael Murray, David Bates. (Saudi Arabia)

105 Assessment of the Representativity of In-Patient Hospital Diagnoses in the German Pharmacoepidemiological Research Database [420]

Tania Schink, Edeltraut Garbe. (Germany)

106 The Relative Value of EMRs and Claims Data in Health Services Research [421]

S L West, W G Johnson. (United States)

Pharmacovigilance

107 Multiple Drug Exposure and Severity of Adverse Drug Reactions [422]

Francisco Batel-Marques, Nuno Craveiro, Ana Filipa-Macedo, Carlos Fontes-Ribeiro, Margarida Caramona, Tice Macedo. (Portugal)

108 Utilization of Medical Information Databases in Drug Safety Evaluation Process in PMDA [423]

Ayumi Endo, Chieko Ishiguro, Eiko Tada, Maki Noguchi, Kazuhiro Matsui. (Japan)

109 Lifestyle Drugs and Psychiatric Adverse Events in Randomised Clinical Trials [424]

M J Willemen, A K Mantel-Teeuwisse, S M Straus, A C Egberts, H G Leufkens. (Netherlands)

POSTER SESSION B Saturday, August 21

110 The Views of Reporters to the UK Yellow Card Scheme on the Importance of Direct Patient Reporting [425]

Janet Krska, Julia Taylor, Anthony J Avery. (United Kingdom)

111 Evaluation of Anaphylaxis Patients Using Commercially Available Japanese Claim Data [426]

Ayumi Endo, Chieko Ishiguro, Maki Noguchi, Eiko Tada, Kazuhiro Matsui. (Japan)

112 Preventability of Reported Adverse Drug Reactions to the Swedish Medical Products Agency [427]

Anna K Jönsson, Henrik Lövborg, Ingela Jacobsson, Thomas Bradley, Staffan Hägg. (Sweden)

113 Monitoring the FDA AERS Database To Identify Safety Issues: Does the Need Diminish as Product Time on the Market Increases? [428]

John Watson, Stephanie Reisinger, Jonathan Morris. (United States)

114 A Novel Approach To Review of Batch Related Adverse Event Reports [429]

Steven R Bailey, Peter Huber, Robert Maroko, Robert Azadian. (United States)

115 Abstract Withdrawn by Author [430]

116 An Evaluation of the Impact of REMS on Spontaneous Reporting for Marketed Products [431]

Reema Jain. (United States)

117 A Statistical Analysis Approach to Trend Analysis within a Company Safety Database [432]

Steven R Bailey, Peter Huber, Robert Azadian, Frank D'Angelo, Robert Maroko. (United States)

118 Documentation Grading To Assess Systematic Variability in the Quality of Individual Case Safety Reports [433]

Tomas Bergvall, Jessica Nilsson, Richard Hill, G Niklas Norén, Marie Lindquist. (Sweden)

119 Comparison of Quantitative Signal Detection Using Observational and Spontaneous Adverse Event Data [434]

Gregory E Powell, Patrick B Ryan, Edward N Pattishall. (United States)

120 Abstract Withdrawn by Author [435]

Poster Walk Biologics SIG

121 Critical Issues in Comparing the Use of Biologicals across Various European Countries: TNF Inhibitors as Case Study [436]

J M Hoebert, A K Mantel-Teeuwisse, L van Dijk, R O Laing, H GM Leufkens. (Netherlands)

122 Treatment Patterns in a Large U.S. Medical-Claims Based Cohort of Breast Cancer (BC) Patients Receiving HER2 Directed Therapy [437]

Lisa Wang, Laura Chu, Sam Agresta, Wei Dong. (United States)



Our partnership.
Their peace of mind.

i3 Drug Safety provides comprehensive pharmacoepidemiology and pharmacovigilance services. Rooted in scientific rigor, using innovative methods and proven expertise, i3 Drug Safety can customize its services for work of any scope or specialty, from safety surveillance and risk assessment in clinical development to post-approval pharmacovigilance. www.i3global.com

Meet with
i3 Drug Safety experts
at our booth.

- ▶ Drug Safety & Epidemiology
- Clinical Research
- Strategic Regulatory Services
- Data Services
- Drug Safety & Epidemiology
- Late Phase Research
- Health Economics & Outcomes Research
- Pharma Informatics
- Staffing & Outsourcing

- Cardiology
- Central Nervous System
- Oncology
- Respiratory & Infectious Disease
- Endocrinology & Metabolic Disease



The company of specialists.

123 Predictors of Tuberculosis Testing in Prescribers of Anti-Tumor Necrosis Factor (TNF) Agents in the European Union [438]

Meredith Y Smith, Brian Attig, Thomas Eagle. (United States)

124 Acute Pancreatitis after Quadrivalent Human Papillomavirus Vaccination: Reports to a Post-Marketing Passive Surveillance System, 2006 – 2009 [439]

Amy Steffey, Rhonda Lizewski, Andrea Sutherland, Jeff Roberts, Nancy Miller, Robert P Wise. (United States)

125 Effectiveness of Recruiting and Retention Strategies for Clinical Studies of Drugs, Medical Devices, and Biologics [440]

Ellen Pinnow, Mary E Ritchey, Andrea Tilley, Danica Marinac-Dabic. (United States)

126 Acute Hemolysis Consistent with Intravascular Hemolysis in Patients Receiving WinRho To Treat ITP [441]

Aileen Buckler, Nisha Jain, Basil Golding, Faith Barash, Robert Wise. (United States)

127 Trastuzumab (T) Treatment Outcomes According to Concomitant Chemotherapy Regimen: Overall Survival (OS) of HER2+ Metastatic Breast Cancer (MBC) Patients [442]

Sallie-Anne Pearson, Preeyaporn Srasuebkul, Carole Harris, Robyn Ward, Timothy Dobbins. (Australia)

128 Updated Post-Licensure Safety Surveillance for Recombinant Human Coagulation Factor VIIa [443]

Alan C Ou, Nisha Jain, Charles W Maplethorpe, Robert P Wise. (United States)

129 The Use of Observed vs Expected Analyses in Real-Time Vaccine Safety Surveillance in the UK during the H1N1 Pandemic [444]

Suzie Seabroke, Philip Bryan, Lesley Wise. (United Kingdom)

130 Risk of Cardiovascular Events among 3,865 Elderly Diffuse Large B-Cell Lymphoma Patients Treated with Doxorubicin-Based Chemotherapy +/- Rituximab: A Population-Based Study [445]

Huei-Ting Tsai, Ruth Pfeiffer, C Ola Landgren. (United States)

131 Proactive Pharmacovigilance of the Human Papillomavirus (HPV) Vaccine [446]

Jenny Wong, Suzie Seabroke, Saira Mahmood, Philip Bryan. (United Kingdom)

Poster Walk Comparative Effectiveness Research SIG

132 Comparative Safety of Antipsychotic Medications in Elderly Medicaid-Eligible Nursing Home Patients [447]

Sebastian Schneeweiss, Krista Huybrechts, Tobias Gerhard, Mark Olsson, Jeremy A Rassen, Raisa Levin, Judith Lucas, Stephen Crystal. (United States)

133 Population-Based Study: Adherence Impact of Antihypertensive Agents on Vascular Events among Patients with Ischemic Stroke [449]

Sylvie Perreault, Robert Cote, Alice Dragomir. (Canada)

134 Prioritizing Comparative Effectiveness Research [450]

A M Walker, A R Patrick, M S Lauer, C T Laurencin, M G Marin, R Platt, P Stang, S Schneeweiss. (United States)

135 Tiotropium and Severe COPD Exacerbations – Comparisons with Long-Acting 2-Mimetics [451]

Ana Afonso, Katia MC Verhamme, Charlotte van Noord, Mendel Haag, Guy GO Brusselle, Miriam CJM Sturkenboom. (Netherlands)

136 Delayed Progression to Insulin in Patients with Type 2 Diabetes Mellitus Treated with Thiazolidinediones: A Population-Based Cohort Study [452]

Colin R Dormuth, Greg Carney, Jenny Sutherland. (Canada)

137 Current and Potential Uses of Clinical Registries for Comparative Effectiveness Research [453]

Richard Gliklich, Michelle B Leavy, Christina D Mack, Laura Whiteside, Dan Champion, Barbara Bartman. (United States)

138 Abstract Withdrawn by Author [454]

139 Examination of Effects of Regression to the Mean and Medication Adherence on HbA1C Levels among New Users of Oral Antidiabetic Drugs [455]

Carlos Grijalva, Robert Greevy, Mary Huizinga, Christianne Roumie, Harvey Murff, Shirley Liu, Adriana Hung, Marie Griffin. (United States)

140 The Standard Care Versus Celecoxib Outcome Trial (SCOT): A Large Streamlined Safety Study [457]

Isla S Mackenzie, Daniel Rutherford, Evelyn A Findlay, Chris J Hawkey, Ian Ford, Thomas M MacDonald. (United Kingdom)

141 Effectiveness of Zanamivir (RELENZA) Prophylaxis for Influenza [458]

Kandace Amend, Vani Vannappagari, Maria Wood-Armay, Rob Gately, John D Seeger. (United States)

Poster Walk Database SIG

142 Chronic Heart Failure Treated with Loop-Diuretics Is Associated with Increased Risk of Hospitalization with Pneumonia: A Population-Based Case-Control Study [459]

Sinna P Ulrichsen, Reimar W Thomsen. (Denmark)

143 Validation of Psoriasis and Its Prevalence, Treatment, and Severity in the Health Improvement Network (THIN) [460]

N M Seminara, K Abuabara, D B Shin, S E Kimmel, D Margolis, A Troxel, J M Gelfand. (United States)

144 Linking Primary Care Data (UK GPRD) to Hospital Records (HES) [461]

Susan C Eaton, Efrosini Setakis, Tim Williams, Tjeerd Van Staa. (United Kingdom)

145 Abstract Withdrawn by Author [462]

146 Validation of a Claims-Based Diagnostic Code for Stevens-Johnson Syndrome (SJS) in a Commercially-Insured Population [463]

Gregory W Daniel, Debra F Eisenberg, Judith K Jones, Earl L Goehring, Peter Winters, Jay Levin, Peter M Wahl, Rhonda L Bohn. (United States)

147 Lipid Levels among Antiretroviral (ARV) Naïve HIV-Infected Individuals in Routine Care [465]

H M Crane, J AC Delaney, E Brown, J W Willig, M Mugavero, P W Hunt, B Rodriguez, W C Matthews, M Saag, M M Kitahata. (United States)

148 The Incidence of Pancreatic and Thyroid Cancers in Patients with Type 2 Diabetes Mellitus Compared to Nondiabetics in a Managed Care Population [466]

Kwame Appenteng, Rebecca Noel, Dale Marmaduke, John Roberts, Stephen Motsko. (United States)

149 Exposure Classification for Case-Control Studies When Variables Are Both Confounders and Intermediaries [468]

Andrea Gruneir, Connie Marras, Hadas Fischer, Xuesong Wang, Sudeep Gill, Paula Rochon, Geoffrey Anderson. (Canada)

Poster Walk Drug Utilization SIG

- 150 Primary Care Prescribing of Anti-Osteoporotic Type Medications Following Hospitalisation for Fractures [469]**
Bernie McGowan, Miriam C Casey, Joe Marry, Kathleen Bennett. (Ireland)
- 151 Adherence to Osteoporosis Drugs and Fracture Prevention: No Evidence of Healthy Adherer Bias in a Frail Cohort of Seniors [470]**
Suzanne M Cadarette, Daniel H Solomon, Jeffrey N Katz, Amanda R Patrick, M Alan Brookhart. (Canada)
- 152 Utilisation of Non-Steroidal Anti-Inflammatory Drugs in Quebec, Canada: Is There a Change in the Patient Risk Profile after the Withdrawal of Rofecoxib? [471]**
Elham Rahme, Jean-Philip Lafrance, Jean-Pascal Roussy, Suzanne Morin. (Canada)
- 153 Clopidogrel Use and Mortality after Peptic Ulcer Bleeding: A Population-Based Cohort Study [472]**
Morten Schmidt, Anders Riis, Christian F Christiansen, Timothy L Lash, Henrik Toft Sørensen. (Denmark)
- 154 Persistence and Compliance of Deferoxamine (DFO) Versus Deferasirox (DFX) in Medicaid Patients with Sickle-Cell Disease (SCD) [473]**
L B Jordan, F Vekeman, A Sengupta, M Corral, A Guo, M S Duh. (United States)
- 155 Why Do Hospital Patients Experience Adverse Drug Events? [474]**
A Dequito, P Mol, J van Doormaal, R Zaal, P van den Bemt, F Haaijer-Ruskamp, J Kosterink. (Netherlands)
- 156 Effectiveness of Cardioprotective Drugs in Elderly Individuals with Type 2 Diabetes [475]**
Caroline Sirois, Jocelyne Moisan, Jean-Pierre Grégoire. (Canada)
- 157 Trends in Use of Gastroprotective Strategies with NSAID Treatment in the United Kingdom, Italy, and the Netherlands [476]**
V Valkhoff, E van Soest, J Dieleman, R Schade, G Mazzaglia, M Molokhia, E Kuipers, M Sturkenboom. (Netherlands)

158 Timing of Prophylaxis Relative to Respiratory Syncytial Virus Seasons [477]

Christian Hampp, Almut G Winterstein. (United States)

159 For What Diagnoses Are Psychotropic Medications Being Prescribed? Implications for Understanding Off-Label Prescribing [478]

Tami L Mark. (United States)

Poster Walk Molecular Epidemiology SIG

160 Association between HTR2C Gene Polymorphisms and the Metabolic Syndrome in Patients Using Antipsychotics: A Replication Study [479]

Arne Risselada, Jelle Vehof, Richard Brugge-
man, Bob Wilffert, Dan Cohen, Asmar Al Hadithy, Johan Arends, Hans Mulder. (Netherlands)

161 Association between the ADRA2A 1291 C/G Polymorphism and the Metabolic Syndrome [480]

Arne Risselada, Jelle Vehof, Richard Brugge-
man, Bob Wilffert, Dan Cohen, Asmar F Al Hadithy, Johan Arends, Hans Mulder. (Netherlands)

162 Dosing Algorithm for Phenprocoumon; Using Patient Characteristics and Genotype Information To Calculate the Optimal Monitoring Dose [481]

Rianne MF van Schie, Saskia le Cessie, Frits R Rosendaal, Anke-Hilse Maitland-van der Zee, The EU-PACT Study Group. (Netherlands)

163 Validation of Warfarin Pharmacogenetic Algorithms in Real Clinical Practice [482]

Melina Marin-Leblanc, Sylvie Perreault, Marie-Pierre Dubé. (Canada)

164 Prognostic Value of Chronic Kidney Disease in Patients with Coronary Heart Disease: Role of GFR Estimating Equations [483]

Qiu-Li Zhang, Hermann Brenner, Wolfgang Koenig, Dietrich Rothenbacher. (Germany)

165 Candidate Genes Associated with Phenprocoumon Maintenance Dosage [484]

Martina Teichert, Mark Eijgelsheim, Loes E Visser, Bruno HC Stricker. (Netherlands)

166 Early-Adulthood Obesity [EOb] Modifies the Cisplatin [C]-DNA Repair Gene Polymorphism XPD ASP312ASN [X] Relationship in Esophageal Cancer (EC) Survival: A Combined Pharmacogenetic-Molecular Epidemiologic Analysis [485]

Daniel Renouf, Linda Coate, Rihong Zhai, Matthew Kulke, Rebecca S Heist, Penelope Bradbury, Wei Xu, Zhengfei Chen, Kofi Asomaning, John Wain, Li Su, Geoffrey Liu, David C Christiani. (Canada)

167 Change in Drug Utilization Patterns in Statin Users with Increased Creatine Phosphokinase (CPK) Levels [486]

Frank de Vries, Efrasini Setakis, Tjeerd van Staa. (United Kingdom)

168 Prognostic Role of Genetic Polymorphisms in Head and Neck Cancer (HNC) Survival [487]

Abul K Azad, Geoffrey Liu, Wei Xu, Dangxiao Cheng, Elodie Samson, Maryam Mirshams, Zhuo Chen, Sevta Savas, John Waldron, Isabelle Bairati, Meyer Francois. (Canada)

169 The Effect of Daily Aspirin on Ovarian Cancer Serum Biomarkers in Healthy Postmenopausal Women [488]

Kimberly Lowe, Robin Forest, Jason Thorp, Lindsay Bergan, CY Wang, Anne McTiernan, Nicole Urban. (United States)

170 Genetic Polymorphisms as Prognostic/Predictive Biomarkers of Single-Agent Erlotinib Therapy in NCIC-CTG BR.21 Non-Small Cell Lung Cancer (NSCLC) Trial [489]

Geoffrey Liu, Dangxiao Cheng, Aurelie Le Maitre, Ni Liu, Zhuo Chen, Lesley Seymour, Keyue Ding, Frances Shepherd, Ming Tsao. (Canada)

POSTER SESSION B Saturday, August 21

Poster Walk Pregnancy SIG

171 The Safety of Citalopram Exposure during Pregnancy – Maternal Characteristics, Birth Outcomes and Early Hospital Admissions for 1157 Children [490]

Lyn Colvin, Linda Slack-Smith, Fiona J Stanley, Carol Bower. (Australia)

172 Exposure to Anti-Infective Drugs during Pregnancy and the Risk of Small-for-Gestational-Age Newborns [491]

Fabiano Santos, Odile Sheehy, Sylvie Perreault, Ema Ferreira, Anick Bérard. (Canada)

173 SSRI Drug Use during Pregnancy and Perinatal Outcome [492]

Heli Malm, Miia Artama, Mika Gissler, Annukka Ritvanen. (Finland)

174 Drug Use during Pregnancy in South-western France [493]

Anne-Laure Voisin, Philippe Latry, Claude Peter, Karin Martin-Latry. (France, Metropolitan)

175 EFEMERIS, the French Prescription Database in Pregnant Women: A 4 Year-Follow Up [494]

Christine Damase-Michel, Isabelle Lacroix, Caroline Hurault, Sylvie Kessler, Claudine Guitard, Sabine Vidal, Jean Louis Monasttruc. (France)

176 Oral Antibiotic Prescribing in Pregnancy in United Kingdom [495]

I Petersen, R Gilbert, A Rudolphi, S Evans, I Nazareth. (United Kingdom)

177 Elevated Risk of Preeclampsia in Pregnant Women with Depression: Disease vs. Antidepressants [496]

Kristin Palmsten, Soko Setoguchi, Andrea V Margulis, Amanda R Patrick, Sonia Hernández-Díaz. (United States)

178 SSRI and Risk of Congenital Cardiac Abnormalities [497]

Irene Petersen, R Gilbert, S Evans, L Marston, I Nazareth. (United Kingdom)

179 Pregnancy Loss in Patients with Type 1 or Type 2 Diabetes during Pregnancy [498]

Anita McGrogan, Julia Snowball, Corinne de Vries. (United Kingdom)

180 Birth Outcomes among Women Exposed to Oseltamivir (Tamiflu) During Pregnancy [499]

Tobias Svensson, Fredrik Granath, Olof Stephansson, Helle Kieler. (Sweden)

End Session B

THE DEGGE GROUP, LTD. *Drug Safety Research and Information*

Risk Management: Risk Evaluation & Mitigation Strategies, Program Evaluation, Registries;

Pharmacoepidemiology: Natural History of Disease, Phase IV Studies, and Literature Reviews;

Pharmacovigilance: Spontaneous Reports, AERS, and Safety & SOP Audits;
Scientific Advisory Panel / Endpoint Adjudication Management, and CRO Oversight



Visit our Booth to see how we can help you,
or visit: www.deggegroup.com

22 years of Consulting and Research in Drug Safety and Pharmacoepidemiology

Bridging Scientific Expertise with Real World Data



80+ database profiles in 17 countries: **Asia** (China, India, Korea, Taiwan), **Europe** (Denmark, France, Germany, Italy, Netherlands, Norway, Spain, Sweden, United Kingdom), **New Zealand, Australia, and North America** (Canada, USA)

www.bridgetodata.org

Your connection to healthcare databases worldwideSM

1616 N. Fort Myer Drive, Suite 1430, Arlington, VA 22209, USA Tel: +1 703 894-0804 Fax: +1 703 894-0803

Anti-Infectives

- 1 **Exposure to Quinolones during Pregnancy: Lack of Association with an Increased Risk for Birth Defects and Other Adverse Pregnancy Outcomes [578]**
Ilan Matok, Gideon Koren, Rafael Gorodischer, Amalia Levy. (Canada)
- 2 **Systemic Antibiotic Use among Children in Germany. An Analysis of Outpatient Dispensations Based on Claims Data of German Statutory Health Insurances [579]**
Jakob Holstiege, Edeltraut Garbe. (Germany)
- 3 **Adverse Events Associated with Antibiotic Use [580]**
Sharon B Meropol, A Russell Localio, Joshua P Metlay. (United States)
- 4 **Evaluation of Antibiotic Prescribing for Acute Upper Respiratory Tract Infection in Private Hospital in Indonesia [581]**
Purwati Pole Rio, Iwan Dwiprahasto, Jarir AT Thobari. (Indonesia)
- 5 **Risk Factors for Non-Tuberculous Mycobacterial Infections Post-Transplantation [582]**
Christopher Vinnard, Sarah Longworth, Ingi Lee, Marie Synnestvedt, Sims Karen, Blumberg Emily. (United States)
- 6 **Vancomycin Use in Children Hospitalized in the United States in 2008 [583]**
Tamar Lasky, Jay V Greenspan, Frank R Ernst, Shirley V Wang, M Liliana Gonzalez. (United States)
- 7 **The Rate of Adherence to an Antibiotic Treatment Guideline [584]**
Maria Matuz, Ria Benko, Edit Hajdu, Peter Doro, Gyongyver Soos. (Hungary)

Burden of Disease/ Epidemiology of Illness

- 8 **Prevalence of Erythema Multiforme/Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in the US 2004-2008 [585]**
Yu Yan, Dale Q Marmaduke, Simon Voss, Shahab Hasnain. (United States)

- 9 **A Prospective Study of Asthma and Subsequent Use of Hypnotics [586]**
Øystein Karlstad, S Skurtveit, A Tverdal, P Nafstad, K Furu. (Norway)
 - 10 **Cataract Is a Frequent Adverse Effect of Widely Used Drugs [587]**
Elena Prokofyeva, Robert Wilke, Eberhart Zrenner. (Germany)
 - 11 **Treatment and Characteristics of Thrombotic Thrombocytopenic Purpura in a Managed Care Population [588]**
Peter M Wahl, James N George, Deirdra R Terrell, Amanda Yu, Keith Rodgers, Bruce Ewenstein, Rhonda L Bohn. (United States)
 - 12 **Regional Variations in Gaucher Disease Presentation: Data from the ICGG Gaucher Registry [589]**
Neal J Weinreb, Adriana Linares, Hyon Kim, J Alexander Cole, Stephan vom Dahl. (United States)
 - 13 **Behavioral Risk Factors among Hispanic and Non-Hispanic White Adults in the United States [590]**
Margaret McDonald, Michael B Lustik. (United States)
 - 14 **Characterization of Acetaminophen Overdose-Related Emergency Department Visits and Hospitalizations in the United States [591]**
Angelika Manthripragada, Esther Zhou, Daniel Budnitz, Maribeth Lovegrove, Mary Willy. (United States)
 - 15 **Abstract Withdrawn by Author [592]**
 - 16 **Prevalence and Incidence of Diabetes Mellitus in Ireland from Prescription Database [593]**
Nur Lisa Zaharan, Kathleen Bennett. (Ireland)
 - 17 **Incidence of Diabetic Retinopathy and Diabetic Macular Edema in Newly Diagnosed Type 1 and Type 2 Diabetic Patients [594]**
Elisa Martin-Merino, Joan Fortuny, Estel Plana, Elena Rivero, Luis A Garcia-Rodriguez. (Spain)
 - 18 **Urinary Desmosine in Relation to Lung Function – A Study from the Swedish Twin Register [595]**
Gunnar Engström, Claes Lindberg, Kristina Forsman-Semb, Maria Gerhardsson de Verdier, Ulf Nihlén, Magnus Dahlbäck, Henrik Lindberg, Anders Blomgren, Henrik Vissing, Sven Kjellström, Magnus Svartengren, Martin Andersson. (Sweden)
 - 19 **Comorbidity Profile of Viral Hepatitis B in a Claims Database [596]**
Michael M Peng, Debra Maldonado, William A Blumentals, Noah Jamie Robinson. (United States)
 - 20 **Comorbidity Profile of Viral Hepatitis C in a Claims Database [597]**
Michael M Peng, Debra Maldonado, William A Blumentals, Noah Jamie Robinson. (United States)
 - 21 **Prevalence of Depression in Patients with Alzheimer's Disease [598]**
Nataliya Volkova. (United States)
 - 22 **Impact of Comorbidities on the Burden for Patients with Parkinson's Disease [599]**
Alex Ward, Shannon L Michels, Stephan Lanes, O'Neill N Gilmore, Papapetropoulos Spyros. (United States)
 - 23 **Elevated Risk for Acute Pancreatitis in Type 2 Diabetes Patients Compared to Those without Diabetes [600]**
Tzuyung D Kou, Bing Cai, Charles M Alexander, Debora Williams-Herman, Leonid Katz, Cynthia J Girman. (United States)
 - 24 **A Systematic Literature Review and Meta-Analysis of Apolipoprotein E ε4 Prevalence in Alzheimer's Disease Patients [601]**
SM Crean, Alex Ward, Catherine J Mercaldi, Jenna M Collins, Michael N Cook, Nicole L Baker, H Michael Arrighi. (United States)
 - 25 **Down's Syndrome (DS) in Children, Adolescents and Adults in the UK General Practice Research Database (GPRD): Prevalence and Comorbidities [602]**
Nadia Foskett, Hans Petri, Anthony Amey, Noah Jamie Robinson. (United Kingdom)
 - 26 **High Levels of Dispensed Short-Acting beta Agonists in Asthma Patients: Results from the L777 Observational Study [603]**
Laurent Laforest, Samy Boutouaba-Combe, Mélanie Broquet, Véronique Ambrosi, Serge Marvalin, Eric Van Ganse. (France)
- Moved to Poster Session A**
- 27 **Association between Bilirubin and Oxidative Stress Mediated Disease [604]**
Laura Horsfall, Greta Rait, Kate Walters, Dallas M Swallow, Stephen P Pereira, Irene Petersen. (United Kingdom)

POSTER SESSION C Sunday, August 22

28 Incidence and Prevalence of Endometriosis: Administrative Health Databases Study from Quebec [605]
Marie-Josée Martel, Nabil Ackad, Jean Lachaine. (Canada)

29 What Is the True Prevalence of Knee Osteoarthritis? [606]
Maria Gerhardsson de Verdier, Gunnar Engström, Jan Roloff, Carl Mellström, Stefan Lohmander. (Sweden)

30 Rare Diseases, Orphan Drugs, and the Legislation in China [607]
Yanjun Zhang, Yan-De Zhang, Jing-Bo Wang, Jeff J Guo. (United States)

31 A Study of Comorbidities in Multiple Sclerosis [608]
Cheryl Enger, Michael Doherty, Yvonne Geissbühler, William Collins, John Seeger. (United States)

Cancer and Immunity

32 Effectiveness and Patterns of Bortezomib (BTZ) Use in a Real-Life Setting: The VESUVE Cohort Study [609]
A Fourrier-Reglat, A Grelaud, J Benichou, A Monnereau, M Sturkenboom, M Rouyer, E Bignon, J Jove, N Moore, and the Vesuve Study Group. (France)

33 Incidence of Brain Metastases and Hemorrhage among Lung Cancer Patients: A Systematic Review [610]
Sonia S Maruti, E Dawn Flick, Leanne Houweling, Myrthe PP van Herk-Sukel, Wei Dong. (United States)

34 Incidence of Thyroid Hormone Therapy in Patients Treated with Sorafenib or Sunitinib [611]
Katrín Schuessel, Sandra Feldt, Renate Quinzler, Sittah Czeche, Alexandra Franzmann, Wolf-Dieter Ludwig, Martin Schulz. (Germany)

35 Resection of Colorectal Cancer (CRC) Metastases after Bevacizumab (BV) Treatment for 1st-Line Therapy: The ETNA Cohort Study [613]
A Fourrier-Reglat, M Rouyer, J Benichou, A Balestra, R Lassalle, A Grelaud, D Smith, A Ravaud, N Moore, and the ETNA Group. (France)

36 Safety of Two Forms of L-Asparaginase in a Children Cohort with Acute Lymphoblastic Leukemia [614]
Heilani K Szejnman, Martine Munzer, Marion T Lafaurie, Frédéric Burde, Thierry P Trenque. (France)

37 Comorbidity Among Hormone Resistant Prostate Cancer Patients in the US [615]
Claudia Cabrera, Ceri Hirst, Cortney Hayflinger, Linda Koo. (Sweden)

38 Bone Marrow Reticulin and Collagen Content in Patients with Adult Chronic Idiopathic Thrombocytopenic Purpura (cITP): A Danish Nationwide Study [616]
Mette Nørgaard, Marianne Schmidt Ettrup, Sean Zhao, Preben Johansen, Henrik Toft Sørensen. (Denmark)

39 Analysis of Patient Exposure to Vectibix Based on the IntrinsiQ Database [617]
Fei Xue, Daniel Blaney, Julie Moloney, Victor Gastanaga, Jason Yuan, Scott Stryker, Gail Hughes, Deborah Arrindell, Sean Zhao. (United States)

40 Use and Costs of Oral Anticancer Drugs (ATC L01) in the Netherlands from 2000 to 2008 [618]
Lonneke Timmers, Jan-Jacob Beckeringh, Myrthe PP van Herk-Sukel, Epie Boven, Jaqueline G Hugtenburg. (Netherlands)

41 Colorectal Cancer Incidence on the GPRD [619]
Rachel Charlton, Julia Snowball, Corinne de Vries. (United Kingdom)

42 Survival by Anatomic Site, Histologic Type and Tumor Stage in Stomach Cancer Patients from the U.S. SEER Cancer Registry [620]
Lisa Wang, Laura Chu, Mona Shing, Wei Dong. (United States)

Cardiovascular

43 Abstract Withdrawn by Author [621]

44 Statin-Associated Total Cholesterol Concentration Change and Outcome of Cardiovascular Event among Chronic Kidney Disease Patients: A Population-Based Cohort Study [622]
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)

45 Dual Antiplatelet Therapy Benefited the Patients Received Percutaneous Coronary Intervention in Taiwan [623]
Chia-Hsien Chang, Yea-Huei Kao Yang. (Taiwan)

46 Abstract Withdrawn by Author [624]

47 Drug Utilization Review of Antihypertensive Therapy among Patients with Compelling Indications in Two Hospitals in South-Eastern Nigeria [625]
Obinna Ikechukwu Ekwunife, Chukwuemeka Micheal Ubaka. (Nigeria)

48 Hypertension Management Is Suppressed by the Start of Diabetes Drugs [626]
Jaco Voorham, Flora M Haaijer-Ruskamp, Bruce H Wolffenbuttel, Ronald P Stolk, Petra Denig. (Netherlands)

49 Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population [627]
Kandace L Amend, Joan Landon, Steve J Niemcryk, Andrew McAfee. (United States)

50 Statins in the Primary and Secondary Prevention of Cardiovascular Disease among Patients with Rheumatoid Arthritis: A Population-Based Cohort Study [628]
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)

51 The Impact of Statins on Total Cholesterol Concentration and Risk of Cardiovascular Disease among Patients with COPD: A Population-Based Cohort Study [629]
Xia Sheng, Li Wei, Thomas M MacDonald. (United Kingdom)

52 Risk of Myocardial Infarction in UK Primary Care Patients with Hepatitis C Virus Infection [630]
Kimberly Forde, Kevin Haynes, James Lewis, Vincent Lo Re. (United States)

53 Concomitant Use of Diuretics and Risk of Digoxin Intoxication among Elderly Heart Failure Patients [631]
Chul Woo Rhee, Dong Yoon Kang, So Young Park, Byung Joo Park. (Republic of Korea)

54 Myocardial Infarction and Cerebrovascular Accident in Patients with Retinal Vein Occlusion [632]
Laura K Chu, Winifred Werther. (United States)

55 Pharmacoepidemiology Safety Study of Statin, Fibrate, or Statin-Fibrate Combination Therapy [633]
Cheryl Enger, Robert Gately, Steve J Niemcryk, Eileen E Ming, Andrew T McAfee. (United States)

POSTER SESSION C Sunday, August 22

- 56 Hyperprolactinemia and Risk of Valvular Heart Disease: A Danish Nationwide Population-Based Cohort Study [634]**
Merete L Dybdal, Jens Otto L Jørgensen, Henrik T Sørensen. (Denmark)
- 57 Prevalence of Atrial Fibrillation (AF) in the US [635]**
Kathy L Schulman, Stephen S Johnston, Jay Lin, Daniel M Huse. (United States)
- 58 Incidence Rates of Retinal Artery Thrombosis in Solid Tumor Cancer Patients in the THIN Database [636]**
Victor Gastanaga, Chuck Wentworth, Gail Hughes, Fei Xue, Vanitha Ganesh, Mukesh Verma, Isaiah Dimery, Sean Zhao. (United States)
- 59 Parameterizing Risk-Benefit Models from Primary Care Data: Recurrence and Exacerbation [637]**
Andrew Maguire, Betina Blak, Kevin Haynes. (United Kingdom)

- 60 Use of Propranolol in Liver Cirrhosis Patient To Prevent Esophageal Varix Bleeding [638]**
Joongyub Lee, Nam-Kyong Choi, Ye-Jee Kim, Ju-young Shin, Byung-Joo Park. (Korea)
- 61 Cardiovascular Events in Statin Recipients: A 3-Year Record-Linkage Study on Prescription and Hospital Discharge Databases [639]**
Elisabetta Poluzzi, Carlo Piccinni, Paolo Carta, Aurora Puccini, Monica Lanzoni, Domenico Motola, Alberto Vaccheri, Fabrizio De Ponti, Nicola Montanaro. (Italy)

CNS

- 62 Defining Persistent Opioid Use from Prescription Registries [640]**
Kristian Svendsen, Olav MS Fredheim, Pål Romundstad, Petter C Borchgrevink, Svetlana Skurtveit. (Norway)

- 63 Hospitalizations Associated with Acetaminophen Poisoning in the United States [641]**
Syed Rizwanuddin Ahmad, Anne Elixhauser. (United States)
- 64 Characteristics of Patients Receiving Varenicline Treatment for Smoking Cessation in UK Primary Care – A THIN Database Study [642]**
Betina T Blak, Koo Wilson, Michael Metcalfe, Michelle Hards, Andrew Maguire, Victoria Gimeno. (United Kingdom)
- 65 Transitions from General Practitioner to Psychiatrist Care (Or Vice Versa) during a First Antidepressant Treatment Episode [643]**
Helga Gardarsdottir, Toine CG Egberts, Eibert R Heerdink. (Netherlands)
- 66 Drug Utilization of Transdermal Fentanyl in Germany [644]**
Ulrike Schmid, Kathrin Jobski, Edeltraut Garbe. (Germany)



Minimizing Risk and Optimizing Use of Medical Products
www.paragonrx.com

ParagonRx is proud to support the
International Society for Pharmacoepidemiology
in leading the advancement of
drug safety and risk management

Visit us at booth #29

POSTER SESSION C Sunday, August 22

- 67 Changes in Antidepressant Use Following Regulatory Agency Advisories [645]**
Amanda R Patrick, Colin R Dormuth, Sebastian Schneeweiss. (United States)
- 68 Pattern of Triptan Use in a Sample of the Italian General Population [646]**
Chiara Biagi, Elisabetta Poluzzi, Domenico Motola, Giuseppe Roberto, Aurora Puccini, Alberto Vaccheri, Roberto D'Alessandro, Nicola Montanaro. (Italy)
- 69 Composite Data-Mining Index for Signal Detection Using Healthcare Claims Database: Methylphenidate Safety as an Example [647]**
Jong-Mi Seong, Nam-Kyong Choi, Yunhee Choi, Ye-Jee Kim, Joongyub Lee, Jin Ho Lee, Byung-Joo Park. (Republic of Korea)
- 70 Factors Associated with the Schizophrenia Specific States: A Population-Based Study [648]**
Alice Dragomir, Ridha Joobor, Jean-Francois Anngers, Jean-Eric Tarride, Sylvie Perreault. (Canada)
- 71 Risk of Cardiac Valve Regurgitation with Dopamine Agonist Use in Parkinson's Disease and Hyperprolactinemia [650]**
G Trifirò, M Mokhles, J Dieleman, E van Soest, G Mazzaglia, R Herings, C de Luise, D Ross, G Brusselle, A Colao, W Haverkamp, R Schade, G van Camp, R Zanettini, M Sturkenboom. (Netherlands)
- 72 Abstract Withdrawn by Author [651]**
- 73 Antipsychotics and Diabetes: Does Effect Differ by Dose? [652]**
H Dakki, M Ulcickas Yood, G DeLorenze, C P Quessenberry Jr, S A Oliveria, A Tsai, E Kim, M Cziraky, J W Newcomer, G J L'Italien. (United States)
- 74 Cause of Death in Patients with Multiple Sclerosis and Controls: The General Practice Research Database [653]**
Arief Lalmohamed, Marloes T Bazelier, Tjeerd P van Staa, Frank de Vries. (Netherlands)
- 75 Association of Handgrip Strength with Dementia in a Korean Elderly Population [654]**
Hee-Young Shin, Jae-Min Kim, Il-Seon Shin, Jin-Sang Yoon. (Korea)
- 76 Prevalence of Alcohol Related Disorders in German Patients Treated with High-Potency Opioids [655]**
Ulrike Schmid, Sigrid Behr, Kathrin Jobski, Frank Andersohn, Edeltraut Garbe. (Germany)
- 77 The Prevalence of Depressive Symptoms and the Effects of Antidepressants in Patients with Psychotic Disorders in Routine Clinical Practice [656]**
Katja Taxis, Irene Lako, Richard Bruggeman, Rikus Knegtering, Dirk Wiersma, Cees Slooff. (Netherlands)
- 78 Association between LEP- and LEPRGene Polymorphisms and Dyslipidemia in Patients Using Atypical Antipsychotic Medication [657]**
Jochem G Gregoor, Jan van der Weide, Harriet M Looovers, Harold J van Megen, Toine C Egberts, Eibert R Heerdink. (Netherlands)
- 79 Abstract Withdrawn by Author [658]**
- 80 A Descriptive Analysis of Acetaminophen Poisoning in the U.S. Military Health Care System [659]**
Lockwood Taylor, Suji Xie, Paula Doulaveris, Trinka Coster. (United States)
- 81 Can a Drug Have Better Results in the 'Real World'? A Case Study of Cholinesterase Inhibitors in Australia [660]**
Maxine Robinson, Kerry Atkins, Ann Leverton. (Australia)
- 82 Prevalence Rates of Comorbidities in Patients with Multiple Sclerosis [661]**
Wendy J Carman, Andrew T McAfee, Julia LaGuette, Shuhua Su, Darryl Chiu. (United States)
- 83 Observational Assessment of Safety in Seroquel XL (OASIS) Study: Design and Rationale of a Non-Randomised Observational Safety Study [662]**
Deborah Layton, Vanessa Marshall, Sarah Clarke, Saad Shakir, Tony Hale. (United Kingdom)
- 84 Prescription Patterns among Children with Attention Deficit Hyperactivity Disorder (ADHD) in the United Kingdom (UK) [663]**
Sudha R Raman, Stephen W Marshall, Til Stürmer. (United States)
- 85 Patient Reports of Antipsychotic-Induced Depressive Symptoms – A Cross Sectional Study in Patients with Psychotic Disorders [664]**
Irene M Lako, Huib Burger, Rikus Knegtering, Richard Bruggeman, Katja Taxis. (Netherlands)
- 86 Age Related Differences in Antidepressant Prescribing [665]**
Thibaut Sanglier, Dominique Milea, Delphine Saragoussi, Jean-Paul Auray, Marie Tournier, Rj Valuck. (France)
- 87 Prescribing Behaviour of Smoking Cessation Products in the UK – A THIN Database Study [666]**
Betina T Blak, Michelle Hards, Hassy Dattani, Mary Thompson. (United Kingdom)
- 88 Antidiabetic Treatment in Japanese Psychotic Inpatients [667]**
Ataru Inagaki, Toshiaki Itoh, Kazumi Tsukada. (Japan)
- 89 Pediatric Atypical Antipsychotic Out-patient Drug Utilization in the US: Y2002 – Y2009 [668]**
Grace P Chai, Hina Mehta, Laura Governale. (United States)
- 90 The Feasibility of Monitoring Paediatric Adverse Drug Reactions (ADRs) Via Specialist Clinics [669]**
Mansour Tobaigy, Derek Stewart, Peter J Helms, James McLay. (United Kingdom)
- 91 Frequency and Predictors of Anti-Epileptic Drug Regimen Change in an Incident Epilepsy Cohort [670]**
Marianne C Cunningham, David J Webb, Ranjani Munjanath. (United Kingdom)
- 92 Effect of Selective Serotonin Re-Uptake Inhibitors on Myocardial Infarction: A Systematic Review [671]**
Ye-Jee Kim, Nam-Kyong Choi, Joongyub Lee, Chul Woo Rhee, So Young Park, Byung-Joo Park. (Republic of Korea)
- 93 Evaluation of Cardiovascular Diseases (CVDs) Risk for Patients with Fibromyalgia Syndrome in the United States [672]**
P J Mease, M S Duh, F Vekeman, P Lefebvre, F Laliberté, M Boerstoele-Streefland, W Jiang, P J Zimetbaum. (United States)
- 94 Prevalence Rate Ratios of Comorbidities and Symptoms in Patients with MS Compared to the General Population, Stratified by Treatment Group [673]**
Wendy J Carman, Andrew T McAfee, Julia LaGuette, Shuhua Su, Darryl Chiu. (United States)
- 95 Changes in Prevalence of Comorbidities and Symptoms among MS Patients by Treatment Group [674]**
Wendy J Carman, Andrew T McAfee, Julia LaGuette, Shuhua Su, Darryl Chiu. (United States)
- 96 Selected Opioid Use in Medicare Part D and Medicaid Elderly [675]**
Rita Ouellet-Hellstrom, Fatmatta Kuyateh, Farzana Ali, Emily Singer, Thomas E Macurdy, David J Graham. (United States)

Drug Utilization Research/
Health Services Research

- 97 Methylphenidate Treatment in Children and Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD): A Drug Utilization Study in a US Database [676]**
Yvonne Geissbühler, Estel Plana, Catherine Tuvblad. (Switzerland)
- 98 Potentially Inappropriate Medication (PIM) Prescribing in Elderly Outpatients: An Evaluation of Claims Data Based on the Beers Criteria [677]**
Martin Huber, Gerd A Kullak-Ublick, Wilhelm Kirch. (Germany)
- 99 Chronic Consumption of Antipsychotic Drugs in Belgian Nursing Home Residents [678]**
Majda Azermai, Robert Vander Stichele, Monique Elseviers, Mirko Petrovic, Luc Van Bortel. (Belgium)
- 100 Factors Associated with Potential Drug Interactions in an Intensive Care Unit [679]**
Adriano Max M Reis, Silvia Helena De B Cassiani. (Brazil)
- 101 When Inappropriate Medications Are Medically Justified in the Elderly [680]**
ML Laroche, S Crépin, S Allouetteau, JP Charmes, L Merle. (France)
- 102 Generic Switching Does Not Influence Patients' Concerns about Medicines. A Prescription Database and Questionnaire Study [681]**
Morten Andersen, Karen Elberg, Annette Foged, Dorte G Hansen, Jesper Hallas, Jens Soendergaard. (Denmark)
- 103 The Pattern of Use of Anti-Depressant Drugs [682]**
Sandra López-León, Joan Fortuny, Estel Plana, Elena Rivero. (Spain)
- 104 The Impact of Withdrawal Rofecoxib on NSAIDs Utilization [683]**
J Atthobari, C Boersma, S T Visser, M J Postma, L TW de Jong-van den Berg. (Indonesia)
- 105 Abstract Withdrawn by Author [684]**
- 106 Chronic Benzodiazepine Consumption in Belgian Nursing Home Residents [685]**
Majda Azermai, Robert Vanderstichele, Monique Elseviers, Mirko Petrovic, Luc Van Bortel. (Belgium)

- 107 Economic Burden of Drug Interactions Among Hospitalized Patients [686]**
Cristiano S Moura, Priscila L Guimarães, Jéssica O Bomfim, Francisco A Acurcio. (Brazil)
- 108 GP's Opinions of the Hospital Discharge Notes – A Survey among GPs [687]**
Anne K Eek, Hege S Blix, Kirsten K Viktil, Trond Moger, Aasmund Reikvam. (Norway)
- 109 Oral Immunosuppressive Drug Utilization and Costs in the U.S. Medicaid Programs: A Trend Analysis from 1991 to 2007 [688]**
Yan-Jun Zhang, Jing-Bo Wang, Jeff J Guo, Christina ML Kelton, Teresa Cavanaugh. (United States)
- 110 Does a National Medicines Policy Improve Medicines Access and Utilisation? [689]**
Lisa G Pont, Anna Kemp, Elizabeth E Roughead. (Australia)
- 111 Disease-Specific Healthcare Utilization Following Implementation of a Therapeutic Interchange Program [690]**
Thomas K Hazlet, Srikanth Kadiyala, Stanley Gu, Elizabeth B James. (United States)
- 112 Is There an Underconsumption of Antidepressants in Nursing Home Residents? [691]**
Majda Azermai, Robert Vander Stichele, Monique Elseviers, Mirko Petrovic, Luc Van Bortel. (Belgium)
- 113 Increase in Use of Hypnotic Drugs among Children and Adolescents Aged 0-17 Years – A Nationwide Prescription Database Study [692]**
Ingeborg Hartz, Kari Furu, Bratlid Trond, Svetlana Skurtveit. (Norway)
- 114 Association between Prescribing Procedure and Rate of Revaluation [693]**
Christina Sjöberg, Susanna M Wallerstedt. (Sweden)
- 115 Abstract Withdrawn by Author [694]**
- 116 Representativity of Dispensations of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in the German Pharmacoepidemiological Research Database [695]**
Tania Schink, Edeltraut Garbe. (Germany)
- 117 The Effects of E-Prescribing on Generic Drug Utilization and Drugs Costs in the Ambulatory Care Setting: A Quasi Experimental [696]**
J Atthobari, E B Sulistiyanto. (Indonesia)

Gut

- 118 Metformin Associated Lactacidosis – An Increasing Problem? [697]**
Steinar Madsen, Tanja Holstad. (Norway)
- 119 Reflux Disease, Gastrointestinal Ulcer or Weight Loss in Patients with COPD [698]**
Cornelia Schneider, Susan S Jick, Ulrich Bothner, Christoph R Meier. (Switzerland)
- 120 Diabetes Mellitus and Risk of Gallstone Disease Followed by Cholecystectomy [699]**
Patrick Imfeld, Michael Bodmer, Yolanda B Brauchli, Stephan Krähenbühl, Susan S Jick, Christoph R Meier. (Switzerland)
- 121 Analysis of Suspected Adverse Reactions to Antidiabetic Drugs Spain, 2008 [700]**
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)
- 122 Assessing Non-Serious Adverse Drug Events in Observational Studies among Type 2 Diabetes Mellitus Patients: A Review of Methods Used [701]**
L Hakobyan, FM Haaijer-Ruskamp, D Dobre, D de Zeeuw, P Denig. (Netherlands)
- 123 Utilization Study of Antidiabetic Drugs in Spain, 2008 [702]**
Maria-Isabel Jimenez-Serrania, Ramona Mateos-Campos. (Spain)
- 124 Drug-Related Upper Gastrointestinal Bleeding: Comparison of Signal Detection Results between Spontaneous Reporting and Longitudinal Healthcare Databases [703]**
Vaishali Patadia, Rosa Gini, Ron Herings, Giampiero Mazzaglia, Gino Picelli, Lorenza Scotti, Lars Pedersen, Johan van der Lei, Miriam Sturkenboom, Gianluca Trifirò. (United States)

Medications in Pregnancy

- 125 Strategies for Analyzing Multiple Gestations and Sequential Pregnancies in Pregnancy Registries [704]**
Deborah Covington, Amanda Golembesky, Carl deMoor. (United States)
- 126 Impact Evaluation of Intermittent Preventive Treatment Implementation for Malaria during Pregnancy in Omdurman-Sudan IDP Camp 2006 [705]**
Ahmed Eisa Saeed. (Sudan)

POSTER SESSION C Sunday, August 22

127 Medication Exposure in Pregnancy Risk Evaluation Program [706]
Susan Andrade, Pamela Scott, Craig Cheetham, William Cooper, Robert Davis, De-Kun Li, Sascha Dublin, Pamala Pawloski, Marsha Raebel, Darren Toh. (United States)

128 Methodological Challenges in Evaluating Long-Term Safety of Quinacrine Non-Surgical Sterilization [707]
Jie Li, Judith K Jones, Arlene Tave, John C Pezzullo. (United States)

129 Global Prevalence of Pregnancy Outcomes [708]
Melissa Whipple Neibauer, Matthew Reynolds, Shannon L Michels, Jenna Collins. (United States)

130 A Claims-Based Algorithm To Estimate the Date of the Last Menstrual Period [709]
Andrea V Margulis, Soko Setoguchi, Sonia Hernández-Díaz. (United States)

131 A Preliminary Assessment of Health Care Databases Potentially Available for the Drug Safety Research in Pregnancy [710]
Wendy Camelo-Castillo, Irini-Alexia Terzakis, Susan S Roberts. (United States)

132 Prevalence and Predictors of Complementary and Alternative Medicine Products Use Among Pregnant Women in New Mexico [711]
Ludmila N Bakhireva, Preeyaporn Sarangarm, Sizhu Liu, Bonnie N Young, Anne Davis, Jean T Cox, Sharon T Phelan, William F Reburn. (United States)

Methods

133 A Database-Driven Adverse Drug Reactions Detection Method – A Pilot Test with Three Illustrative Cases [712]
Man Young Park, Dukyong Yoon, KiYoung Lee, Rae Woong Park. (Republic of Korea)

134 Trends of the Medical Consumption of Benzodiazepines during Years 2003 to 2007 in Taiwan and Preliminary Cross-National Comparisons [713]
Ching-Hsing Chang, Jiin-Shain Lai, Chun-Sheng Chien, Jaw-Jou Kang. (Taiwan)

135 Innovative Signal Detection: Optimization of Empirica Signal – A Case Study [714]
Conny Berlin, Carles Blanch, David Lewis, Michel Petrin, Dionigi Maladorno, Severine Sarp, Christiane Michel, Philippe Close. (Spain)

136 Can Data Mining Spontaneously Reported Adverse Events Be Used To Assess Drug Abuse Potential [715]
Cynthia Arons, Eric Hung, Sian Ratcliffe, Doug Feltner, Manfred Hauben. (United Kingdom)

137 Identification and Characterization of Cancer Patients Using Health Insurance Database [716]
Fei Xue, Jason Yuan, Deborah Arrindell, Sean Zhao. (United States)



We discover the value within.

IMS helps you realize the potential of your products.

Combining commercial insight with scientific evidence is required to maximize market access. That's why IMS has built a global team of more than 300 experts in Pricing, Local Market Access, and Health Economics and Outcomes Research and the world's most extensive databases.

Our team combines rigorous scientific research — evidenced by more than 350 publications since 2008 — with commercially savvy consulting to help determine, demonstrate, communicate and realize product value.

We have unparalleled claims, medical, hospital and patient-centered pharmaceutical databases. Our HEOR experts use them to create an Evidence-Based ConsultingSM powerhouse.

So the next time you're thinking about product value, find out what we're thinking.

Contact our consulting team at +1.703.286.2900 or visit www.imshealth.com/heor

ims

INTELLIGENCE.
 APPLIED.

© 2010 IMS Health Incorporated or its affiliates. All rights reserved.

138 Use of a Ranking Statistic To Assess Pharmacovigilance Data Mining Algorithms [717]

Stephanie Reisinger, Manfred Hauben, Alan Hochberg, Ronald K Pearson. (United States)

139 Identifying Early Presentation of Multiple Sclerosis: A Challenge Using Insurance Claims Data [718]

Suellen M Curkendall, Cheng Wang, Barbara H Johnson, Ronald Preblich, Amelito Torres, Volker Knappertz, Kathleen Gondek. (United States)

140 Prospective, Active Surveillance for Medication Safety in Population-Based Health Networks: A Pilot Study [719]

Taliser R Avery, Yury Vilk, Martin Kulldorff, Lingling Li, T Craig Cheetham, Sascha Dublin, John Hsu, Robert L Davis, Liyan Liu, Richard Platt, Jeffrey S Brown. (United States)

141 Potentially Inappropriate Drug Prescription in the Elderly in France: Results from the EGB Database [720]

ML Laroche, B Bongué, S Gutton, L Merle, A Colvez. (France)

142 Automated Method for Detecting Temporal Changes in Spontaneous AE Data [721]

Nancy Yuen, Nassrin Payvandi, Wendy Booth, June Almenoff, David Fram, William DuMouchel. (United States)

143 Abstract Withdrawn by Author [722]

144 Drug Purchases during Pregnancy in Finland, 1996-2006: Focus on Antidepressants [723]

Miia Artama, Heli Malm, Mika Gissler, Annukka Ritvanen, Drugs and Pregnancy Group. (Finland)

145 Establishing Drug-Era Persistence Window for Active Surveillance [724]

Abraham Hartzema, Patrick Ryan, Paul Stang, Judy Racoosin, Marc Overhage. (United States)

146 Completeness of Laboratory Data in a U.S. Claims Database [725]

Laura N Horne, Charles Doyle, Krista M Schladweiler, Eileen E Ming. (United States)

147 A Sorting and Classification Method for Interactive Visualization of Drug/Event Patterns across Many Patient Timelines [726]

Sigfried Gold, Suji Xie, Lockwood Taylor, Ana Szarfman, Trinka Coster. (United States)

148 Chiral Pharmacovigilance: Spontaneous Reporting Profiles of Racemates vs. Enantiomers [727]

Manfred Hauben, Meg Richards. (United States)

149 Development of Prediction Model for Severity of Adverse Drug Reactions in Hospitalized Patients [728]

Thiyagu Rajakannan, Laxminarayana K Bairy, Padma GM Rao, Vasudeva Guddattu, SurulivelRajan Mallayasamy. (India)

150 Guiding Antibiotic Selection: Differences in Methicillin-Resistant Staphylococcus aureus (MRSA) Rates among Hospitalized and Primary Care Patients [729]

Jessina C McGregor, David T Bearden, John M Townes, Dale F Kraemer, David H Smith. (United States)

151 Users of Preserved Eye Drops: Who Switches to Preservative-Free Alternatives? [730]

Jakob Petersen, Lesley Wise. (United Kingdom)

152 Methods for Assessing the Preventability of Adverse Drug Events – A Systematic Review [731]

Katja M Hakkarainen, Karolina Andersson, Max Petzold, Staffan Hägg. (Sweden)

153 An Algorithm for the Diagnosis of Suicide in the THIN Database [732]

Alejandro Arana, Felix M Arellano, Charles W Wentworth, Janet Price. (Spain)

154 Influence of Selection Criteria on Cohort Characteristics [733]

Suellen Curkendall, Tami Mark, Huifang Liang, Helga Gardarsdottir. (United States)

155 Linking UK Death Certificate Data to UK Primary Care Data (General Practice Research Database) [734]

Efrosini Setakis, Shivani Puri, Arlene Gallagher, Susan Eaton, Frank DeVries, Tim J Williams, Tjeerd P VanStaa. (United Kingdom)

156 Lessons Learned from Mapping the THIN Database to the Observational Medical Outcome Partnership (OMOP) Common Data Model (CDM) [735]

X Zhou, S Murugesan, C Wentworth, H Bhullar, A Bate. (United States)

157 Representiveness of Subset of the General Practice Research Database (GPRD) Linked to Other Data Sources [736]

Efrosini Setakis, Shivani Puri, Tim J Williams, Tjeerd P VanStaa. (United Kingdom)

158 Vaccine Signal Detection: Comparative Results of Several Innovative Data Mining Approaches [737]

Steven R Bailey, Peter Huber, Robert Azadian. (United States)

Muscles and Bones

159 Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on Blood Pressure in Patients with Hypertension [738]

Hisham Aljadhey, Michael Murray, D Craig Brater. (Saudi Arabia)

160 SALT-I (Study of Acute Liver Transplant): A Study of NSAID-Exposed Acute Liver Failure in European Transplant Centres [739]

Ezgi Gulmez, Séverine Lignot, Corinne de Vries, Miriam Sturkenboom, Susanna Perez-Gutthann, Jacques Bénichou, Franco Bissoli, Dominique Larrey, Georges Pageaux, Yves Horsmans, Jacques Bernuau, Bruno Stricker, Douglas Thorburn, Patrick Blin, Nicholas Moore. (France)

161 A Review of RCTs on the Gastrointestinal and Cardiovascular Safety of NSAIDs in Children: The SOS Project [740]

M Balzarin, F Salvo, A Fourier-Réglat, N Moore, M Haag, M Sturkenboom, F Zulian, C Giaquinto, A Pariente. (France)

162 Multiple Myeloma and IV Bisphosphonate Are Risk Factors for Osteonecrosis of the Jaw [741]

Pat Tennis, Kenneth J Rothman, Rhonda Bohn, Hiangkai Tan, Mary Anthony, Athanosios Zavras, Brian Calingaert. (United States)

163 The SOS Project: Nonsteroidal Anti-Inflammatory Drugs and Upper Gastrointestinal Complications: Meta-Analysis of Epidemiological Studies [742]

Nuria Riera-Guardia, Jordi Castellsague, Brian Calingaert, Cristina Varas-Lorenzo, Annie Fourier-Reglat, Federica Nicotra, Miriam CJM Sturkenboom, Susana Perez-Gutthann. (Spain)

164 The Utilization of Biological Agents in Rheumatoid Arthritis Patients in Southern Taiwan [743]

Hui-Chen Chang, Li-Chia Chen, Jin-Song Wu, Hui-Ling Tseng. (Taiwan)

POSTER SESSION C Sunday, August 22

165 Methodological Issues and Knowledge Gaps in RCTs Evaluating the Safety of NSAIDs in Adults: The SOS Project [744]

F Salvo, A Fourrier-Reglat, M Balzarin, F Bazin, N Riera, M Haag, N Moore, M Sturkenboom, A Pariente. (France)

166 Prescribing Trends of Bisphosphonates in General Practice, UK 1995-2008 [745]

Jakob Petersen, Lesley Wise. (United Kingdom)

167 Chronic Use of Non-Steroidal Anti-Inflammatory Drugs and the Risk of Atrial Fibrillation [746]

Raffaele De Caterina, Ana Ruigómez, Luís Alberto García Rodríguez. (Spain)

168 Chemoprevention of Breast Cancer with Bisphosphonates [747]

Sharon Hensley Alford, Christine Cole Johnson, Stephen B Gruber, Sofia D Merajver. (United States)

169 Pattern of Use of NSAIDs in Italian Population and Frequency of Risk Factors for Gastrointestinal Injury [748]

Chiara Sacripanti, Elisabetta Poluzzi, Alessandra Berti, Elisa Rossi, Marisa De Rosa, Nicola Montanaro. (Italy)

170 Factors Associated with Methodological Quality of RCTs Evaluating the Safety of NSAIDs: The SOS Project [749]

F Salvo, A Fourrier-Réglat, F Bazin, M Balzarin, M Haag, N Moore, M Sturkenboom, A Pariente. (France)

Pharmacovigilance

171 Trends in Reporting of Adverse Drug Reactions to HIV Medicines [750]

Paul L Barrow, Catherine A King, Jane A Woolley. (United Kingdom)

172 Characteristics of Paediatric Individual Case Safety Reports within the WHO-UMC Database [751]

S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturkenboom. (Netherlands)

173 Differences in Causality Assessments of Adverse Drug Reactions According to the Reports from Different Professional Groups [752]

Nuno Craveiro, Carlos Alves, Francisco Batel-Marques. (Portugal)

174 Topical NSAIDs Adverse Drug Reaction Reports in Thaivigibase [753]

Pakawadee Sriphiromya, Sareeya Wechwithan. (Thailand)

175 The Pattern of Drug-Induced Rhabdomyolysis Reports in Taiwan [754]

Wei-Ming Ke, Wen-Wen Chen, Churn-Shiouh Gau. (Taiwan)

176 Multicentre Study on Adverse Drug and Vaccine Reactions in Children during A-H1N1 Virus Pandemic [755]

Francesca Menniti-Ippolito, Roberto Da Cas, Concita Rafaniello, Giuseppe Traversa, Multicenter Study Group on Safety of Drugs and Vaccines in Children. (Italy)

177 Detection of Late Effects of Drugs Children Using a Spontaneous Report ADR Database [756]

S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturkenboom. (Netherlands)

178 Patient Reporting of ADRs in the UK: How Do Patient Reports Affect Potential Signals Generated by Healthcare Professionals? [757]

L Hazell, V Cornelius, S Shakir, A Avery. (United Kingdom)

179 The Yellow Card Scheme: Experience of Patient Reporting of Adverse Drug Reactions 5 Years Since Launch [758]

Sarah L Cumber, Sarah J Heffer, Shelley Gandhi, Anthony J Avery. (United Kingdom)

180 Spontaneous Reports as a Source for Risk Assessment of Long Term Drug Use in Children [759]

S de Bie, KMC Verhamme, SMJM Straus, GW 't Jong, BHC Stricker, MCJM Sturkenboom. (Netherlands)

Vaccines

181 Importance of Medical Record Review for Database Studies: Example of Febrile Convulsion (FC) [760]

Patricia Saddier, Trung Tran, Bradley Ackerson, Lina Sy, Janis Yao, Craig Cheatham, Steven Jacobsen. (United States)

182 Reactogenicity of the Bivalent Human Papillomavirus Vaccine [761]

Jeanet M Kemmeren, Nicoline AT van der Maas, Hester E de Melker. (Netherlands)

183 Risk of Incident Autoimmune Diseases after Hepatitis B Vaccination – A Large Cohort Study in the GPRD [762]

Marco Egbring, Gerd A Kullak-Ublick, Stefan Russmann. (Switzerland)

184 Pilot Swine Flu Vaccination Active Surveillance Study: Interim Results [763]

D Layton, D Rutherford, T M MacDonald, S AW Shakir, I S Mackenzie. (United Kingdom)

185 Adverse Events Following Bivalent Human Papillomavirus Vaccination Reported to the Enhanced Passive Surveillance System of the Netherlands [764]

Nicoline van der Maas, Corrie Wesselo, Tieke Phaff, Patricia Vermeer-de Bondt, Bregje Oostvogels. (Netherlands)

186 Characteristics of H1N1 Vaccine Exposures in a Large, Commercially Insured Population [765]

Peter M Wahl, Tao Gu, Gregory W Daniel, Marcus Wilson. (United States)

187 Pilot Swine Flu Vaccination Active Surveillance Study: Design and Rationale [766]

D Layton, D Rutherford, T M MacDonald, S AW Shakir, I S Mackenzie. (United Kingdom)

188 Adverse Events of Special Interest (AESI): H1N1 Vaccines Versus Seasonal Influenza Vaccines [767]

A Hidalgo-Simon, A Segec, J Slattery, A Szmigiel, I Skibicka, J Durand, A Addis, X Kurz. (United Kingdom)

189 Interim Results Should Be Taken with Caution: Example of a Vaccine Safety Study [768]

Patricia Saddier, John Hansen, Michael Emery, Bruce Fireman, Trung Tran, Roger Baxter. (United States)

190 Safety of a Monovalent 2009 Influenza A (H1N1) Vaccine in Adult and Pediatric Clinical Trial Populations [769]

A Graves Jones, S Bassal, P Thomas, M Greenberg, G Hartel, D Washington. (Australia)

191 Postmarketing Safety Review for Rotarix®: Data from the Vaccine Adverse Event Reporting System (VAERS), April 2008-October 2009 [770]

Wei Hua, Rosemary Tiernan, Amy Steffey, David Martin, Robert Wise. (United States)

192 Risk of Guillain-Barré Syndrome and Vaccination Against Seasonal Flu [771]

Lamia Grimaldi-Bensouda, Michel Rossignol, Laurent Magy, Anne Cosson, Lucien Abenhaim. (France)

193 Adverse Events Following Varicella-Zoster Virus Vaccination (Zostavax): Reports to the Vaccine Adverse Event Reporting System, 2006-2009 [772]

Yandong Qiang, Manette Niu, David Martin, Hector Izurieta. (United States)

194 Participation of General Practices in a Swine Flu Vaccination Study [773]

Isla S Mackenzie, Moira Dryburgh, Daniel Rutherford, Thomas M MacDonald, Saad AW Shakir, Deborah Layton. (United Kingdom)

195 Vaccine Vigilance: Safety of Pandemic Flu Vaccine in the Population of Stockholm, Sweden [774]

Carola Bardage, Jonny Olsson, Ingemar Persson, Ulf Bergman, Åke Örtqvist. (Sweden)

196 Safety of the Influenza A (H1N1) 2009 Monovalent Vaccine Among the Indian Health Service User Population [775]

Yandong Qiang, Amy Groom, John Redd, Dana Haberling, Robert Holman, Cheyenne Jim, Hector Izurieta, Andrea Sutherland, Larry Layne, Theresa Cullen, James Cheek. (United States)

197 Reactogenicity of a Combined dT-IPV and a MMR Vaccine in Healthy 9-Year Old Children [776]

Jeanet M Kemmeren, Nicoline AT van der Maas, Hester E de Melker. (Netherlands)

198 Immediate Occurring Adverse Events Following Bivalent Human Papillomavirus Vaccination in the Netherlands [777]

Nicoline van der Maas, Irmgard Zonnenberg-Hoff, Jeanet Kemmeren, Hester de Melker. (Netherlands)

199 Effectiveness of Pandemic Influenza Vaccination in a Dutch Population [778]

Leonoor Wijnans, Jeanne Dieleman, Bettie Voordouw, Miriam Sturkenboom. (Netherlands)

200 The EudraVigilance Database of Spontaneous Adverse Reactions as a Tool for H1N1 Vaccine Safety Monitoring [779]

X Kurz, J Slattery, A Addis, J Durand, A Segec, I Skibicka, A Szmigiel, Ana Hidalgo-Simon. (United Kingdom)

Meeting Notes

End Session C

KANTAR+HEALTH



Who is Kantar Health?

Kantar Health, a global consultancy and marketing insights organization, delivers value to our clients in the life sciences industry through four globally integrated practice areas: Treatment Value, Commercial Development, Brand and Stakeholder Management, and Marketing Insights.

Formed in 2009 by uniting Consumer Health Sciences, MattsonJack, TNS Healthcare, and Ziment, Kantar Health is the next-generation decision-support partner, delivering evidence-based guidance to accelerate clients' global and local success.

Come by our booth – #25 – to learn more about our gold-standard databases: Epi Database, Epi Database BRIC, CancerMPact, National Health and Wellness Survey, and custom epidemiology and safety capabilities.

Inspired by

Consumer Health Sciences
MattsonJack
TNS Healthcare
Ziment

www.kantarhealth.com

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20				
1		9:00 AM	Clarence	Oral
2		9:15 AM	Clarence	Oral
6		9:30 AM	Clarence	Oral
4		9:45 AM	Clarence	Oral
5		10:00 AM	Clarence	Oral
3		10:15 AM	Clarence	Oral
7		9:00 AM	Dukes	Oral
8		9:15 AM	Dukes	Oral
9		9:30 AM	Dukes	Oral
10		9:45 AM	Dukes	Oral
11		10:00 AM	Dukes	Oral
12		10:15 AM	Dukes	Oral
13		9:00 AM	Hall 4	Oral
14		9:15 AM	Hall 4	Oral
15		9:30 AM	Hall 4	Oral
16		9:45 AM	Hall 4	Oral
17		10:00 AM	Hall 4	Oral
18		10:15 AM	Hall 4	Oral
19		9:00 AM	Buckingham	Oral
20		9:15 AM	Buckingham	Oral
21		9:30 AM	Buckingham	Oral
22		9:45 AM	Buckingham	Oral
557		10:00 AM	Buckingham	Oral
24		10:15 AM	Buckingham	Oral
25		9:00 AM	Balmoral	Oral
26		9:15 AM	Balmoral	Oral
345		9:30 AM	Balmoral	Oral
28		9:45 AM	Balmoral	Oral
29		10:00 AM	Balmoral	Oral
30		10:15 AM	Balmoral	Oral
31		9:00 AM	Cambridge	Oral
32		9:15 AM	Cambridge	Oral
33		9:30 AM	Cambridge	Oral
34		9:45 AM	Cambridge	Oral
35		10:00 AM	Cambridge	Oral
36		10:15 AM	Cambridge	Oral
Methodological Challenges in Cross-National Comparisons of Drug Utilization (Drug Utilisation / Health Services Research SIG Symposium)				
37		3:30 PM	Balmoral	Sympos.
Methodological Controversies from Comparative Effectiveness (CE) Studies Using Claims vs. Electronic Health Record (EHR) Data				
38		3:30 PM	Cambridge	Sympos.
Ascertaining the Use of Biologics (Biologics SIG Symposium)				
39		3:30 PM	Dukes	Sympos.
Guidance Regarding the Identification, Development, Validation and Translation of Coding Algorithms in Electronic Healthcare (EH) Databases (Database SIG Symposium)				
40		3:30 PM	Hall 4	Sympos.
Identifying the Genetic Basis of Serious Adverse Events: Will High-Profile Genome-Wide Association (GWA) Studies Improve Drug Safety in the Next Decade? (A Joint MEBPharmacogenomics-SIG & iSAEC Symposium)				
41		3:30 PM	Buckingham	Sympos.

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
Identification and Classification of Birth Defects in Pharmacoepidemiology: A Comparison of Approaches (Medications in Pregnancy SIG Symposium)				
42		3:30 PM	Clarence	Sympos.
The Public Health Burden of Acetaminophen Poisonings: Risk Management Efforts To Mitigate it				
575		3:30 PM	Ambassador	Sympos.
Poster Session A				
Anti-infectives				
43	1	7:30 AM - 6:00 PM		Poster
44	2	7:30 AM - 6:00 PM		Poster
45	3	7:30 AM - 6:00 PM		Poster
46	4	7:30 AM - 6:00 PM		Poster
47	5	7:30 AM - 6:00 PM		Poster
Blood				
48	6	7:30 AM - 6:00 PM		Poster
49	7	7:30 AM - 6:00 PM		Poster
50	8	7:30 AM - 6:00 PM		Poster
51	9	7:30 AM - 6:00 PM		Poster
52	10	7:30 AM - 6:00 PM		Poster
53	11	7:30 AM - 6:00 PM		Poster
54	12	7:30 AM - 6:00 PM		Poster
55	13	7:30 AM - 6:00 PM		Poster
56	14	7:30 AM - 6:00 PM		Poster
Cancer and Immunity				
57	15	7:30 AM - 6:00 PM		Poster
58	16	7:30 AM - 6:00 PM		Poster
59	17	7:30 AM - 6:00 PM		Poster
60	18	7:30 AM - 6:00 PM		Poster
61	19	7:30 AM - 6:00 PM		Poster
62	20	7:30 AM - 6:00 PM		Poster
63	21	7:30 AM - 6:00 PM		Poster
64	22	7:30 AM - 6:00 PM		Poster
65	23	7:30 AM - 6:00 PM		Poster
Cardiovascular				
66	24	7:30 AM - 6:00 PM		Poster
67	25	7:30 AM - 6:00 PM		Poster
68	26	<i>Abstract Withdrawn by Author</i>		
69	27	7:30 AM - 6:00 PM		Poster
70	28	7:30 AM - 6:00 PM		Poster
71	29	7:30 AM - 6:00 PM		Poster
72	30	7:30 AM - 6:00 PM		Poster
73	31	7:30 AM - 6:00 PM		Poster
74	32	7:30 AM - 6:00 PM		Poster
75	33	<i>Abstract Withdrawn by Author</i>		
76	34	7:30 AM - 6:00 PM		Poster
77	35	7:30 AM - 6:00 PM		Poster
78	36	7:30 AM - 6:00 PM		Poster
79	37	7:30 AM - 6:00 PM		Poster
80	38	7:30 AM - 6:00 PM		Poster
81	39	7:30 AM - 6:00 PM		Poster
82	40	7:30 AM - 6:00 PM		Poster
83	41	7:30 AM - 6:00 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
84	42	7:30 AM - 6:00 PM		Poster
85	43	<i>Abstract Withdrawn by Author</i>		
86	44	7:30 AM - 6:00 PM		Poster
87	45	<i>Abstract Withdrawn by Author</i>		
88	46	7:30 AM - 6:00 PM		Poster
89	47	7:30 AM - 6:00 PM		Poster
90	48	7:30 AM - 6:00 PM		Poster
Classical Pharmacoepidemiology				
91	49	7:30 AM - 6:00 PM		Poster
92	50	7:30 AM - 6:00 PM		Poster
93	51	7:30 AM - 6:00 PM		Poster
94	52	7:30 AM - 6:00 PM		Poster
95	53	7:30 AM - 6:00 PM		Poster
96	54	7:30 AM - 6:00 PM		Poster
97	55	7:30 AM - 6:00 PM		Poster
98	56	7:30 AM - 6:00 PM		Poster
99	57	7:30 AM - 6:00 PM		Poster
100	58	7:30 AM - 6:00 PM		Poster
101	59	7:30 AM - 6:00 PM		Poster
CNS				
102	60	7:30 AM - 6:00 PM		Poster
103	61	7:30 AM - 6:00 PM		Poster
105	62	7:30 AM - 6:00 PM		Poster
106	63	7:30 AM - 6:00 PM		Poster
107	64	7:30 AM - 6:00 PM		Poster
108	65	7:30 AM - 6:00 PM		Poster
109	66	7:30 AM - 6:00 PM		Poster
110	67	7:30 AM - 6:00 PM		Poster
111	68	7:30 AM - 6:00 PM		Poster
112	69	7:30 AM - 6:00 PM		Poster
113	70	7:30 AM - 6:00 PM		Poster
114	71	7:30 AM - 6:00 PM		Poster
115	72	7:30 AM - 6:00 PM		Poster
117	73	7:30 AM - 6:00 PM		Poster
658	74	7:30 AM - 6:00 PM		Poster
Drug Utilization Research/Health Services Research				
118	75	<i>Abstract Withdrawn by Author</i>		
119	76	7:30 AM - 6:00 PM		Poster
120	77	7:30 AM - 6:00 PM		Poster
121	78	7:30 AM - 6:00 PM		Poster
122	79	<i>Abstract Withdrawn by Author</i>		
123	80	7:30 AM - 6:00 PM		Poster
124	81	7:30 AM - 6:00 PM		Poster
125	82	7:30 AM - 6:00 PM		Poster
126	83	7:30 AM - 6:00 PM		Poster
127	84	7:30 AM - 6:00 PM		Poster
128	85	7:30 AM - 6:00 PM		Poster
129	86	7:30 AM - 6:00 PM		Poster
130	87	7:30 AM - 6:00 PM		Poster
131	88	7:30 AM - 6:00 PM		Poster
132	89	7:30 AM - 6:00 PM		Poster
133	90	7:30 AM - 6:00 PM		Poster
134	91	7:30 AM - 6:00 PM		Poster
135	92	7:30 AM - 6:00 PM		Poster
136	93	7:30 AM - 6:00 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
Gut				
137	94	7:30 AM - 6:00 PM		Poster
138	95	7:30 AM - 6:00 PM		Poster
139	96	7:30 AM - 6:00 PM		Poster
140	97	7:30 AM - 6:00 PM		Poster
141	98	7:30 AM - 6:00 PM		Poster
142	99	7:30 AM - 6:00 PM		Poster
143	100	7:30 AM - 6:00 PM		Poster
144	101	7:30 AM - 6:00 PM		Poster
145	102	7:30 AM - 6:00 PM		Poster
146	103	7:30 AM - 6:00 PM		Poster
Lungs				
147	104	7:30 AM - 6:00 PM		Poster
148	105	7:30 AM - 6:00 PM		Poster
149	106	7:30 AM - 6:00 PM		Poster
150	107	7:30 AM - 6:00 PM		Poster
151	108	7:30 AM - 6:00 PM		Poster
152	109	7:30 AM - 6:00 PM		Poster
153	110	7:30 AM - 6:00 PM		Poster
154	111	7:30 AM - 6:00 PM		Poster
Medications in Pregnancy				
155	112	7:30 AM - 6:00 PM		Poster
156	113	7:30 AM - 6:00 PM		Poster
157	114	7:30 AM - 6:00 PM		Poster
158	115	7:30 AM - 6:00 PM		Poster
159	116	7:30 AM - 6:00 PM		Poster
160	117	7:30 AM - 6:00 PM		Poster
161	118	7:30 AM - 6:00 PM		Poster
162	119	7:30 AM - 6:00 PM		Poster
163	120	7:30 AM - 6:00 PM		Poster
164	121	7:30 AM - 6:00 PM		Poster
165	122	7:30 AM - 6:00 PM		Poster
166	123	7:30 AM - 6:00 PM		Poster
167	124	7:30 AM - 6:00 PM		Poster
Methods				
168	125	7:30 AM - 6:00 PM		Poster
169	126	7:30 AM - 6:00 PM		Poster
170	127	7:30 AM - 6:00 PM		Poster
171	128	7:30 AM - 6:00 PM		Poster
172	129	7:30 AM - 6:00 PM		Poster
173	130	7:30 AM - 6:00 PM		Poster
174	131	7:30 AM - 6:00 PM		Poster
176	132	7:30 AM - 6:00 PM		Poster
177	133	7:30 AM - 6:00 PM		Poster
178	134	7:30 AM - 6:00 PM		Poster
179	135	7:30 AM - 6:00 PM		Poster
180	136	7:30 AM - 6:00 PM		Poster
181	137	7:30 AM - 6:00 PM		Poster
182	138	7:30 AM - 6:00 PM		Poster
183	139	7:30 AM - 6:00 PM		Poster
184	140	7:30 AM - 6:00 PM		Poster
185	141	7:30 AM - 6:00 PM		Poster
186	142	7:30 AM - 6:00 PM		Poster
187	143	7:30 AM - 6:00 PM		Poster
188	144	7:30 AM - 6:00 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Friday, August 20 ...continued				
189	145	7:30 AM - 6:00 PM		Poster
191	146	7:30 AM - 6:00 PM		Poster
192	147	7:30 AM - 6:00 PM		Poster
193	148	7:30 AM - 6:00 PM		Poster
194	149	7:30 AM - 6:00 PM		Poster
195	150	7:30 AM - 6:00 PM		Poster
196	151	7:30 AM - 6:00 PM		Poster
197	152	7:30 AM - 6:00 PM		Poster
198	153	7:30 AM - 6:00 PM		Poster
199	154	7:30 AM - 6:00 PM		Poster
200	155	7:30 AM - 6:00 PM		Poster
201	156	7:30 AM - 6:00 PM		Poster
202	157	7:30 AM - 6:00 PM		Poster
203	158	7:30 AM - 6:00 PM		Poster
204	159	7:30 AM - 6:00 PM		Poster
205	160	7:30 AM - 6:00 PM		Poster
206	161	7:30 AM - 6:00 PM		Poster
175	162	7:30 AM - 6:00 PM		Poster
207	163	7:30 AM - 6:00 PM		Poster
208	164	7:30 AM - 6:00 PM		Poster
209	165	7:30 AM - 6:00 PM		Poster
210	166	7:30 AM - 6:00 PM		Poster
211	167	7:30 AM - 6:00 PM		Poster
Muscles and Bones				
212	168	7:30 AM - 6:00 PM		Poster
213	169	7:30 AM - 6:00 PM		Poster
214	170	7:30 AM - 6:00 PM		Poster
215	171	7:30 AM - 6:00 PM		Poster
216	172	7:30 AM - 6:00 PM		Poster
Pharmacovigilance				
217	173	<i>Abstract Withdrawn by Author</i>		
218	174	7:30 AM - 6:00 PM		Poster
219	175	7:30 AM - 6:00 PM		Poster
220	176	7:30 AM - 6:00 PM		Poster
221	177	7:30 AM - 6:00 PM		Poster
222	178	7:30 AM - 6:00 PM		Poster
223	179	7:30 AM - 6:00 PM		Poster
224	180	7:30 AM - 6:00 PM		Poster
225	181	7:30 AM - 6:00 PM		Poster
226	182	7:30 AM - 6:00 PM		Poster
227	183	7:30 AM - 6:00 PM		Poster
228	184	7:30 AM - 6:00 PM		Poster
Risk Management / Communication				
229	185	7:30 AM - 6:00 PM		Poster
230	186	7:30 AM - 6:00 PM		Poster
231	187	7:30 AM - 6:00 PM		Poster
232	188	<i>Abstract Withdrawn by Author</i>		
233	189	7:30 AM - 6:00 PM		Poster
234	190	7:30 AM - 6:00 PM		Poster
235	191	7:30 AM - 6:00 PM		Poster
236	192	7:30 AM - 6:00 PM		Poster
Miscellaneous				
248	193	7:30 AM - 6:00 PM		Poster
249	194	7:30 AM - 6:00 PM		Poster
605	195	7:30 AM - 6:00 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21				
237		8:30 AM	Balmoral	Oral
238		8:45 AM	Balmoral	Oral
239		9:00 AM	Balmoral	Oral
240		9:15 AM	Balmoral	Oral
241		9:30 AM	Balmoral	Oral
242		9:45 AM	Balmoral	Oral
243		8:30 AM	Cambridge	Oral
244		8:45 AM	Cambridge	Oral
245		9:00 AM	Cambridge	Oral
246		9:15 AM	Cambridge	Oral
247		9:30 AM	Cambridge	Oral
190		9:45 AM	Cambridge	Oral
464		8:30 AM	Buckingham	Oral
250		8:45 AM	Buckingham	Oral
251		9:00 AM	Buckingham	Oral
252		9:15 AM	Buckingham	Oral
253		9:30 AM	Buckingham	Oral
254		9:45 AM	Buckingham	Oral
255		8:30 AM	Dukes	Oral
256		8:45 AM	Dukes	Oral
257		9:00 AM	Dukes	Oral
258		9:15 AM	Dukes	Oral
259		9:30 AM	Dukes	Oral
260		9:45 AM	Dukes	Oral
261		8:30 AM	Clarence	Oral
262		8:45 AM	Clarence	Oral
263		9:00 AM	Clarence	Oral
264		9:15 AM	Clarence	Oral
265		9:30 AM	Clarence	Oral
266		9:45 AM	Clarence	Oral
267		8:30 AM	Oxford	Oral
268		8:45 AM	Oxford	Oral
269		9:00 AM	Oxford	Oral
270		9:15 AM	Oxford	Oral
271		9:30 AM	Oxford	Oral
272		9:45 AM	Oxford	Oral
273		10:30 AM	Dukes	Oral
274		10:45 AM	Dukes	Oral
275		11:00 AM	Dukes	Oral
276		11:15 AM	Dukes	Oral
277		11:30 AM	Dukes	Oral
278		11:45 AM	Dukes	Oral
279		10:30 AM	Oxford	Oral
280		10:45 AM	Oxford	Oral
612		11:00 AM	Oxford	Oral
282		11:15 AM	Oxford	Oral
283		11:30 AM	Oxford	Oral
284		11:45 AM	Oxford	Oral
285		10:30 AM	Cambridge	Oral
286		10:45 AM	Cambridge	Oral
287		11:00 AM	Cambridge	Oral
288		11:15 AM	Cambridge	Oral
289		11:30 AM	Cambridge	Oral
290		11:45 AM	Cambridge	Oral
291		10:30 AM	Balmoral	Oral
292		10:45 AM	Balmoral	Oral
293		11:00 AM	Balmoral	Oral
294		11:15 AM	Balmoral	Oral

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
295		11:30 AM	Balmoral	Oral
296		11:45 AM	Balmoral	Oral
297		10:30 AM	Buckingham	Oral
298		10:45 AM	Buckingham	Oral
299		11:00 AM	Buckingham	Oral
300		11:15 AM	Buckingham	Oral
301		11:30 AM	Buckingham	Oral
302		11:45 AM	Buckingham	Oral
303		10:30 AM	Clarence	Oral
304		10:45 AM	Clarence	Oral
305		11:00 AM	Clarence	Oral
306		11:15 AM	Clarence	Oral
307		11:30 AM	Clarence	Oral
308		11:45 AM	Clarence	Oral
Edlavitch Award (Best Student Abstracts)				
309		2:30 PM	Oxford	Oral
Optimizing Global Vaccine Safety Monitoring: Lessons Learned from H1N1				
310		4:00 PM	Hall 4	Sympos.
Matching on Propensity Scores: Good Practices and New Directions				
311		4:00 PM	Balmoral	Sympos.
Regulatory Risk Communication Are We Getting Ahead?				
312		4:00 PM	Oxford	Sympos.
Role of Meta-Analysis in Drug Safety: Methodological Considerations and Regulatory Implications				
313		4:00 PM	Buckingham	Sympos.
The Panacea of Study Designs in Pharmacoepidemiology: Which One? Antipsychotics and Myocardial Infarct in the Demented Elderly Population				
314		4:00 PM	Dukes	Sympos.
How Can Better Scientific Methods Result in Better Drug Regulation - Two Recent Case Studies				
315		4:00 PM	Clarence	Sympos.
Evaluating Adverse Pregnancy Outcomes – A Workshop to Develop an Inventory of Methodological Issues Related to Different Approaches				
780		4:00 PM	Ambassador	Sympos.
Poster Session B				
Anti-infectives				
316	1	8:00 AM - 6:00 PM		Poster
317	2	8:00 AM - 6:00 PM		Poster
318	3	8:00 AM - 6:00 PM		Poster
319	4	8:00 AM - 6:00 PM		Poster
320	5	8:00 AM - 6:00 PM		Poster
321	6	8:00 AM - 6:00 PM		Poster
322	7	8:00 AM - 6:00 PM		Poster
323	8	8:00 AM - 6:00 PM		Poster
324	9	<i>Abstract Withdrawn by Author</i>		
325	10	8:00 AM - 6:00 PM		Poster
326	11	8:00 AM - 6:00 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
327	12	8:00 AM - 6:00 PM		Poster
328	13	<i>Abstract Withdrawn by Author</i>		
349	14	8:00 AM - 6:00 PM		Poster
Cardiovascular				
329	15	8:00 AM - 6:00 PM		Poster
330	16	8:00 AM - 6:00 PM		Poster
331	17	8:00 AM - 6:00 PM		Poster
332	18	8:00 AM - 6:00 PM		Poster
333	19	8:00 AM - 6:00 PM		Poster
334	20	8:00 AM - 6:00 PM		Poster
335	21	8:00 AM - 6:00 PM		Poster
336	22	8:00 AM - 6:00 PM		Poster
337	23	8:00 AM - 6:00 PM		Poster
338	24	<i>Abstract Withdrawn by Author</i>		
339	25	8:00 AM - 6:00 PM		Poster
340	26	8:00 AM - 6:00 PM		Poster
341	27	8:00 AM - 6:00 PM		Poster
342	28	8:00 AM - 6:00 PM		Poster
343	29	8:00 AM - 6:00 PM		Poster
344	30	8:00 AM - 6:00 PM		Poster
346	31	8:00 AM - 6:00 PM		Poster
347	32	8:00 AM - 6:00 PM		Poster
348	33	8:00 AM - 6:00 PM		Poster
Classical Pharmacoepidemiology				
350	34	8:00 AM - 6:00 PM		Poster
351	35	8:00 AM - 6:00 PM		Poster
352	36	8:00 AM - 6:00 PM		Poster
353	37	8:00 AM - 6:00 PM		Poster
354	38	8:00 AM - 6:00 PM		Poster
CNS				
355	39	8:00 AM - 6:00 PM		Poster
356	40	8:00 AM - 6:00 PM		Poster
357	41	8:00 AM - 6:00 PM		Poster
358	42	8:00 AM - 6:00 PM		Poster
359	43	8:00 AM - 6:00 PM		Poster
360	44	8:00 AM - 6:00 PM		Poster
361	45	<i>Abstract Withdrawn by Author</i>		
649	46	8:00 AM - 6:00 PM		Poster
Drug Utilization Research/Health Services Research				
362	47	8:00 AM - 6:00 PM		Poster
363	48	8:00 AM - 6:00 PM		Poster
364	49	8:00 AM - 6:00 PM		Poster
365	50	8:00 AM - 6:00 PM		Poster
366	51	8:00 AM - 6:00 PM		Poster
367	52	8:00 AM - 6:00 PM		Poster
368	53	8:00 AM - 6:00 PM		Poster
369	54	8:00 AM - 6:00 PM		Poster
370	55	8:00 AM - 6:00 PM		Poster
371	56	8:00 AM - 6:00 PM		Poster
372	57	<i>Abstract Withdrawn by Author</i>		
373	58	8:00 AM - 6:00 PM		Poster
374	59	8:00 AM - 6:00 PM		Poster
375	60	8:00 AM - 6:00 PM		Poster
376	61	8:00 AM - 6:00 PM		Poster
377	62	8:00 AM - 6:00 PM		Poster
378	63	8:00 AM - 6:00 PM		Poster
379	64	8:00 AM - 6:00 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
380	65	8:00 AM - 6:00 PM		Poster
381	66	8:00 AM - 6:00 PM		Poster
382	67	8:00 AM - 6:00 PM		Poster
383	68	8:00 AM - 6:00 PM		Poster
Gut				
384	69	8:00 AM - 6:00 PM		Poster
385	70	8:00 AM - 6:00 PM		Poster
386	71	8:00 AM - 6:00 PM		Poster
387	72	8:00 AM - 6:00 PM		Poster
388	73	8:00 AM - 6:00 PM		Poster
389	74	8:00 AM - 6:00 PM		Poster
390	75	8:00 AM - 6:00 PM		Poster
391	76	8:00 AM - 6:00 PM		Poster
392	77	8:00 AM - 6:00 PM		Poster
393	78	8:00 AM - 6:00 PM		Poster
394	79	<i>Abstract Withdrawn by Author</i>		
395	80	8:00 AM - 6:00 PM		Poster
396	81	8:00 AM - 6:00 PM		Poster
397	82	8:00 AM - 6:00 PM		Poster
398	83	8:00 AM - 6:00 PM		Poster
399	84	8:00 AM - 6:00 PM		Poster
Methods				
400	85	8:00 AM - 6:00 PM		Poster
401	86	<i>Abstract Withdrawn by Author</i>		
402	87	8:00 AM - 6:00 PM		Poster
403	88	8:00 AM - 6:00 PM		Poster
404	89	8:00 AM - 6:00 PM		Poster
405	90	8:00 AM - 6:00 PM		Poster
406	91	8:00 AM - 6:00 PM		Poster
407	92	8:00 AM - 6:00 PM		Poster
408	93	8:00 AM - 6:00 PM		Poster
409	94	8:00 AM - 6:00 PM		Poster
410	95	8:00 AM - 6:00 PM		Poster
Muscles and Bones				
411	96	8:00 AM - 6:00 PM		Poster
412	97	8:00 AM - 6:00 PM		Poster
413	98	8:00 AM - 6:00 PM		Poster
414	99	8:00 AM - 6:00 PM		Poster
415	100	8:00 AM - 6:00 PM		Poster
416	101	8:00 AM - 6:00 PM		Poster
Other				
417	102	8:00 AM - 6:00 PM		Poster
418	103	8:00 AM - 6:00 PM		Poster
419	104	8:00 AM - 6:00 PM		Poster
420	105	8:00 AM - 6:00 PM		Poster
421	106	8:00 AM - 6:00 PM		Poster
Pharmacovigilance				
422	107	8:00 AM - 6:00 PM		Poster
423	108	8:00 AM - 6:00 PM		Poster
424	109	8:00 AM - 6:00 PM		Poster
425	110	8:00 AM - 6:00 PM		Poster
426	111	8:00 AM - 6:00 PM		Poster
427	112	8:00 AM - 6:00 PM		Poster
428	113	8:00 AM - 6:00 PM		Poster
429	114	8:00 AM - 6:00 PM		Poster
430	115	<i>Abstract Withdrawn by Author</i>		

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
431	116	8:00 AM - 6:00 PM		Poster
432	117	8:00 AM - 6:00 PM		Poster
433	118	8:00 AM - 6:00 PM		Poster
434	119	8:00 AM - 6:00 PM		Poster
435	120	<i>Abstract Withdrawn by Author</i>		
Poster Walk - Biologics SIG				
436	121	8:00 AM - 6:00 PM	Poster Walk	
437	122	8:00 AM - 6:00 PM	Poster Walk	
438	123	8:00 AM - 6:00 PM	Poster Walk	
439	124	8:00 AM - 6:00 PM	Poster Walk	
440	125	8:00 AM - 6:00 PM	Poster Walk	
441	126	8:00 AM - 6:00 PM	Poster Walk	
442	127	8:00 AM - 6:00 PM	Poster Walk	
443	128	8:00 AM - 6:00 PM	Poster Walk	
444	129	8:00 AM - 6:00 PM	Poster Walk	
445	130	8:00 AM - 6:00 PM	Poster Walk	
446	131	8:00 AM - 6:00 PM	Poster Walk	
Poster Walk - Comparative Effectiveness Research SIG				
447	132	8:00 AM - 6:00 PM	Poster Walk	
449	133	8:00 AM - 6:00 PM	Poster Walk	
450	134	8:00 AM - 6:00 PM	Poster Walk	
451	135	8:00 AM - 6:00 PM	Poster Walk	
452	136	8:00 AM - 6:00 PM	Poster Walk	
453	137	8:00 AM - 6:00 PM	Poster Walk	
454	138	<i>Abstract Withdrawn by Author</i>		
455	139	8:00 AM - 6:00 PM	Poster Walk	
457	140	8:00 AM - 6:00 PM	Poster Walk	
458	141	8:00 AM - 6:00 PM	Poster Walk	
Poster Walk - Database SIG				
459	142	8:00 AM - 6:00 PM	Poster Walk	
460	143	8:00 AM - 6:00 PM	Poster Walk	
461	144	8:00 AM - 6:00 PM	Poster Walk	
462	145	<i>Abstract Withdrawn by Author</i>		
463	146	8:00 AM - 6:00 PM	Poster Walk	
465	147	8:00 AM - 6:00 PM	Poster Walk	
466	148	8:00 AM - 6:00 PM	Poster Walk	
468	149	8:00 AM - 6:00 PM	Poster Walk	
Poster Walk - Utilization SIG				
469	150	8:00 AM - 6:00 PM	Poster Walk	
470	151	8:00 AM - 6:00 PM	Poster Walk	
471	152	8:00 AM - 6:00 PM	Poster Walk	
472	153	8:00 AM - 6:00 PM	Poster Walk	
473	154	8:00 AM - 6:00 PM	Poster Walk	
474	155	8:00 AM - 6:00 PM	Poster Walk	
475	156	8:00 AM - 6:00 PM	Poster Walk	
476	157	8:00 AM - 6:00 PM	Poster Walk	
477	158	8:00 AM - 6:00 PM	Poster Walk	
478	159	8:00 AM - 6:00 PM	Poster Walk	
Poster Walk - Molecular - Epidemiology SIG				
479	160	8:00 AM - 6:00 PM	Poster Walk	
480	161	8:00 AM - 6:00 PM	Poster Walk	
481	162	8:00 AM - 6:00 PM	Poster Walk	
482	163	8:00 AM - 6:00 PM	Poster Walk	
483	164	8:00 AM - 6:00 PM	Poster Walk	

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Saturday, August 21 ...continued				
484	165	8:00 AM - 6:00 PM	Poster Walk	
485	166	8:00 AM - 6:00 PM	Poster Walk	
486	167	8:00 AM - 6:00 PM	Poster Walk	
487	168	8:00 AM - 6:00 PM	Poster Walk	
488	169	8:00 AM - 6:00 PM	Poster Walk	
489	170	8:00 AM - 6:00 PM	Poster Walk	
Poster Walk -Pregnancy SIG				
490	171	8:00 AM - 6:00 PM	Poster Walk	
491	172	8:00 AM - 6:00 PM	Poster Walk	
492	173	8:00 AM - 6:00 PM	Poster Walk	
493	174	8:00 AM - 6:00 PM	Poster Walk	
494	175	8:00 AM - 6:00 PM	Poster Walk	
495	176	8:00 AM - 6:00 PM	Poster Walk	
496	177	8:00 AM - 6:00 PM	Poster Walk	
497	178	8:00 AM - 6:00 PM	Poster Walk	
498	179	8:00 AM - 6:00 PM	Poster Walk	
499	180	8:00 AM - 6:00 PM	Poster Walk	
Sunday, August 22				
500		8:30 AM	Oxford	Oral
501		8:45 AM	Oxford	Oral
502		9:00 AM	Oxford	Oral
503		9:15 AM	Oxford	Oral
504		9:30 AM	Oxford	Oral
456		9:45 AM	Oxford	Oral
506		8:30 AM	Buckingham	Oral
507		8:45 AM	Buckingham	Oral
508		9:00 AM	Buckingham	Oral
509		9:15 AM	Buckingham	Oral
510		9:30 AM	Buckingham	Oral
511		9:45 AM	Buckingham	Oral
512		8:30 AM	Balmoral	Oral
513		8:45 AM	Balmoral	Oral
467		9:00 AM	Balmoral	Oral
515		9:15 AM	Balmoral	Oral
516		9:30 AM	Balmoral	Oral
517		9:45 AM	Balmoral	Oral
518		8:30 AM	Cambridge	Oral
519		8:45 AM	Cambridge	Oral
520		9:00 AM	Cambridge	Oral
521		9:15 AM	Cambridge	Oral
522		9:30 AM	Cambridge	Oral
523		9:45 AM	Cambridge	Oral
524		8:30 AM	Clarence	Oral
525		8:45 AM	Clarence	Oral
526		9:00 AM	Clarence	Oral
527		9:15 AM	Clarence	Oral
528		9:30 AM	Clarence	Oral
529		9:45 AM	Clarence	Oral
530		8:30 AM	Dukes	Oral
531		8:45 AM	Dukes	Oral
532		9:00 AM	Dukes	Oral
533		9:15 AM	Dukes	Oral
534		9:30 AM	Dukes	Oral
116		9:45 AM	Dukes	Oral
536		10:30 AM	Oxford	Oral
537		10:45 AM	Oxford	Oral

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
538		11:00 AM	Oxford	Oral
539		11:15 AM	Oxford	Oral
540		11:30 AM	Oxford	Oral
541		11:45 AM	Oxford	Oral
542		10:30 AM	Balmoral	Oral
543		10:45 AM	Balmoral	Oral
544		11:00 AM	Balmoral	Oral
104		11:15 AM	Balmoral	Oral
448		11:30 AM	Balmoral	Oral
547		11:45 AM	Balmoral	Oral
548		10:30 AM	Cambridge	Oral
549		10:45 AM	Cambridge	Oral
550		11:00 AM	Cambridge	Oral
551		11:15 AM	Cambridge	Oral
552		11:30 AM	Cambridge	Oral
553		11:45 AM	Cambridge	Oral
554		10:30 AM	Buckingham	Oral
555		10:45 AM	Buckingham	Oral
556		11:00 AM	Buckingham	Oral
23		11:15 AM	Buckingham	Oral
558		11:30 AM	Buckingham	Oral
559		11:45 AM	Buckingham	Oral
560		10:30 AM	Dukes	Oral
561		10:45 AM	Dukes	Oral
562		11:00 AM	Dukes	Oral
563		11:15 AM	Dukes	Oral
564		11:30 AM	Dukes	Oral
565		11:45 AM	Dukes	Oral
566		10:30 AM	Clarence	Oral
567		10:45 AM	Clarence	Oral
568		11:00 AM	Clarence	Oral
569		11:15 AM	Clarence	Oral
570		11:30 AM	Clarence	Oral
571		11:45 AM	Clarence	Oral
Lessons Learned from Collaboration among EU Biologics Registries in Rheumatology				
572		1:30 PM	Hall 4	Sympos.
The Industry-Academic Nexus: Experiences, Perspectives, and Suggestions for Enhancing Research Relationships				
573		1:30 PM	Cambridge	Sympos.
The Alternate Life of Regulators				
574		1:30 PM	Oxford	Sympos.
Rare Diseases: Unmet Medical Needs, Epidemiology and Regulatory Considerations				
576		1:30 PM	Dukes	Sympos.
Linking Administrative and Electronic Medical Record Databases Using Hybrid Probabilistic and Deterministic Techniques				
577		1:30 PM	Balmoral	Sympos.
Challenges and Opportunities in Shaping Medical Device Epidemiology				
781		1:30 PM	Buckingham	Sympos.
Observed vs Expected Methodologies in Vaccine Safety Surveillance				
782		1:30 PM	Clarence	Sympos.

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
Poster Session C				
Anti-infectives				
578	1	8:00 AM - 1:45 PM		Poster
579	2	8:00 AM - 1:45 PM		Poster
580	3	8:00 AM - 1:45 PM		Poster
581	4	8:00 AM - 1:45 PM		Poster
582	5	8:00 AM - 1:45 PM		Poster
583	6	8:00 AM - 1:45 PM		Poster
584	7	8:00 AM - 1:45 PM		Poster
Burden of Disease/Epidemiology of Illness				
585	8	8:00 AM - 1:45 PM		Poster
586	9	8:00 AM - 1:45 PM		Poster
587	10	8:00 AM - 1:45 PM		Poster
588	11	8:00 AM - 1:45 PM		Poster
589	12	8:00 AM - 1:45 PM		Poster
590	13	8:00 AM - 1:45 PM		Poster
591	14	8:00 AM - 1:45 PM		Poster
592	15	<i>Abstract Withdrawn by Author</i>		
593	16	8:00 AM - 1:45 PM		Poster
594	17	8:00 AM - 1:45 PM		Poster
595	18	8:00 AM - 1:45 PM		Poster
596	19	8:00 AM - 1:45 PM		Poster
597	20	8:00 AM - 1:45 PM		Poster
598	21	8:00 AM - 1:45 PM		Poster
599	22	8:00 AM - 1:45 PM		Poster
600	23	8:00 AM - 1:45 PM		Poster
601	24	8:00 AM - 1:45 PM		Poster
602	25	8:00 AM - 1:45 PM		Poster
603	26	8:00 AM - 1:45 PM		Poster
604	27	8:00 AM - 1:45 PM		Poster
605	28	8:00 AM - 1:45 PM		Poster
606	29	8:00 AM - 1:45 PM		Poster
607	30	8:00 AM - 1:45 PM		Poster
608	31	8:00 AM - 1:45 PM		Poster
Cancer and Immunity				
609	32	8:00 AM - 1:45 PM		Poster
610	33	8:00 AM - 1:45 PM		Poster
611	34	8:00 AM - 1:45 PM		Poster
613	35	8:00 AM - 1:45 PM		Poster
614	36	8:00 AM - 1:45 PM		Poster
615	37	8:00 AM - 1:45 PM		Poster
616	38	8:00 AM - 1:45 PM		Poster
617	39	8:00 AM - 1:45 PM		Poster
618	40	8:00 AM - 1:45 PM		Poster
619	41	8:00 AM - 1:45 PM		Poster
620	42	8:00 AM - 1:45 PM		Poster
Cardiovascular				
621	43	<i>Abstract Withdrawn by Author</i>		
622	44	8:00 AM - 1:45 PM		Poster
623	45	8:00 AM - 1:45 PM		Poster
624	46	<i>Abstract Withdrawn by Author</i>		
625	47	8:00 AM - 1:45 PM		Poster
626	48	8:00 AM - 1:45 PM		Poster
627	49	8:00 AM - 1:45 PM		Poster
628	50	8:00 AM - 1:45 PM		Poster
629	51	8:00 AM - 1:45 PM		Poster
630	52	8:00 AM - 1:45 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
631	53	8:00 AM - 1:45 PM		Poster
632	54	8:00 AM - 1:45 PM		Poster
633	55	8:00 AM - 1:45 PM		Poster
634	56	8:00 AM - 1:45 PM		Poster
635	57	8:00 AM - 1:45 PM		Poster
636	58	8:00 AM - 1:45 PM		Poster
637	59	8:00 AM - 1:45 PM		Poster
638	60	8:00 AM - 1:45 PM		Poster
639	61	8:00 AM - 1:45 PM		Poster
CNS				
640	62	8:00 AM - 1:45 PM		Poster
641	63	8:00 AM - 1:45 PM		Poster
642	64	8:00 AM - 1:45 PM		Poster
643	65	8:00 AM - 1:45 PM		Poster
644	66	8:00 AM - 1:45 PM		Poster
645	67	8:00 AM - 1:45 PM		Poster
646	68	8:00 AM - 1:45 PM		Poster
647	69	8:00 AM - 1:45 PM		Poster
648	70	8:00 AM - 1:45 PM		Poster
650	71	8:00 AM - 1:45 PM		Poster
651	72	<i>Abstract Withdrawn by Author</i>		
652	73	8:00 AM - 1:45 PM		Poster
653	74	8:00 AM - 1:45 PM		Poster
654	75	8:00 AM - 1:45 PM		Poster
655	76	8:00 AM - 1:45 PM		Poster
656	77	8:00 AM - 1:45 PM		Poster
657	78	8:00 AM - 1:45 PM		Poster
658	79	<i>Abstract Withdrawn by Author</i>		
659	80	8:00 AM - 1:45 PM		Poster
660	81	8:00 AM - 1:45 PM		Poster
661	82	8:00 AM - 1:45 PM		Poster
662	83	8:00 AM - 1:45 PM		Poster
663	84	8:00 AM - 1:45 PM		Poster
664	85	8:00 AM - 1:45 PM		Poster
665	86	8:00 AM - 1:45 PM		Poster
666	87	8:00 AM - 1:45 PM		Poster
667	88	8:00 AM - 1:45 PM		Poster
668	89	8:00 AM - 1:45 PM		Poster
669	90	8:00 AM - 1:45 PM		Poster
670	91	8:00 AM - 1:45 PM		Poster
671	92	8:00 AM - 1:45 PM		Poster
672	93	8:00 AM - 1:45 PM		Poster
673	94	8:00 AM - 1:45 PM		Poster
674	95	8:00 AM - 1:45 PM		Poster
675	96	8:00 AM - 1:45 PM		Poster
Drug Utilization Research/Health Services Research				
676	97	8:00 AM - 1:45 PM		Poster
677	98	8:00 AM - 1:45 PM		Poster
678	99	8:00 AM - 1:45 PM		Poster
679	100	8:00 AM - 1:45 PM		Poster
680	101	8:00 AM - 1:45 PM		Poster
681	102	8:00 AM - 1:45 PM		Poster
682	103	8:00 AM - 1:45 PM		Poster
683	104	8:00 AM - 1:45 PM		Poster
684	105	<i>Abstract Withdrawn by Author</i>		
685	106	8:00 AM - 1:45 PM		Poster
686	107	8:00 AM - 1:45 PM		Poster
687	108	8:00 AM - 1:45 PM		Poster

ABSTRACT INDEX Final Program

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
688	109	8:00 AM - 1:45 PM		Poster
689	110	8:00 AM - 1:45 PM		Poster
690	111	8:00 AM - 1:45 PM		Poster
691	112	8:00 AM - 1:45 PM		Poster
692	113	8:00 AM - 1:45 PM		Poster
693	114	8:00 AM - 1:45 PM		Poster
694	115	<i>Abstract Withdrawn by Author</i>		
695	116	8:00 AM - 1:45 PM		Poster
696	117	8:00 AM - 1:45 PM		Poster
Gut				
697	118	8:00 AM - 1:45 PM		Poster
698	119	8:00 AM - 1:45 PM		Poster
699	120	8:00 AM - 1:45 PM		Poster
700	121	8:00 AM - 1:45 PM		Poster
701	122	8:00 AM - 1:45 PM		Poster
702	123	8:00 AM - 1:45 PM		Poster
703	124	8:00 AM - 1:45 PM		Poster
Medications in Pregnancy				
704	125	8:00 AM - 1:45 PM		Poster
705	126	8:00 AM - 1:45 PM		Poster
706	127	8:00 AM - 1:45 PM		Poster
707	128	8:00 AM - 1:45 PM		Poster
708	129	8:00 AM - 1:45 PM		Poster
709	130	8:00 AM - 1:45 PM		Poster
710	131	8:00 AM - 1:45 PM		Poster
711	132	8:00 AM - 1:45 PM		Poster
Methods				
712	133	8:00 AM - 1:45 PM		Poster
713	134	8:00 AM - 1:45 PM		Poster
714	135	8:00 AM - 1:45 PM		Poster
715	136	8:00 AM - 1:45 PM		Poster
716	137	8:00 AM - 1:45 PM		Poster
717	138	8:00 AM - 1:45 PM		Poster
718	139	8:00 AM - 1:45 PM		Poster
719	140	8:00 AM - 1:45 PM		Poster
720	141	8:00 AM - 1:45 PM		Poster
721	142	8:00 AM - 1:45 PM		Poster
722	143	<i>Abstract Withdrawn by Author</i>		
723	144	8:00 AM - 1:45 PM		Poster
724	145	8:00 AM - 1:45 PM		Poster
725	146	8:00 AM - 1:45 PM		Poster
726	147	8:00 AM - 1:45 PM		Poster
727	148	8:00 AM - 1:45 PM		Poster
728	149	8:00 AM - 1:45 PM		Poster
729	150	8:00 AM - 1:45 PM		Poster
730	151	8:00 AM - 1:45 PM		Poster
731	152	8:00 AM - 1:45 PM		Poster
732	153	8:00 AM - 1:45 PM		Poster
733	154	8:00 AM - 1:45 PM		Poster
734	155	8:00 AM - 1:45 PM		Poster
735	156	8:00 AM - 1:45 PM		Poster
736	157	8:00 AM - 1:45 PM		Poster
737	158	8:00 AM - 1:45 PM		Poster

Abstract #	Poster #	Presentation Time	Room	Format
Sunday, August 22 ...continued				
Muscles and Bones				
738	159	8:00 AM - 1:45 PM		Poster
739	160	8:00 AM - 1:45 PM		Poster
740	161	8:00 AM - 1:45 PM		Poster
741	162	8:00 AM - 1:45 PM		Poster
742	163	8:00 AM - 1:45 PM		Poster
743	164	8:00 AM - 1:45 PM		Poster
744	165	8:00 AM - 1:45 PM		Poster
745	166	8:00 AM - 1:45 PM		Poster
746	167	8:00 AM - 1:45 PM		Poster
747	168	8:00 AM - 1:45 PM		Poster
748	169	8:00 AM - 1:45 PM		Poster
749	170	8:00 AM - 1:45 PM		Poster
Pharmacovigilance				
750	171	8:00 AM - 1:45 PM		Poster
751	172	8:00 AM - 1:45 PM		Poster
752	173	8:00 AM - 1:45 PM		Poster
753	174	8:00 AM - 1:45 PM		Poster
754	175	8:00 AM - 1:45 PM		Poster
755	176	8:00 AM - 1:45 PM		Poster
756	177	8:00 AM - 1:45 PM		Poster
757	178	8:00 AM - 1:45 PM		Poster
758	179	8:00 AM - 1:45 PM		Poster
759	180	8:00 AM - 1:45 PM		Poster
Vaccines				
760	181	8:00 AM - 1:45 PM		Poster
761	182	8:00 AM - 1:45 PM		Poster
762	183	8:00 AM - 1:45 PM		Poster
763	184	8:00 AM - 1:45 PM		Poster
764	185	8:00 AM - 1:45 PM		Poster
765	186	8:00 AM - 1:45 PM		Poster
766	187	8:00 AM - 1:45 PM		Poster
767	188	8:00 AM - 1:45 PM		Poster
768	189	8:00 AM - 1:45 PM		Poster
769	190	8:00 AM - 1:45 PM		Poster
770	191	8:00 AM - 1:45 PM		Poster
771	192	8:00 AM - 1:45 PM		Poster
772	193	8:00 AM - 1:45 PM		Poster
773	194	8:00 AM - 1:45 PM		Poster
774	195	8:00 AM - 1:45 PM		Poster
775	196	8:00 AM - 1:45 PM		Poster
776	197	8:00 AM - 1:45 PM		Poster
777	198	8:00 AM - 1:45 PM		Poster
778	199	8:00 AM - 1:45 PM		Poster
779	200	8:00 AM - 1:45 PM		Poster

PDS Pharmacoepidemiology & Drug Safety

Official Journal of the International Society for Pharmacoepidemiology

Editor-in-Chief: Professor Brian L. Strom

Pharmacoepidemiology & Drug Safety provides an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology.

★ Free online access for ISPE members via the society website

★ Latest Impact Factor: 2.527 (JCR® 2009)

A selection of the top-downloaded papers from the 2009 Volume (18)

- Quantitative signal detection using spontaneous ADR reporting.
A. Bate, S. J. W. Evans. Volume 18, Issue 6, Pages 427-36
- Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis.
Zeina A. Habib, Leonidas Tzogias, Suzanne L. Havstad, et al. Volume 18, Issue 6, Pages 437-47
- Drug-induced *torsades de pointes*: data mining of the public version of the FDA Adverse Event Reporting System (AERS).
Elisabetta Poluzzi, Emanuel Raschi, Ugo Moretti, et al. Volume 18, Issue 6, Pages 512-18
- Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn.
Susan E. Andrade, Heather McPhillips, David Loren, et al. Volume 18, Issue 3, Pages 246-52
- Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.
Christianne L. Roumie, Neesha N. Choma, Lisa Kaltenbach, et al. Volume 18, Issue 11, Pages 1053-63




For more information on these top papers and other journal features, please visit

www.interscience.wiley.com/journal/pds

Print ISSN: 1053-8569 • Online ISSN: 1099-1557 • 2010 Volume: 19 • Frequency: Monthly

 **WILEY-BLACKWELL**

HILTON BRIGHTON METROPOLE Meeting Rooms



26th International Conference
on Pharmacoepidemiology and
Therapeutic Risk Management